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Vilhelm Ellerman and Olaf Bang, first demonstrated that avian sarcoma 
leukosis virus could be transmitted after cell-free filtration to healthy chickens, 
inducing leukemia [1] and later Rous Peyton extended Ellerman and Bang’s 
experiments and identified transmissible cancer-causing agents [2]. 
In 1936, John J. Bittner observed an incidence of mouse mammary tumors 
which were developed by the mouse mammary tumor virus (MMTV) through the 
mother's milk [3]. The mouse mammary tumor virus (MMTV) is found as exogenous 
as well as endogenous part of the germ cell genome in their host species [4]. 
In 1970 H.M. Temin, S. Mizutani and D. Baltimore discovered the RSV reverse 
transcriptase enzyme (RNA dependent DNA polymerase) that is essential for the 
transcription of retroviral single stranded RNA into double stranded DNA provirus [5].  
The first human retrovirus was isolated in 1979 by Robert Gallo and his co-
workers. This virus was identified as the human T-lymphotropic virus or human T-cell 
lymphotropic virus (HTLV) that is known to develop a type of cancer called adult T-
cell leukemia/lymphoma (ATLL) [6]. 
In 1983, Robert Gallo isolated a novel retrovirus which infected AIDS patients, 
and was similar in shape to other human T-lymphotropic viruses (HTLVs) so Gallo 
called the newly isolated virus HTLV-III [7]. At the same time, Montagnier's group 
identified a virus from a patient suffering from symptoms of AIDS [8]. The AIDS 
causing virus discovered by the two separate working groups is called Human 




Retroviruses are a large and diverse group of viruses infecting the animals 
and the humans. The International Committee for Taxonomy on Viruses (ICTV) 
broadly divides the Retroviridae family into two taxonomic sub-families, 
Orthoretrovirinae and Spumaretrovirinae. The first sub-family contains the genera 
Alpha-retrovirus, Beta-retrovirus, Gamma-retrovirus, Delta-retrovirus, Epsilon 
Introduction  7 
 
retrovirus and Lentivirus while the second contains the single Spumavirus genus (see 
Fig. 1). The current classification is based on phylogenetic analysis especially in pol. 
This taxonomy correlates with other genetic characteristics: the number and size of 
virion proteins, structure of the virion, presence of additional genes and the host 
tRNA used as primer [9]. 
 Moreover, retroviruses are alternatively classified into simple and complex 
viruses according to genome organization. Simple retroviruses are characterized by 
the presence of only gag, pro, pol, and env, while complex retroviruses (e.g. 
lentiviruses and spumaviruses) encode additional and auxiliary proteins that directly 
and specifically regulate the gene expression [10] [9]. 
 In addition, retroviruses can be divided into endogenous and exogenous 
retroviruses. Endogenous retroviruses are normal and usually non-pathogenic 
genetic elements in the vertebrate DNA germline vertically inherited to offspring and 
are able to be moved within the genome to act as possible enhancer sequences that 
stimulate the expression of the adjacent human genes [11] [12]. On the contrary, 
exogenous retroviruses (e.g. HIV) are horizontally transmitted from an individual to 





Figure 1: Phylogenetic tree of the Retroviridae. They are classified 
currently into two sub-families, Orthoretrovirinae and 
Spumaretrovirinae either exogenous or endogenous 
retroviruses. Modified from Antoinette, 2011 [13]. 
 




Retrovirus virions consist of characteristic, enveloped particles with a diameter 
of about 100 nm [14]. These infectious retroviral particles contain two single-stranded 
positive sense RNA copies differing in length from 7 to 12 Kilo bases (kb) depending 
on the type of virus as well as they possess a 5' cap structure and 3' polyadenylation 




Figure 2: Structure of an HIV virion particle (Andrea Rubbert, 2011) 
[15]. 
 
The detailed explanation of the main virion components and their basic 
function is mentioned as follows: 
 
I. Membrane Envelope: composed of lipids taken from the plasma membrane of the 
infected cells during budding process. It is lined by the gag-encoded Matrix protein as 
well as glycoprotein encoded by the env gene [16]. The retroviral envelope serves 
three important functions: protection of the viral RNA genome from the extracellular 
environment via the lipid bilayer, enabling the retrovirus to enter/exit host cells 
through endosomal membrane trafficking, and the ability to directly enter cells by 
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II. env-Encoded structural glycoproteins: 
1. gp120/gp41 proteins: gp120 is essential for virus penetration into cells because it 
has a necessary role in binding to specific cell surface receptors [17].gp41/TM 
(trans-membrane) protein contains peptide which promotes fusion of virion 
membrane with target cell membrane for the virion entry [18]. 
2. SU (surface unit): located outside the membrane, non-covalently bound to TM. It 
binds to specific cell-surface receptors of the host cell, targeting these cells for 
the virus adsorption and infection [19].  
 
III. Virion core: Structure composed of gag (group specific antigen) encoded matrix, 
capsid and nucleocapsid proteins which protect the core and is the most abundant 
proteins in the virus particle. Within the core are located: 
 
1. Two viral genomic RNA transcripts, coated by the gag encoded 
Nucleocapsid protein 
 
2. pol-encoded enzymes: 
 
A. Reverse transcriptase enzyme (DNA polymerase) which mediates the 
retrotranscription of a viral single stranded RNA genome into a double 
stranded DNA genome serving as a DNA intermediate product during virus 
replication and incorporating into the host cell genome to form DNA provirus. 
This RNA to DNA reversion was the first example of a 'backwards' direction of 
genetic information in living cells [20]. Also, Reverse transcriptase enzyme 
(RT) has RNase H activity allowing breakdown of RNA from DNA-RNA hybrid 
strands. 
B. Integrase, an enzyme which inserts the produced retroviral double stranded 
DNA into host cell genome. 
C. Protease, an enzyme that catalyzes the proteolytic cleavage of Gag and Pol 









The morphology of retroviruses was examined by thin section and negative 
stain electron microscopy (Bernhard, 1958). The average size of the retroviral 
particles is ranging between 100-150 nm. A-type virus possessed a non-enveloped 
immature intracellular particle which may be resulted from endogenous retrovirus like 
genetic elements. B-type viruses were extra-cellular with prominent envelope spikes 
and an electron dense, acentric core, typified by MMTV. The C-type group including 
most mammalian and avian retroviruses was similar to B-type viruses with a central 
core but with poorly visible envelope spikes. The D-type virus group is appeared 
slightly larger, up to 120 nm in size, with less prominent envelope proteins e.g. 
Mason-Pfizer monkey virus which is currently classified as a Betaretrovirus. 
 
Figure 3: Electron Microscope visualization of prototypic exogenous retroviruses at 
the budding, the immature and the mature stages (Book "retroviruses" 
edited by R Kurth and N Bannert [19]. 
 
In the immature stage, the centre of the particles is bright and has a dark Gag 
ring. During particle maturation process, the Gag Precursor protein is cleaved by the 
viral protease so the appearance of the interior of the immature particles changes 
clearly except spumaviruses. The mature virions are morphologically distinguished in 
the centre of various retrovirus strains type A, B, C and D depending on their core 
structure. 
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1.1.5 Retrovirus life cycle 
 
The replicative cycle of retroviruses is divided into two well-defined stages: the 
early stage concerns with the steps of infection from cell surface attachment to the 
integration of the provirus DNA into the host cell genome, while the late stage starts 
with the expression of retroviral genes, the budding and maturation of progeny viral 




Figure 4: The general features of the retroviral life cycle. A schematic 
representation of early and late phases of the retroviral replication 
cycle. The initial step of the retroviral life cycle is the adsorption of viral 
particles to the target cell surface that leads to fusion of the viral and host cell 
membranes. The viral enzymes release into the cytoplasm by uncoating 
process. The initiation of reverse transcription reaction is coupled to the 
onset uncoating of the nucleocapsid [21]. The viral RNA transcriptase 
converts the viral RNA into double stranded DNA which is transported as a 
pre-integration complex (PIC) into the cell nucleus and then it is incorporating 
into the host cell genome as a provirus by integrase enzyme. If the provirus 
DNA is transcribed, the various RNA molecules are transported to the 
cytoplasm and translated. In addition, the viral genomic RNA transcript is 
produced in an unspliced form in the cytoplasm. Gag proteins are translated 
and aggregated as virion core while the genomic RNA copies are packaged 
into virus particles. The virus buds are derived from the host plasma 
membranes that are bound to the viral Envs. The virus maturation is 
achieved after the budding process. Nisole et al., 2005 [22]. 
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The retroviral entry involves the specific binding between the viral envelope 
glycoprotein and the target cell surface receptors. Following the initial interaction 
step, the virions entry into the host cell is performed by dissociation of gp120 from 
gp41 and a conformational change, resulting in the insertion of transmembrane 
peptide into the cell membrane, leading to fusion of the viral and cellular membranes. 
The viral core is released into the cytoplasm, the capsid is disassembled by a 
process known as uncoating [23] [24]. Immediately, the viral genomic RNA is reverse 
transcribed in the cytoplasm by reverse transcription process catalyzed by the virion-
packaged reverse transcriptase (RT), producing a linear double-stranded DNA 
molecule [20]. The generated double stranded DNA molecule is transported as pre-
integration complexes (PICs) into the cell nucleus where it integrates into host 
chromosomal DNA, establishing the provirus [25] [26]. The integrated provirus 
becomes a permanent genetic material of the cell, may remain latent and is 
replicated along with the host DNA if the infected cell is undergoing cell division [9]. 
Depending on the type of the viral strain, 2-30 different mRNA transcripts are formed 
by splicing machinery [27].  
 However, expression of the provirus, serves either as viral genomic RNA 
which is packaged into newly synthesized virus particles or as mRNA for translation 
into Gag, Pol and Env precursor viral proteins. The Env precursor gp41 
transmembrane (TM) and gpl20 surface (SU) proteins are expressed from a singly 
spliced viral mRNA at the rough endoplasmic reticulum (RER) which is integrated into 
the virion membrane. The viral full length RNA is unspliced and then encapsidated 
into the virions by a specific binding to nucleocapsid of the Gag precursor. The matrix 
protein (MA) is responsible for stimulating the specific interaction between the NC 
and the viral full length RNA genome [28].  
Gag proteins forms virus-like particles (VLPs) that bud from the infected cells, 
independent of a viral-encoded protease (PR). The assembly and budding processes 
are controlled principally by viral Gag domains, such as the membrane-targeting (M) 
domain, the Gag-Gag interaction (I) domain essential for virion formation, and the 
late assembly (L) domain necessary for the separation of the newly formed immature 
virus particle from the host cell membrane [29]. Subsequently, the Gag and Gag-Pro-
Pol precursors are proteolytically processed by the viral active protease [30]. This 
process is known as virus maturation involved in formation of infectious virus 
particles which are able to invade new host cells [31]. 
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1.2 Endogenous retroviruses 
 
Endogenous retroviruses are genetic retroelements characterized by a long 
terminal repeat (LTR) [32] as a result of retrovirus infection of the ancestors millions 
of years ago [33]. They are investigated in all vertebrates including humans, 
integrated into the host genome of the germline (sperms and oocytes) as a non-
pathogenic and defective provirus DNA that is vertically transmitted to offspring 
according to Mendelian mechanisms [34].  
Endogenous retroviruses (ERVs) comprise between 5% and 10% of the 
vertebrate animals genome while these retroviral genetic elements occupy up to 8% 
of the human genome in different locations [35] [36]. Using bioinformatics 
technologies, more than 98 000 human ERVs (HERVs) have been estimated [37]. 
Also, the human genome carries at least 31 different human endogenous retrovirus 
(HERV) families, each resulting from 31 independent germline infections with 
retroviruses, the largest of which HERV-H has 1300 full length copies [37].  
The LTR containing retroelements can be divided into 6 superfamilies. 8 Class 
I–III HERVs have limited nucleotide sequence homologies to C-, B- or 
spumaspumaretroviruses, respectively while the other superfamilies MER4, MST and 
MLT are ancient retrotransposons that may be not currently active in humans [38]. 
ERVs are inactivated by recombinational deletions and mutations [39] but the 
provirus of ERVs may be activated by physical and chemical agents such as X-
irradiation, and inflammatory cytokines, and then transcripts are synthesized and 
expressed as infectious virus particles [40]. Koalas, koala gammaretrovirus (KoRV) 
can exist as a replication-competent, full-length provirus DNA in the host genome but 
their sequences are significantly similar to exogenous gibbon ape leukemia virus 
(GALV) [41] [42]. 
Some ERVs prove a beneficial role in regulating the human genes [43]. For 
example, an ERV LTR sequence contributes to the expression of the beta1, 3-
galactosyltransferase-5 gene specifically in colorectal tissue [44]. Furthermore, the 
env genes of ERVW express syncytin proteins which participate in the differentiation 
of syncytiotrophoblast in chorionic villi, helping in normal placental development 
during pregnancy [45] [46]. Simultaneously, other ERVs, notably ERVK, may be 
detrimental to the host by its replicative ability to encode viral RNA and proteins. 
There is no doubt that ERVK is implicated and transcriptionally active in inflammatory 
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diseases including Rheumatoid Arthritis (RA) [47], Systemic Lupus Erythematosus 
(SLE) [48], Amyotrophic Lateral Sclerosis (ALS) [49], and multiple types of cancers 
[50]. 
There are distinct mechanisms by which the endogenous retroviruses are able 
to proliferate: re-infection, retrotransposition and complementation in trans as shown 
in Figure 5. The life cycle of endogenous retroviruses starts with the initial 
colonization of the germline. Reinfection process refers to the re-entry of the ERV 
progeny into the host germline and then the provirus is replicating in the somatic cells 
leading to increasing in the retrovirus fitness. The retroviral functional gag, pol, env 
genes are essential for the reinfection mechanism. Retrotransposition represents an 
intracellular amplification process of retrotransposons and ERVs within the germline 
cells in which the virion core containg the viral genomic RNA molecules are 
biosynthesized. The Complementation of the defective viruses in trans is processed 
by proteins and LTRs promoter derived from other viruses [37]. Therefore, ERVs 
form infectious exogenous particles that have the ability to reinfect germline cells 
[33]. Some mutations, such as stop codons and frame shift mutations may be 
acquired in the new genetic retroelements during reinfection, retrotransposition or 
during cell division. These implemented mutations can inhibit or reactivate the 




Figure 5: Amplification mechanisms of the endogenous retroviruses. The proliferation 
processes Reinfection (a), retrotransposition (b) and complementation in trans (c) 
are explained in details in section 1.1.7 (Bannert and Kurth, 2006) [33]. 
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By phylogenetic analysis, the genetic distance between the ERV 5, and 3, 
LTRs determines the mutation frequency occurred since the integration time and 
therefore is proportional to the provirus age. Additionally, the comparison of the 
sequence homology of LTR sequences demonstrates the time of the provirus 
integration because these sequences are identical at the time of the germline 
infection and each mutation is achieved after 300,000 years [38]. HERV-KC4, HERV-
KHML6.17, and RTVL-Ia are investigated in both old world monkeys (OWMs) and 
hominoids, which are reported to have last shared a common ancestor over 31 
million years ago. In contrast, HERV-K18, RTVL-Ha, and RTVL-Hb are present only 
in humans, chimpanzees, and gorillas [51] [52] [53]. The last common ancestor of 
humans and chimpanzees was estimated 5-6 million years ago [51] [52] [53]. 
 
1.2.1 HERV-K(HML-2) Family and HERV-K113 
 
HERV families were discovered during analyses of human gene loci (e.g. 
HERV-H and HERV-I) [54] [55]. Some other HERVs were screened by probes 
isolated from animal retrovirus genomes that detected HERV proviruses (e.g. HERV-
E and HERV-K) [56] [57]. Moreover, oligonucleotides with homology to the retroviral 
primer binding sites were utilized to assess other HERVs (e.g. HERV-P) [58]. In 
1982, HERV-K 1982 was discovered in the human genome due to the similarity to 
MMTV [59]. 
A temporary systematic HERVs nomenclature is based on the specificity of the 
primer binding site to tRNA that serves as a primer to initiate the reverse transcription 
process. The one-letter code for the specific amino acid is appended to HERV [60]. 
But, this nomenclature system has limitations when closely related families are 
sharing homologies in the primer binding site or when cloned proviruses are either 
without a 5' end or are only partially sequenced. All class II elements identified to 
have a lysine primer binding site that is recognized by lysine carrying tRNA (e.g. 
HERV-K use lysine (K) tRNA while HERV-W use the tryptophan (W) tRNA) [4]. 
HERVs have been divided into two classes according to their similarities to 
animal retroviruses [61]. Class I families have sequence homology to mammalian 
retrovirus strain type C. Three families proved homologies in the sequences of the 
pol, gag and env genes and they are grouped into a superfamily, the ERI family that 
closely resemble murine leukemia virus (MuLV) and baboon endogenous virus 
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(BaEV). Class II families show similarity to mammalian retroviruses type B and D. 
The Provirus sequences of HERV-K family (HERV-K 10) [62] and of the HERV-K 
(C4) family]63[ exhibit homologies in the gag, pol, and env genes. 
HERV-K(HML-2) is a biologically active family of HERV, one of the most 
studied and amplified family integrated into the human genome less than 5 million 
years ago [64]. They were remarkably present and highly conserved in the genome 
of Old World monkeys ancestor 35 millions of years ago [4]. 
The HERV-K family has ten groups (HML-1-10) that are closely similar to 
mouse mammary tumor virus [65]. It has been reported that the human endogenous 
retrovirus type K (HERV-K) family comprises more than 90 proviral copies and more 
than 2,500 solitary LTRs per haploid genome in humans resulting from ancestral 
exogenous retroviral infections [33] [66]. Some proviruses of Betaretrovirus like 
HERV-K(HML-2) group are displaying intact open reading frames (ORF) with coding 
capacity for viral particles [65]. The intact HERV-K(HML-2) provirus was specifically 
distributed on human chromosome 7p22 [67] [68]. More than 20 HERV-K(HML-2) 
proviruses are [69] expressed in human teratocarcinoma-derived cells and all 
essential retroviral proteins (e.g. Gag, Pro, Pol, and Env proteins) that are up 
regulated in normal placental tissues [70], several cancerous tissues such as breast, 
ovarian tissues, lymphomas, and rheumatoid arthritis [65]. Hence, HERV-K(HML-2) 
proviruses can generate infectious particles [71]. Therefore, HERV-K(HML-2) activity 
indeed is linked to malignancies and cancer development. 
HML-2 proviruses are grouped according to their LTR sequence [72] or based 
upon the presence (type 1) or absence (type 2) of a 292 bp deletion within the pol-
env junction which is important for Rec protein formation [73]. Type 1 proviruses are 
defective because the 292 bp deletion which occurred after the evolutionary human-
chimpanzee split misses the necessary Env protein and inhibits the Rec protein 
expression but biosynthesizes an alternative protein known as Np9 [74]. Type 1 
proviruses are produced in many transformed cells [75]. Type 2 proviruses express 
the accessory Rec, a nuclear export factor that displays functional homologies to the 
HIV Rev protein [74]. Only few HML-2 proviruses are characterized by integration 
polymorphism processes within the human population [32] [76]. For instance, 
HERVK113, identified on 19p12 [77] had insertionally polymorphic proviruses in the 
human genomes of some individuals less than 200,000 years ago [78]. HERVK113 is 
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one of HERV-K type II proviruses and one of the most recently and the best 
preserved of the HERV-K proviruses. 
 
1.2.2 Proviral structure of HERV-K113 
 
The DNA length of the integrated HERV-K113 provirus is 8.9 kb and is flanked 
by the two LTRs which regulate the retroviral gene expression. The genomic provirus 
has open reading frames for all essential retroviral genes therefore; HERV-K113 is 
active and presumably pathogenic [79]. In Figure 6, it has been shown that the 
HERV-K113 has the same genomic structure of the characterized exogenous 
retroviruses, 5'-gag - pro - pol - env- 3' [32]. The gag gene encodes for the matrix, 
Capsid and nucleocapsid proteins. The pro gene expresses protease which converts 
the immature Gag and Pol proteins into mature molecules by the proteolysis process. 
The pol gene encodes for enzymes important for the viral replication, namely reverse 
transcriptase, RNase H and integrase. The env gene encodes for the envelope 




Figure 6: Genomic structural scheme of HERV-K113 provirus. HERV-K113 has a 
flanking long terminal repeats (the 5´and the 3´ LTR) and a central provirus. LTRs 
are composed of 3 genetic regions designated U3, R, U5. The provirus contains 
various genes, gag, group specific antigen gene; pro, protease gene; env, 
envelope gene; pol, polymerase gene which expresses various enzymes 
including reverse transcriptase and integrase as well as the accessory protein 
Rec. Modified from Hohn et al., 2013 [80]. 
 
In addition to the HERV-K113 genes expressing structural proteins and viral 
enzymes, there is gene for an accessory protein, known as Rec protein which 
functionally resembles the HIV-1 Rev and HTLV Rex proteins necessary for the viral 
mRNA export from nucleus into cytoplasm for their translation [81] [82]. 




1.3.1 Discovery and origin 
 
SIVs are lentiviruses and able to infect over 40 African non-human primates. 
The most characteristic feature of these infections is limited immune activation and 
resistance of the natural hosts to AIDS disease progression therefore this event help 
researchers understanding HIV infection in humans and to develop vaccine and 
therapeutic strategies [83] leading to a peaceful coexistence of primate lentiviruses 
and the immune system of the natural hosts. Based on epidemiological data, the 
SIVs have been present in monkeys at least 32,000 years ago. Primate lentiviruses 
have been isolated from most of the African monkeys of the genus Cercopithecus 
(e.g. SIVgsn, SIVdeb, SIVmus), African green monkeys (Chlorocebus), the 
mangabeys (SIVrcm), mandrills (SIVmnd) and drills (SIVdrl), colobus monkeys 
(SIVcol), and a variety of apes, two subspecies of chimpanzees (Pan) (SIVcpz) and 
gorillas (SIVgor) [84]. 
SIVs were first studied by AIDS researchers after observation of 
immunodeficiency in macaques in the California, and Washington primate centers 
[85]. The virus isolated from macaques originated from sooty mangabey monkeys. In 
addition, SIVs were transmitted to human population by zoonoses inducing AIDS 
disease and HIV pandemic [86]. Therefore, SIVmac and SIVsmm infected rhesus 
macaques are used as a new animal model for studying HIV infection. 
In Figure 7, phylogenetic data reveal that cross-species transmissions of two 
SIVs, chimpanzees SIVcpz and sooty mangabeys SIVsmm, to humans generated 
HIV-1 and HIV-2 epidemics, respectively [87] [88] [89]. 
 




Figure 7: phylogenetic relationships between various primate lentiviruses. Modified 
from Charles et al., 2001 [90]. 
 
On the other hand, AIDS was first clinically discovered in 1981 in the United 
States when it was observed in injecting drug users and gay men suffering from loss 
of immunity and occurrence of rare opportunistic infections [91]. Afterwards, HIV-1 
was isolated from AIDS patients by two separate working groups in 1983 [92], 
whereas HIV-2 was first detected in West African infected individuals in 1986 [93] 
[94]. HIV-2 is less pathogenic rate, slower immunodeficiency progression than HIV-1 
and worldwide is more restricted in its distribution (rare in North America, Europe and 
Central or East Africa) [95]. 
 
1.3.2 SIV/HIV genomic organization  
 
All lentiviruses including SIVmac239 and HIV carry a common genomic 
organization encoding the structural and enzymatic proteins 5'gag, pol, env3'. Also, 
they have several important accessory genes as displayed in Figure 8, such as tat, 
rev, vif, vpr, and nef genes whose products that mediate the viral gene expression 
and infectivity [96] [84]. 
 




Figure 8: Genomic organization of the SIVmac239. Gray boxes show protein coding 
regions, while dark lines show the boundaries of the mature viral proteins. 
Modified from Elizabeth et al., 2013 [97]. 
 
The pro-pol sequence encodes the protease, integrase and reverse 
transcriptase enzyme with RNase activity. Pol precursor is enzymatically processed 
into the protease, the reverse transcriptase and the integrase. The reverse 
transcriptase uses the viral genomic RNA as a template for the generation of cDNA 
copies. The integrase enzyme inserts the synthesized cDNAs into the genome of the 
target cell via formation of two characteristic identical LTR genetic segments flanking 
the viral genome. The gag gene expresses the group specific antigens that occupy 
about 50% of the entire virus particles [98]. During the maturation stage, protease 
catalyzes the proteolysis of Gag into matrix, capsid and nucleocapsid proteins. 
Furthermore, protease is essential for separation of Env into the transmembrane 
protein (gp41) and the surface protein (gp120) subunits [99]. The env gene is 
transcribed into a single spliced mRNA transcript that is translated into the Env 
precursor (gp160) and then protease enzyme separate the Env precursor into the 
transmembrane protein (gp41) and the surface protein (gp120) subunits [100]. 
 
1.3.3 HIV epidemiology and therapy 
 
 HIV is the etiologic agent of acquired immunodeficiency syndrome (AIDS) in 
humans. The central feature of HIV infection is an obvious increase in activation of 
the adaptive and the innate immunity. HIV-1 infection results in destroying the activity 
of cell-mediated immunity by progressive depletion of CD4+ T lymphocytes, 
macrophages and dendritic cells, resulting in AIDS disease that leads to more 
susceptibility to cancer development and opportunistic infections such as Candidiasis 
of bronchi, Cryptococcosis, Kaposi's sarcoma, Pneumocystis carinii pneumonia and 
Kaposi's sarcoma [101]. 
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 The main routes of HIV transmission are sexual transmission (infected semen 
or vaginal and cervical secretions), infected blood transfusion, infected needles 
usage, infected breast milk [102]. Worldwide, it has been estimated that 35 million 
people were living with HIV, nearly 39 million people have died of HIV at the end of 
2013 [103] and about 5 million new HIV infections detected per year [104]. HIV-1 is a 
major health threat worldwide in most countries particularly in sub-Saharan Africa 
and Southeast Asia [104]. 
Antiretroviral treatment is the best strategy for inhibition of the viral replication 
and, subsequently, for reduction of morbidity and mortality rate [105]. However, 
effective HIV vaccines are complex due to high genetic diversity as well as current 
drugs do not cure or eradicate HIV infection but when they are taken in combination, 
they can impair the virus multiplication. Combination of many effective antiretroviral 




Figure 9: HIV life cycle showing the replication steps against which HAART drugs is 
effective. Changed from Gary et al., 2014 [105]. 
 
The mechanisms of antiretroviral action (Figure 9) depend on targeting the 
viral envelope gp40 segment (prevention of the cell-virus fusion process before the 
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virus entry), the viral reverse transcriptase and integrase (viral replication 
suppression) and viral protease (maturation step inhibition) [106]. 
 
1.4 Rev/Rec proteins 
 
The retroviral Rev/Rec (Regulator of Expression of Virions) proteins are a 
posttranscriptional acting trans-activator which has been shown to be absolutely 
necessary for regulation of viral gene expression and stimulation of genomic RNA 
encapsidation 20- to 70-fold [107]. Rev/Rec interact with the Rev/Rec responsive 
element (RRE), a highly structured RNA sequence located on the unspliced RNA 
transcript and the single spliced env mRNA [108]. RRE appears to be vital for the 
Rev/Rec function so following binding to the RRE, Rev export the unspliced 9 kb 
RNA encoding Gag and Gag–Pol, and the five singly 4 kb spliced mRNAs encoding 
Vif, Vpr, Vpu, and Env via the CRM-1 export pathway from the nucleus into the 
cytoplasm [109]. Consequently, the Rev protein effectively enhances the cytoplasmic 
translation of gag-pol open reading frames (unspliced viral mRNA) and env transcript 
encoding the viral structural proteins [107]. 
HIV-1 Rev trans-activator mediates transport of unspliced HIV-1, HIV-2 and 
SIV mRNA transcripts, whereas the Rev proteins of HIV-2 and SIV were not able to 
induce the HIV-1 unspliced mRNAs nucleocytoplasmic shuttling and expression 
[110]. Rev mutagenesis or RRE deletion in HIV-1 vector during viral production 
significantly decreases the vector titers [107]. 
As illustrated by Figure 10, Rev/Rec proteins contain distinct functional 
domains comprising RNA binding domain (RBD) which appears to overlap with short 
stretches of basic amino acid residues named as NLS (Nuclear localization signal). 
The NLS/RBD region is arginine-rich motif (ARM) present in the N-terminal domain, 
and is flanked by two loop or multimerization domains (OLIGO). Moreover, the 
Rev/Rec proteins have NES (nuclear export signal) domain located within the 
leucine-rich carboxy-terminal domain. NLS allows Rev/Rec to enter nucleus while 
NES is involved in the export of viral RNA transcripts from nucleus to cytoplasm for 
translation so NLS and NES exhibit the biological function of Rev/Rec. Therefore, in 
the absence of Rev/Rec, the viral mRNAs are retained in the nucleus, preventing 
their translation [111] [112] [113]. 
 




Figure 10: Schematic representation shows the Rev/Rec proteins structure. The 
Rev/Rec proteins consist of several functional domains: Nuclear localization 
signal (NLS) which seems to overlap with the RNA binding domain (RBD) in 
blue. The multimerization region (OLIGO) in green borders the ARM/NLS. 
Also, Rev/Rec have the nuclear export signal (NLS) in dark gray which is 
required for transport of the viral RNA from the nucleus into the cytoplasm. 
Modified from Dimattia et al., 2010 [111]. 
 
The mechanism of Rev/Rec dependent RNA transport can be achieved via a 
specific attachment of the RBD region of the Rev/Rec to the RNA target sequence for 
Rev/Rec, termed as a rev/rec responsive element [114]. RRE is conserved region 
within the N terminus of gp40 of env gene. The HIV-1 RRE is composed of 351 
nucleotides [115], whereas the conserved SIVsm RRE is identified between 
nucleotide 8154 to 8375 [116]. The SIV and HIV-2 RRE sequences shared nearly 
90% homology with each other and about 69% with HIV-l [110]. 
The viral regulatory protein Rev binds to the RRE of the unspliced and single 
spliced viral mRNAs and shuttles them from the nucleus to the cytoplasm by a 









Figure 11: Schematic presentation of Rev/Rex dependent retroviral introns 
containing RNAs transport pathway. The Rev is transported into the 
nucleus by importin-β and then it binds to the RRE of the viral RNAs in 
presence of CRM1, RanGTP and DDX1 forming the transport complex which 
is exported from the nucleus into the cytoplasm. Modified from Hisatoshi 
Shida, 2012 [117]. 
 
The NLS of Rev/Rex/Rec protein is bound to importin-β to enter the nucleus 
and initially interacts with single Rev binding site within the RRE. As a consequence, 
RNA bound to the RRE induces further Rev/Rex/Rec multimerization, which 
subsequently recruit several hCRM1 molecules [118] [81]. The process is further 
activated by the DDX1 (an RNA-dependent ATPase) that binds specifically to 
Rev/Rex/Rec. The NES associates with the cellular CRM1 (chromosome region 
maintenance 1) in the presence of RanGTP and then the transport ribonucleoprotein 
complex including viral RNA, Rev/Rex/Rec , CRM1, and other cellular constituents 
are released via the nuclear pores from the nucleus into the cytoplasm [109]. 
Afterwards, RanGTP, CRM1 are hydrolyzed leading to separation of Rev/Rex/Rec 
from the target mRNAs so the NLS of Rev/Rex/Rec is reimported into the nucleus by 
its functional NLS and importin-β [119] [81]. 
Interestingly, it has been observed that Rev promotes packaging of the viral 
RNA into the viral particles to a larger extent than its effect on cytoplasmic RNA 
amounts therefore, interaction of Rev to the viral RNA during an early nuclear event 
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is correlated with RNA encapsidation occurring at a late stage of the virus replication 
cycle [107]; moreover, Rev affect subsequent events in the cytoplasm, including the 
translation of the cognate mRNA, the movement of Gag proteins to the plasma 
membrane, and the production of new virus particles [117]. 
 
1.5 The Staufen protein 
 
Staufen is a highly conserved double stranded RNA binding protein first 
identified in Drosophila. There are two types of Staufen proteins named as Staufen-1 
and Staufen-2 found in the vertebrates including mammals, fish and birds. Staufen-1 
is expressed ubiquitously [120], while expression of Staufen-2 is restricted [121]. The 
Staufen-1 and Staufen-2 have a molecular weight of 55 kDa and 63/65 kDa, 
respectively [122]. The human Staufen (hStau) protein displays four copies of 
functional dsRBDs 2, 3, 4 and 5 (double-stranded RNA-binding domains), which 
structurally and functionally resemble dsRBD 2 to 5 of the Drosophila melanogaster 
Staufen (dStau) as illustrated by Figure 12 [123]. Staufen-1 DNA is characterized by 
absence of dsRBD1 and presence of region between dsRBD4 and dsRBD5 known 
as tubulin binding domain (TBD) capable of interacting with tubulin [123]. The 
structure of dsRBD3 shows the highest affinity of a strong binding to RNAs, and 
protects the short RNA hairpin from the RNases activity [124]. In contrast, dsRBD4 




Figure 12: Schematic representation showing the structure of hStau and dStau 
molecules. Human Staufen is composed of four copies of double-stranded 
RNA-binding domains (dsRBD2 to dsRBD5), which demonstrated homology to 
dsRBD2, dsRBD3, dsRBD4 and dsRBD5 belonging to Drosophila 
melanogaster Staufen. The dStau contains also a dsRBD1 domain, while 
hStau has a tubulin binding domain (TBD) shown in blue which is located 
between dsRBD4 and dsRBD5. Modified from Marión et al., 1999 [120]. 
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The Staufen-1 and Staufen-2 molecules are expressed and located in the 
cytoplasm; however these proteins were also detected in the nucleus particularly in 
the nucleolus [123] because dsRBD3 contains a functional NLS in the carboxyl 
terminus, by which the Staufen is moved into the nucleus and the nucleolus [125]. 
The nucleolar trafficking and the cytoplasmic retention termed MOI (modulation of 
import) process can be carried out by the nuclear localization signal (NLS) with a 
supporting effect of dsRBD2 and dsRBD4 [125]. Due to lack of NES in the Staufen 
structure, mammalian Staufen was found to shuttle through the nucleus and exits 
through exportin-5 and/or CRM1 (Chromosomal Region Maintenance 1)-dependent 
pathway [126]. 
 Staufen mediates the transport and the translation of the target mRNA, for 
instance, the Staufen of Drosophila was observed to be correlated with the 
localization of the mRNAs in oocytes and neuroblasts [127]. Moreover, Staufen 
molecules appeared to be packaged along with the HIV-1 RNA into virus particles 
[128]. In addition, it regulates the degradation of mammalian cell mRNAs (Staufen 
mediated mRNA decay) and the formation of RNA granules [129]. Furthermore, 
Staufen-1 and Staufen-2 associate to the rough endoplasmic reticulum and the 
polyosomes and polyribosomal units in the mammalian cytoplasm, and it is examined 
in the ribonucleoprotein complexes in neurons, therefore, these observations proved 
the importance of Staufen protein in inducing the RNA transport and the translation 
event [128]. Staufen is considered as a regulatory component of the stress granules 
(SGs) containing silenced RNPs (ribonucleoproteins) which are assembled during 
cellular stress conditions, so Staufen controls the disassembly and formation of the 
stress granules [129]. 
 
1.5.1 Interaction of Staufen-1 with Retroviruses 
 
There are several mechanisms of interaction process is between the Staufen-
1 and retroviruses. For example, it has been observed that during HIV-1 replication 
cycle, the Staufen-1 via its dsRBD3 binds to NC domain of the Gag precursor pr55 
through the two zinc finger motifs leading to an enhancement of HIV-1 assembly and 
an increase in production of new HIV-1 virions by modulating the Gag precursor pr55 
multimerization [130] [131] [132]. Interestingly, the Staufen-1 N-terminus domain 
regulates the Staufen-1 mediated HIV assembly [131]. Also, it has been indicated 
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that over-expression or depletion of stau1 from cells induced an increase in the viral 
particles release and the Gag precursor pr55 multimerization [130]. 
Furthermore, Staufen is responsible for regulation of HIV-1 gene expression 
by mediating the viral RNA transcripts transport to ribosomes in which Staufen-1 
activates the specific mRNA binding to the translation initiation factor known as eIF4E 
[129]. HIV-1 has the trans-acting responsive (TAR) region located adjacent to the 
transcription Initiation site at the 5' end of all viral mRNAs and forms a stable 
secondary RNA stem loop [133]. The RNA TAR structure forms RNA cap structure 
preventing the accessibility to translation initiation factors leading to inhibition of the 
translation event [133]. The dsRNA-dependent kinase (PKR) also controls translation 
of TAR-containing transcripts by attachment of PKR to TAR region resulting in 
activation of PKR and thus stimulating the phosphorelation of the translation initiation 
factor 2a (eIF-2a) and inhibition of the translation [134] [135]. In contrast, TAR-RNA 
binding protein prevents the activation of PKR and therefore, it initiates the 
translation of TAR bearing RNAs [136]. Staufen-1 shares sequence homology to the 
TAR-RNA binding protein (TRBP), which binds to TAR sequence so it promotes the 
translation of TAR-containing RNA transcripts, and increases the generation of viral 
particles [137]. Additionally, it has been reported that the addition of Staufen-1 
caused the up-regulation of reporter activity and the translation process driven by the 
TAR-carrying RNA. By contrast, Staufen-1 had no influence on translation of 
translated mRNAs lacking an apparent structured 5' end, indicating that Staufen-1-
interaction with the 5' end and ribosomes facilitates the translation initiation [138]. 
Earlier studies have demonstrated that Staufen-1 is packaged into the HIV-1 
and HIV-2 viral particles via its dsRBD3 domain [128]. This suggested that Staufen-1 
is necessary for the viral genomic RNA transport, encapsidation for both HIV-1 and 
HIV-2 because it is bound to the viral RNA genome during the virus assembly and 
maturation events [139] [132]. Also, overexpression and silencing of Staufen-1 
impaired the virus infectivity at several stages such as the reverse transcription, the 
integration, the level of the packaged genomic RNA and the efficiency of the 
encapsidation [128] [140]. In addition, the interaction of Staufen-1 with HTLV-1 Rex 
and HERV-K(HML-2) Rec was studied [141]. It has been observed that 
overexpression of Staufen-1 induced the nuclear export and/or translation of 
unspliced HERV-K RNAs, and an increase in the production of new viral particles. 
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Additional findings revealed that overexpression of Staufen-1 had a positive influence 
on the assembly of new HIV-1 and HIV-2 virions [142] [143]. 
In conclusion, Staufen-1 stimulates the generation of the retroviral particles by 
mediating the translation rate of viral proteins, and binding to Gag and Rev/Rec/Rex 
and therefore enhancing the nuclear export of the viral RNA transcripts [128] [132] 
[138]. 
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2 Aims and Objectives of work 
 
The replication of retroviruses relies on interactions between a multitude of 
cellular factors. The Rec and Gag proteins of HERV-K(HML-2) are known to bind to 
the cellular protein Staufen-1. Staufen-1 also interacts with the TAR-region HIV-1 
RNA and with the HIV-1 Gag protein [137]. Overexpression of Staufen-1 results in a 
3-fold increase in the release of HIV-1 from infected cells and a 20-fold enhancement 
of HERV-K(HML-2) particle production [128] [141]. Moreover, an interaction between 
Staufen-1 and the HIV-1 Rev protein, a functional homolog of Rec, has also been 
recently demonstrated [142], but no data are available regarding the potential role of 
Staufen-1 on SIVmac expression. 
The primary objective of this study is therefore to evaluate the impact of 
Staufen-1 on the expression of SIVmac, including a clarification of the potentially 
direct interaction between Staufen-1 and SIVmac Rev. The investigation should also 
provide data on the consequences of Staufen-1 overexpression and downregulation 
for SIVmac particle production. It should include attempts to describe the underlying 
molecular mechanisms and to identify the regions on SIVmac Rev and on Staufen-1 
involved in the potential modulation of SIVmac expression by Staufen-1.  
This analysis of the effect of Staufen-1 on SIVmac should be performed in 
direct comparison to HIV-1 and HERV-K(HML-2). Should different effects be 
observed, experiments should be done to shed light on the underlying basis for such 
differences. The involvement of Staufen-1 in the nucleocytoplasmic transport of viral 
mRNA should form the focus of this part of the project. 
Moreover, within the framework of this study, a HERV-K(HML-2) molecular 
clone incapable of expressing Rec should be generated. This could be used to 
investigate the Rec-dependence of HERV-K(HML-2) expression and the ability of 
Staufen-1 to compensate for Rec. This delta-Rec mutant could also be used to 
confirm and extend previous knowledge regarding the ability of HIV-1 Rev, HTLV Rex 
and other retroviral proteins with known or potentially similar functions to substitute 
for Rec. In this context, the synergistic effect of Staufen-1 should also be clarified 
 
Materials and Methods  30 
 




3.1.1 Laboratory Equipment 
 
The machines and supplies used to perform the experiments are shown in Table 1.  
 
Table 1: Laboratory equipment 
Model company 
Balance PR803 Mettler Toledo, Giessen, Germany 
Balance Ohaus Navigator N2B110 Ohaus, Nänikon, Swiss 
Beckman Coulter-Counter Z2 Beckman Coulter, Fullerton, USA 
Confocal Microscope LSM 780 Carl Zeiss, Oberkochen, Germany 
CPA225D Analytical Balance    Sartorius 
CO2 Incubator HeraCell 150 Thermo Scientific, Logan, USA 
C24 Incubator Shaker New Brunswick Scientific, Edison, 
USA 
Dry Block Heater Grant Instrument Ltd, Cambridgeshire, 
England 
Dialysis membrane  Carl Roth GmbH, Karlsruhe, Germany 
Eppendorf Centrifuge 5415D Eppendorf, Wesseling-Berzdorf, 
Germany 
Eppendorf Centrifuge 5804R Eppendorf, Wesseling-Berzdorf, 
Germany 
Eppendorf Centrifuge 5810R Eppendorf, Wesseling-Berzdorf, 
Germany 
Extra Thick Blot Paper BioRad, Hercules, USA 
Film Processing Machine Curix 60 Agfa, Cologne, Germany 
Fume Hood Köttermann GmbH & Co KG, 
Uetze/Hänigsen, Germany 
Gene Pulser XCell + Shock Pod BioRad, Hercules, USA 
Gel Documentation machine 2000 BioRad, Hercules, USA 
Heraeus Biofuge Primo R centrifuge Thermo Scientific 
Heraeus multifige 1 S-R  Thermo Fischer Scientific 
Hettich Mikro 200R Centrifuge DJB Labcare Ltd, Buckinghamshire, 
England 
Horizontal Shaker 3016 GFL – Society for Laboratory 
Technology, Burgwedel, Germany 
Incubator Innova 4330 New Brunswick Scientific, Edison, 
USA 
Inverse Light Microscope ID03 Carl Zeiss, Oberkochen, Germany 
Microplate Luminometer Centro LB 960 Berthold Technologies, Oak Ridge, 
USA 
Microplate Absorbance Reader Sunrise Tecan, Männedorf, Swiss 
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Mini-PROTEAN Tetra Cell Electrophoresis BioRad, Hercules, California, USA 
NanoDrop Spectrophotometer ND-1000 Nanodrop, Wilmingon, USA 
Nitrocellulose Membrane (0.45 µm) BioRad, Hercules, USA 
Overhead Rotator Reax 2 Heidolph Instruments GmbH & Co. 
KG, Schwabach, Germany 
PCR Thermocycler BioRad, Hercules, USA 
pH-Meter MP220 Mettler Toledo, Giessen, Germany 
PowerPAC HC BioRad, Hercules, USA 
PowerPACTM 200 BioRad, Hercules, USA 
PVDF Membrane Carl Roth GmbH, Karlsruhe, Germany 
SONIFIER 250  Branson 
Sub-Cell GT Agarose Gel Electrophoresis 
System 
BioRad, Hercules, California, USA 
Safety cabinet HeraSafe Thermo Fischer Scientific 
Sprout-R Mini-Centrifuge Heathrow Scientific LLC, Illinois, USA 
Trans-Blot SD Semi-Dry Electrophoretic 
Transfer Cell 
BioRad, Hercules, California, USA 
UV Transilluminator TFX-20.M Vilber Lourmat, Paris, France 
Water Bath GFL – Society for Laboratory 
Technology, Burgwedel, Germany 
Whatman® Puradisc 25 syringe Filters   
(0.2 µm) 
Sigma-Aldrich Chemie GmbH, Munich, 
Germany 
X-ray Film Eastman Kodak Company, Rochester, 




Chemicals utilized in this study are listed in Table 2. 
 
Table 2: Chemicals 
Chemical Company 
Agarose Peqlab Biotechnologie GmbH, 
Erlangen, Germany 
Ammonium persulfate (w/v) 10% 
(APS) 
Carl Roth GmbH, Karlsruhe, 
Germany 
Acrylamide (30%) Carl Roth GmbH, Karlsruhe, 
Germany 
Agar-agar Carl Roth GmbH, Karlsruhe, 
Germany 
BSA (10x) New England Biolabs Inc., Beverly, 
USA 
β-Mercaptoethanol Sigma-Aldrich Chemie GmbH, 
Munich, Germany 
Complete protease inhibitor cocktail tablets Roche Diagnostics GmbH, 
Mannheim, Germany 
Coomassie Brilliant Blue G Concentrate Sigma-Aldrich Chemie GmbH, 
Munich, Germany 
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Dimethylsulfoxide (DMSO) 50% Sigma-Aldrich Chemie GmbH, 
Munich, Germany 




Carl Roth GmbH, Karlsruhe, 
Deutschland 
Ethylenediaminetetraacetic acid (EDTA) Sigma-Aldrich Chemie GmbH, 
Munich, Germany 
Ethidium bromide Carl Roth GmbH, Karlsruhe, 
Deutschland 
Ethanol Carl Roth GmbH, Karlsruhe, 
Germany 
GelRed Biotium, Hayward, USA 
Glycerin (100%) Serva, Heidelberg, Deutschland 
Hydrogen peroxide (30%) Carl Roth GmbH, Karlsruhe, 
Germany 





Isopropanol Carl Roth GmbH, Karlsruhe, 
Deutschland 
Methanol MERCK, Darmstadt, Deutschland 
Magnesium chloride (MgCl2) Roche Diagnostics GmbH, 
Mannheim, Germany 
Ni-NTA Agarose Qiagen GmbH, Hilden, Germany 
o-Phenylenediamine dihydrochloride 
(OPD) 
Sigma-Aldrich Chemie GmbH, 
Munich, 
Germany 
Paraformaldehyde (PFA) Carl Roth GmbH, Karlsruhe, 
Germany 
Phenylmethanesulfonylfluoride (PMSF) AppliChem 
Sodium dodecyl sulfate (SDS) Sigma-Aldrich Chemie GmbH, 
Munich, Germany 
Skimmed milk powder Carl Roth GmbH, Karlsruhe, 
Germany 
Super SignalWest Dura Extended Duration 
Substrate 
Thermo Scientific, Logan, USA 
Sulfuric acid, 2.5M Carl Roth GmbH, Karlsruhe, 
Germany 
Tween-20 Carl Roth GmbH, Karlsruhe, 
Germany 
TrisHCl Carl Roth GmbH, Karlsruhe, 
Germany 
TEMED Carl Roth GmbH, Karlsruhe, 
Germany 








Kits used in this work are mentioned in Table 3. 
 
Table 3: List of the used kits and their companies. 
Kit Company 
Dual-Glo® Luciferase Assay System Promega Corporation, Madison, USA 
Endo-free Plasmid Maxi Kit Qiagen GmbH, Hilden, Germany 
Expand High Fidelity PCR System Roche Diagnostics GmbH, Mannheim 
ECL Plus Western Blot Detection 
System 
GE Healthcare, Fairfield, USA 
Luciferase 1000 Assay System Promega Corporation, Madison, USA 
MetafectenePro Biontex, Munich, Germany 
PolyFect Transfection Reagent Qiagen GmbH, Hilden, Germany 
QIAquick Gel Extraction Kit Qiagen GmbH, Hilden, Germany 
QIAprep Spin Miniprep Kit Qiagen GmbH, Hilden, Germany 
QuikChange® Site-Directed  
Mutagenesis Kit 
Agilent Technologies, Inc., Santa Clara, 
California, USA 
QuikChange Multi Site-Directed 
Mutagenesis Kit 
Agilent Technologies, Inc., Santa Clara, 
California, USA 
QIAquick PCR Purification Kit Qiagen GmbH, Hilden, Germany 
Super Signal West Dura Extended 
Duration Substrate 
Thermo Scientific, Logan, USA 
 
3.1.4 Buffers and culture media 
 
All buffers used in the experiments are stated in Table 4. 
 
Table 4: Buffers and culture media 
Buffer Component/Company 
Annealing buffer (10x)  Sigma-Aldrich Chemie GmbH, Munich,  
Germany 
Bacterial lysis buffer 
 
250mM HEPES pH 7, 100mM  Na2SO4, 
400mM (NH4)2SO4, 200mM NaCl, 0.1% 
Tween-20, 2mM β-mercaptoethanol, 
2mM fresh PMSF, protease inhibitor 
cocktail (one tablet/50ml) 
Buffer A  
 
50mM Tris pH 8.0, 250mM NaCl, 
400mM (NH4)2SO4, 100mM Na2SO4, 
20mM Imidazole, 2mM β-
mercaptoethanol 
Buffer A+  
 
50mM Tris pH 8.0, 0.1% Tween-20, 
2mM NaCl, 400mM (NH4)2SO4, 100mM 
Na2SO4, 20mM Imidazole, 2mM β-
mercaptoethanol 
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Blocking buffer 5% skimmed milk powder in PBS with 
0.1% Tween-20 
CutSmart buffer (10x)  New England Biolabs Inc., Beverly, USA 
Calcium chloride Carl Roth GmbH, Karlsruhe, Germany 
Carbonate bicarbonate buffer Sigma-Aldrich Chemie GmbH, Munich,  
Germany 
DNA sample buffer (6x) 10mM tris-acetate, 50mM EDTA, 10% 
Ficoll-400 (w/v) (Serva), 0.4% Orange- G 
(w/v) (Sigma) in a double distilled water 
DNA polymerase buffer (10x) Agilent Technologies, Inc., Santa Clara, 
California, USA 
Dulbecco’s Modified Eagle Medium 
(DMEM) 
PAA Laboratories GmbH, 
Pasching,Austria (with 1 g/L glucose and 
2mM L-glutamine and 1x 
Penicillin/Streptomycin) 
Expand High Fidelity buffer (10x) Roche Diagnostics GmbH, Mannheim, 
Germany 
FCS (Fetal calf serum) Biochrom, Berlin, Germany 
2x HBS (HEPES Buffer Saline) 50mM HEPES, 280mM NaCl, 1.5mM 
disodium phosphate, Double distilled 
water, pH 7.1  
Isoton R II Diluent Beckman Coulter, Inc., Fullerton, USA 
IGEPAL lysis buffer Sigma-Aldrich Chemie GmbH, Munich,  
Germany 
Lysis buffer 50mM Tris HCL pH 7.5, 150mM NaCl, 
5mM EDTA, fresh protease inhibitor 
tablet (1 tablet/50ml) 
Laemmli sample buffer (4x) 200mM Tris-Cl, 8% (w/v) SDS, 0.2% 
(w/v) bromophenol blue, 40% (v/v) 
glycerol, 400mM DTT 
LB medium 1% tryptone, 0.5% bacto yeast extract, 
1% NaCl, pH 7.5 
LB-Agar  LB medium with 20 g/L agar-agar 
NEB and EcoRI buffers New England Biolabs Inc., Beverly, USA 
NP-40 New England Biolabs Inc., Beverly, USA 
Phosphate buffered saline (PBS) 123mM sodium chloride, 2.7mM 
potassium chloride, 10mM disodium 
hydrogen phosphate, 2mM potassium 
dihydrogen phosphate, pH 7 
PM 2% skimmed milk powder in PBS 
PMT 2% skimmed milk powder in PBS with 
0.05% Tween-20 
PBS/Tween PBS with 0.05% Tween-20 
Phosphate citrate buffer 0.05mM, pH 
5.0 
Sigma-Aldrich Chemie GmbH, Munich, 
Germany 
Resolving gel buffer BioRad, Hercules, California, USA 
Running buffer BioRad, Hercules, California, USA 
RPMI PAA Laboratories GmbH, Pasching, 
Austria 
Stacking gel buffer BioRad, Hercules, California, USA 
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Stripping buffer 62.5 mM Tris, 2%SDS 100 mM                      
ß-Mercaptoethanol, pH 6.7 
SOC-Medium 20 g/L bacto tryptone, 5 g/L bacto yeast 
extract, 4 g/L glucose, 2.5mM KCl, 
10mM NaCl, 5mM MgCl, pH 7.0 
Tango buffer (10x) Fermentas International Inc., Burlington, 
Canada 
Transfer buffer BioRad, Hercules, California, USA (2,5 
mM Tris, 19.2 mM Glycin, 20 % 
Methanol, pH 8.3) 
TE (1x) 10 mM Tris/HCl, 1 mM EDTA, pH 8,0 
TAE (1x) 40mM Tris, 1mM EDTA, 20mM acetate, 
pH 8.0 
T4 DNA ligase buffer New England Biolabs Inc., Beverly, USA 
Washing buffer PBS with 0.1% Tween-20 
 
3.1.5 Bacterial Strains 
 
The bacterial strains utilized in this study are displayed in Table 5. 
 
Table 5: The used bacterial strains 
Bacterial strains Company 
One Shot® Stbl3 Chemically competent 
E. coli 
Invitrogen Corporation, Carlsbad, USA 
One Shot® Stbl4 Chemically competent 
E. coli 
Invitrogen Corporation, Carlsbad, USA 
One Shot® Stbl3 Electrocompetent E. 
coli 
Invitrogen Corporation, Carlsbad, USA 
One Shot® Stbl4 Electrocompetent E. 
coli 
Invitrogen Corporation, Carlsbad, USA 
One Shot® BL21 (DE3) Chemically 
Competent E. coli 
Invitrogen Corporation, Carlsbad, USA 
One Shot® TOP10 Chemically 
competent E. coli 
Invitrogen Corporation, Carlsbad, USA 
One Shot® TOP10 Electrocompetent 
E. coli 
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Table 6: The used antibiotics 
Antibiotic Company 
Penicillin/Streptomycin (10,000 μg/ml) Biochrom, Berlin, Germany 
Ampicillin (100 μg/ml)  Carl Roth GmbH, Karlsruhe, Germany 
Kanamycin (50 μg/ml) Carl Roth GmbH, Karlsruhe, Germany 
 
3.1.7 Cell lines 
 
The eukaryotic cells used in the current research were Human Embryonic 
Kidney 293 cells referred to as HEK-293T cells, whereas the virus infection 
experiments were carried out by using C8166 cells. Cells were obtained from ATCC, 
LGC Standards GmbH, Wesel, Germany. 
 
3.1.8 Growth Media 
 
HEK 293T cells were cultivated in Dulbecco’s Modified Eagle Medium (DMEM) 
comprising 1 g/L glucose, 2 mM L-glutamine and o.5% Penicillin/Streptomycin, 10% 
FCS while C8166 cells were grown in RPMI medium containing 1 g/L glucose and L-
glutamine, supplemented with 10% FCS and 0.5% Penicillin/Streptomycin. The 
different types of the bacterial cells were grown in LB broth and agar media. 
 
3.1.9 Enzymes  
 
The enzymes included in this work are listed in Table 7. 
 
Table 7: Enzymes 
Enzyme Source 
AatII New England Biolabs Inc., Beverly, USA 
ApaI New England Biolabs Inc., Beverly, USA 
BamHI New England Biolabs Inc., Beverly, USA 
BigDye 3. 1. ABI Terminator Chemie, Applied 
Biosystems; Foster City 
ClaI New England Biolabs Inc., Beverly, USA 
DpnI New England Biolabs Inc., Beverly, USA 
EcoRI New England Biolabs Inc., Beverly, USA 
Expand High Fidelity enzyme mix Roche Diagnostics GmbH, Mannheim, 
Germany 
HindIII New England Biolabs Inc., Beverly, USA 
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Hot Star Taq- Polymerase Qiagen GmbH, Hilden, Germany 
Lysozyme Carl Roth GmbH, Karlsruhe, Germany 
NotI New England Biolabs Inc., Beverly, USA 
PstI New England Biolabs Inc., Beverly, USA 
PfuTurbo DNA Polymerase Agilent Technologies, Inc., Santa Clara, 
California, USA 
Polynukleotid kinase New England BioLabs, Ipswich 
0.05% Trypsin (pH 7.2), 0.02% EDTA 
in PBS 
Biochrom, Berlin, Germany 
SalI New England Biolabs Inc., Beverly, USA 
SpeI New England Biolabs Inc., Beverly, USA 
SacI New England Biolabs Inc., Beverly, USA 
ScaI New England Biolabs Inc., Beverly, USA 
T4 DNA Ligase Fermentas International Inc., Burlington, 
Canada 
Taq DNA Polymerase Sigma Life sciences, München 
XhoI New England Biolabs Inc., Beverly, USA 
XbaI New England Biolabs Inc., Beverly, USA 
XmaI New England Biolabs Inc., Beverly, USA 
Tth111I New England Biolabs Inc., Beverly, USA 




The specific antibodies used in Western blot analysis, ELISA test and 
Immunofluorescence assay are illustrated by Table 8.  
 
Table 8: Antibodies 
Antibody Origin Company/Source 
AlexaFluor 568 α-Mouse-
IgG (1:2000) 
Goat Invitrogen Corporation, Carlsbad, USA  






Sigma-Aldrich Chemie GmbH, Munich, 
Germany 
α-Staufen (1:4000) Rat Dr. Kirsten Hanke & Dr. Oliver Hohn 
α-HIV/SIV Gag (AG3.0) 
(1:800) 
Mouse Dr. Stephen Norley 
α-V5-Tag (1:5000) 
 
Mouse AbD Serotec, MorphoSys AG, Martinsried, 
Deutschland 
α-GAPDH (1:1000) Mouse Sigma-Aldrich Chemie GmbH, Munich, 
Germany 
α-Rat IgG-HRP (1:5000) Goat LI-COR, Lincoln, Nebraska, USA 
α-V5-HRP (1:5000) Mouse Invitrogen Corporation, Carlsbad, USA 
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α-V5-agarose Mouse Sigma-Aldrich Chemie GmbH, Munich, 
Germany 
α-Rabbit IgG-HRP (1:5000) Donkey LI-COR, Lincoln, Nebraska, USA 
α-Human IgG-HRP (1:2000) Rabbit Sigma-Aldrich Chemie GmbH, Munich, 
Germany 




Mouse Jackson Immuno Research, Baltimore, 
USA 
α-Mouse-IgG-Cy3 (1:750) Goat Jackson Immuno Research, Baltimore, 
USA 
Monoclonal α-HERV-K Gag 
Herma 7 (1:100) 
Rat PEI, Langen 
α-HERV-K capsid (1:5000) Rat George et al. [144] 
HIV plasma pool (1:2000) Human Dr. Stephen Norley 
α-HERV-K113-Rec (1:1000) Rat Hanke et al. [141] 









All oligonucleotides were synthesized and lyophilized by Invitrogen 
Corporation, Carlsbad, USA and Life Technologies GmbH, Darmstadt, Germany. The 
sequencing primers used are listed in Table 9, while the primers for DNA 
mutagenesis reactions are mentioned in Table 10. 
 
Table 9: Sequencing primers 
Primer name Primer sequence 5’→ 3’ 
BGH-Rev TAGAAG GCA CAG TCG AGG 





H1-up Seq-For TCGCTATGTGTTCTGGGAAA 
Seq-pBSK-ori- 9011- F CACTGGGACATGGTTAGACG 
Seq-pBSK-ori- 9556 -R TCCTGCACCGCCCTTAATCC 
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Seq-pBSK-ori -8053 -R CGCACTATTGGCCACACATTC 








pLVTHMShRNA staufen 3084 (Forward) TCGCTATGTGTTCTGGGAAA 
pLVTHMShRNA staufen 3084(Reverse) ATTTAGGTGACACTATAG 
 
Table 10: Mutagenic oligonucleotide primers 






























3.1.12 Ladders and Standards 
 
The DNA and protein markers utilized for the DNA gel electrophoresis and 
Western blot tests are shown in Table 11. 
 
Table 11: Ladders and Standards 
Ladder Company 
PageRuler Prestained Protein Ladder Thermo Scientific, Logan, USA 
PageRuler Plus Prestained Protein 
Ladder 
Thermo Scientific, Logan, USA 
Generuler 100 bp Ladder Fermentas International Inc., Burlington, 
Canada 
Generuler 100 bp Plus Ladder Fermentas International Inc., Burlington, 
Canada 
Generuler 1 kb Ladder Fermentas International Inc., Burlington, 
Canada 









pCMV-Tag2b Agilent Technologies, Inc., Santa Clara, 
California, USA 
pLVTHM Tronolab, Lausanne 
pcDNA4-V5-His/B Invitrogen Corporation, Carlsbad, USA 
pVSV‐G Tronolab, Lausanne 
psPAX2 Tronolab, Lausanne 
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3.1.14 Recombinant Plasmids 
 
The recombinant plasmids utilized in this study are listed in Table13. 
 
Table 13: Recombinant Plasmids 
Recombinant Plasmid Source/Publication 
pLVTHM-shStauen_A7 Jula Wamara (Exon 14, 
GCTGCGCTGAACATCTTAAAG) [145]  
pLVTHM-shStauen_A2C4 Jula Wamara (Exon 8/9, 
GCCACAGACAAGCCCAGAATA) [145] 
pLVTHM-shStauen_B3 Jula Wamara (Exon 15, = 3’-UTR, 
GCAGGGAAGACAACAGAAACA) [145]  
pLVTHM-shStauen_C1 Jula Wamara (Exon 6/7, 
GGAGGTGAATGGAAGAGAATC) [145]  
pLVTHM-shStauen_C3 Jula Wamara (Exon 8b, 
GCCTGCAGTTGAACGAGTAAA) [145] 
pLVTHM-shStaufen-3086 In this study (Exon 15, = 3’-UTR, 
aaatagcacagtttggaaact) 
pLVTHM-shCofilin Jula Wamara [145] 
Shuttle Hanke et al.[141] 
Shuttle HIV-2RRE Anna Klara-Amler [143] 
pCMV-Renilla luciferase Dr. Kirsten Hanke 
pCMV-FLAG-Staufen-1 Hanke et al. [141]  
pCMV-FLAG-Staufen-1_F135A Jula Wamara [145]  
pCMV-FLAG-Staufen-1_ΔRBD3 Jula Wamara [145] 
pCMV-FLAG-Staufen-1_ΔRBD4 Jula Wamara [145]  
pCMV-FLAG-Staufen-1_ΔTBD/RBD5 Jula Wamara [145] 
pET-16b- V5-Staufen-1  Dr. Kirsten Hanke 
pCDNA3-V5-Staufen-1 Hanke et al. [141]  
pCDNA3-V5-HERV-K113-orico Rec  Hanke et al. [141] 
pCDNA3-V5-HIV-1-coRev In this study 
pCDNA4-V5-SIVmac-coRev In this study 
pCMV-FLAG- SIVmac-coRev In this study 
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pBR_SIVmac239 full length molecular 
clone 
kindly provided by F. Kirchhoff, 
University Ulm 
pNL4-3 HIV-1 molecular clone The following reagent was obtained 
through the NIH AIDS Reagent Program, 
Division of AIDS, NIAID, NIH: pNL4-3 
from Dr. Malcolm Martin [146] 
pBSK ori HERV-K113 molecular clone Chudak et al. and George et al. [147] 
[144] 
ovalbumin expression vector (pTH-OVA) Dr. Oliver Hohn 
pCMV-FLAG-SIVmac-coRevΔ31 In this study 
pCMV-FLAG-SIVmac-coRevΔ59 In this study 
pCMV-FLAG-SIVmac-coRev-ΔM5 In this study 
pCMV-FLAG-SIVmac-coRev-ΔSLT40 In this study 
SHIV luciferase reporter gene Dr. Veronika Lausch 
pBSK ori HERV-K113BCD Prof. Dr. Norbert Bannert 
Mut-SD2-ori-BCD In this study 
Mut-SA2-ori-BCD In this study 
Deleted-SD2-ori-BCD In this study 
pBSK ori HERV-K113 ΔRec In this study 
pCDNA4a-V5-np9-5q33-GFP Dr. S. Stengel 


















In table 14, Software used is shown. 
 
Table 14: Software 





Microsoft Office 2010 



























3.2.1 Cell culture 
 
3.2.1.1 Growth conditions 
 
HEK-293T cells were cultivated in DMEM medium containing 1 g/L glucose 
and L-glutamine, supplemented with 10% fetal calf serum (FCS) and 0.5% 
Penicillin/Streptomycin. C8166 cells were grown in RPMI 1860 medium containing 1 
g/L glucose and L-glutamine, supplemented with 10% FCS and 0.5% 
Penicillin/Streptomycin. All cell lines were cultured at 37 °C in a humidified 5% CO2 
atmosphere. 
 
3.2.1.2 Cell splitting 
 
For splitting of HEK-293T cells and C8166 cells, the conditioned growth 
medium was discarded, cells were washed once with 10mL 1x PBS and 
Trypsin/EDTA was added and gently mixed around the flask. The trypsin/EDTA 
treated cells were incubated for 3 min in 37°C CO2 incubator. Afterwards, cells were 
rinsed from the culture flask by adding fresh growth medium, transfered to 50ml 
centrifuge tube and spinned down at 300g for 5 min. The supernatant was discarded 
and cells were resuspended in fresh growth medium. An appropriate number of cells 
were dispensed to a new culture flask containing fresh growth medium and placed 
back into the 37°C CO2 incubator. 
 
3.2.1.3 Sowing cells 
 
First, cells were washed and treated with trypsin/EDTA as described above 
(see 3.2.1.2). Suspended cells were counted using the Coulter Counter Z2 and sown 
into multiwell plates and 100 mm dishes for transfection and infection experiments. 
Cells were sown in a proper cell number with a given volume of fresh growth medium 
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Table 15: Parameters for cell transfection in different reservoirs. 
Type of 
Reservoir 
Cell number to 
sow 
Cell yield Medium volume 
(ml) 
T300 flask (300 
cm2) 
15 * 106 cells/ml 3.6 * 107 cells/ml 200 
T150 flask (150 
cm2) 
7.5 * 106 cells/ml 18.4*106 cells/ml 20 
100 mm dish 1 * 106 cells/ml 4 * 106 cells/ml 10 
6-well plate 3 * 105 cells/ml 2.4 * 106 cells/ml 3 
12-well plate 6 * 104 cells/ml 2.4 * 105 cells/ml 1 
96-well plate 1 * 104 cells/ml 4 * 104 cells/ml 0.3 
 
3.2.1.4 Transfection  
 
Cells cultured in 100 mm dishes were transfected by using the calcium 
phosphate transfection technique. One day before transfection, cells were grown as 
previously described (see 3.2.1.3). At approximately 80% the cells were transfected 
with the following calcium phosphate-DNA mixture:  15 – 30 μg DNA was diluted and 
brought to a final volume of 450 μl with double distilled water. The mixture was gently 
mixed and then 50 μl 2.5M CaCl2 was added and gently mixed again. Subsequently, 
drops of the DNA mixture were carefully pipetted onto the surface of 500 μl               
2x HEPES in a 1.5ml tube. The DNA mixture was incubated for 30 min at room 
temperature for complex formation. During incubation period, cells were washed 
once with 10 ml 1x PBS and a fresh growth medium was added. This transfection 
mixture was transferred to the cells dropwise and the dish was swirled gently to 
confirm uniform distribution of the DNA complexes. In the following day, the 
conditioned growth medium was discarded; cells were washed once with 10 ml 1x 
PBS and new growth medium was added. Cells grown in 6-well, 12-well or 96-well 
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3.2.1.5 Cell lysis and preparation of supernatant 
 
Before cell lysis 48 h post transfection the supernatant was collected, cell free 
centrifuged at 1500g for 10 min, aliquoted and stored at -80 °C. For transfection with 
the pBSK-HERV-K113 molecular clone, cell culture supernatants were centrifuged at 
27410g and 4 °C for three hours to pellet the virus. The supernatants were carefully 
discarded followed by dissolving the virus pellets in 80 μl 0.5% NP-40 or 0.5% 
IGEPAL lysis buffer. The cells were washed once with ice-cold 1x PBS. After 
removing PBS, an appropriate volume of 0.5% NP-40 or IGEPAL lysis buffer with 
fresh protease inhibitor was added. By using a cell scraper, the cells were removed 
from the dishes or plates, agitated at 4 °C for 30 min to ensure the cell lysis and the 
lysate was centrifuged at 13400g and 4 °C for 20 min. The supernatant was carefully 




For the infection with full length SIVmac239 virus the cells at an appropriate 
density were sown in 100 mm dishes. After one day, 1 ml of the virus stock was 
added to the cells in 9 ml fresh growth RPMI medium containing 1 g/L glucose and L-
glutamine,  supplemented with 10% FCS and 0.5% Penicillin/Streptomycin. One day 
post infection, the old media were discarded and replaced with fresh growth media.  
Afterwards, the supernatants were collected at 4, 6, and 8 days post incubation, and 
the concentration of Gag protein was determined by ELISA. 
 
3.2.2 DNA analysis 
 
3.2.2.1 Polymerase Chain Reaction (PCR) 
 
PCR assay was applied to amplify the target DNA segment in vitro. This 
reaction was performed by using specific PCR primers and Taq DNA polymerase 
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Table 16: The components of PCR reaction 
Component Concentration Volume Final concentration 
Standard Taq 
reaction  buffer/ 
25 mM MgCl2 
10x 2.5 μl 1x 
dNTPs 2.5 mM each 1 μl 0.1 mM each 
Forward primer 10 μM 1 μl 400 nM 
Reverse primer 10 μM 1 μl 400 nM 
Template  DNA - 500 pg - 100 ng - 
Taq polymerase 250 U/μl 0.125 μl 1.25 U/μl 
Double distilled 
water 
- To 25 μl - 
 
PCR cycling conditions for DNA amplification were given in Table 17. The 
annealing temperature is variable depending on the PCR primers used in this 
technique. 
 
Table 17: Thermocycling conditions for PCR assay 
Step Temperature Time Number of cycles 
Initial denaturation 95 °C 10 min 1 
Denaturation 95 °C 30 sec  
35 Annealing X °C 20 sec 
Extension 72 °C 1 min 
Final extension 72 °C 5 min 1 
 
3.2.2.2 Expand High Fidelity PCR 
 
Expand High Fidelity PCR System contains a mixture of Taq (Thermus 
aquaticus) DNA polymerase and Tgo (Thermococcus gorgonarius) DNA polymerase 
with proofreading activity for higher DNA yield, synthesis, accuracy and Repair of 
mismatched primers at 3’ end. Two PCR reaction mixtures were prepared to avoid 
partial degradation of the primers and the template DNA by the 3’-5’ exonuclease 
activity of the proofreading polymerase. After setting up the reaction both mixtures 
were combined. The components of the reaction mixes and thermal profile for 
Expand High Fidelity PCR are included in Table 18 and Table 19 respectively. 
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Table 18: The compositions of the reaction mixtures for Expand High Fidelity PCR 
Reaction Mixture 1 
Component Concentration Volume Final concentration 
dNTPs 10 mM each 1 μl 200 μM each 
Forward primer 10 μM 1.5 μl 300 nM 
Reverse primer 10 μM 1.5 μl 300 nM 
Template  DNA - 50 ng-250 ng - 
Double distilled 
water 
- To 25 μl - 
Reaction Mixture 2 
Component Concentration Volume Final concentration 
Expand High Fidelity 
buffer/ Mgcl2 
10x 5 μl 1x 
Expand High Fidelity 
enzyme mixture 
3.5 U/μl 0.75 μl 2.6 U 
Double distilled 
water 
- To 25 μl - 
  
Table 19: The thermal profile of Expand High Fidelity PCR 
Step Temperature Time Number of cycles 
Initial denaturation 94 °C 2 min 1 
Denaturation 94 °C 15 sec  
10 Annealing X °C 30 sec 
Extension 68 °C 8 min 
Denaturation 94 °C 15 sec  
20 Annealing X °C 30 sec 
Extension 68 °C 8 min+5 s 
Final extension 72 °C 7 min 1 
 
3.2.2.3 DNA Mutagenesis 
 
The PCR Site directed mutagenesis method was performed to introduce 
mutations in the DNA sequence of the desired gene, causing either substitution or 
deletion of amino acids. The QuikChange Site-Directed Mutagenesis method was 
carried out according the protocol of the manufacture. The sample reaction is 
indicated in Table 20, while the cycling parameters for the site-directed mutagenesis 
PCR is given in Table 21. 
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Table 20: sample reaction of site directed mutagenesis 
Component Concentration Volume Final 
concentration 
Reaction  buffer/ 25 mM MgCl2 10x 5 μl 1x 
dNTPs 2.5 mM each 1 μl 500 nM each 
Forward primer 10 μM 1 μl 200 nM 
Reverse primer 10 μM 1 μl 200 nM 
Template  DNA - 50 ng - 
PfuTurbo DNA Polymerase 2.5 U/μl 1 μl 0.05 U/μl 
Double distilled water - To 50 μl - 
 
Table 21: Cycling parameters for site-directed mutagenesis PCR 
Step Temperature Time Number of cycles 
Initial denaturation 95 °C 30 seconds 1 
Denaturation 95 °C 30 seconds  
18 Annealing 55 °C 1 min 
Extension 68 °C 1 minute/kb of DNA 
Additionally, the QuikChange® Multi Site-Directed Mutagenesis Kit was 
carried out according to the manufacturer’s instructions. The Mutant Strand Synthesis 
Reaction and the cycling parameters for Multi-Site-Directed Mutagenesis assay are 
stated in Table 22 and Table 23 respectively. 
 
Table 22: The Mutant Strand Synthesis Reaction 
Component Concentration Volume Final concentration 
QuickChange Multi Reaction  
buffer/ 25 mM MgCl2 
10x 2.5 μl 1x 
QuikSolution - 0.5 μl  1x 
dNTPs 2.5 mM each 1 μl 1 mM each 
Forward primer 10 μM 1 μl 400 nM 
Reverse primer 10 μM 1 μl 400 nM 
Template  DNA - 100 ng - 
PfuTurbo DNA Polymerase 2.5 U/μl 1 μl 0.1 U/μl 
Double distilled water - To 25 μl - 
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Table 23: Cycling parameters for the Multi-site-directed mutagenesis PCR 
Step Temperature Time Number of 
cycles 
Initial denaturation 95 °C 1 min 1 
Denaturation 95 °C 1 min  
30 Annealing X °C 1 min 
Extension 65 °C 2 minute/kb of plasmid length  
 
Following DpnI digestion, the site-directed mutagenesis PCR products were 
transformed into bacterial cells (see 3.2.2.8), plasmid DNA was extracted (see 
3.2.2.9) and sequenced (see 3.2.2.11). To verify the successful mutation, the original 
sequences were aligned with the mutated sequences using MegAlign. 
 
3.2.2.4 Restriction Enzyme Digest 
 
Restriction enzymes referred to as digestion endonucleases that cleave 
double-stranded DNA (dsDNA) at specific sequences within or adjacent to their 
recognition sites generating ends with 5 'overhang. Each restriction enzyme has its 
specific optimal reaction buffer which yields 100% activity for the enzyme. In Table 
24, the restriction enzyme digest reaction is shown. 
 
Table 24: Components of the restriction digest reaction 
 Component Volume for cloning Volume for detection of 
the target plasmid 
Restriction Enzyme 10X 
Buffer 
3 μl 2 μl 
10x BSA 3 μl 2 μl 
Restriction Endonuclease 1 μl 0.5 μl 
DNA 5 μg 0.5-1 μg 
Double distilled water To 30 μl To 20 μl 
 
The DNA digestion mixtures were gently mixed by pipetting, and centrifuged 
for a few seconds in a microcentrifuge and then incubated at the enzyme’s optimum 
temperature (25°C or 37°C) for 2 hours.  After incubation, loading buffer to a 1X final 
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concentration was added and proceeded to gel electrophoresis analysis (see 
3.2.2.5). 
 
3.2.2.5 Agarose Gel Electrophoresis 
 
Agarose gel electrophoresis was used to separate a population of the mixed 
DNA molecules by their length in agarose gel matrix. This method was performed by 
adding an appropriate amount of a powdery agarose (0.8 g to 1.5 g) to 50 ml or 100 
ml 1x TAE electrophoresis buffer according to the expected DNA size. Subsequently, 
agarose gel was completely dissolved in the buffer by heating in a microwave until a 
clear, transparent solution was observed. Ethidium bromide to a final concentration of 
0.5 µg/ml were added to the molten agarose, gently mixed by swirling and poured 
into a mold containing a suitable comb allowing hardening. Upon solidification, 
samples mixed with an appropriate quantity of 6x DNA loading buffer were slowly 
loaded into the slots of the submerged gel. Also, the approximate length of the DNA 
fragment was identified by loading Generuler 1 kb Ladder, Generuler 1 kb Plus 
Ladder, Generuler 100 bp Ladder, or Generuler 100 bp Plus Ladder, according to the 
expected length of the target DNA fragments. Voltage of electrophoresis was applied 
at 70 to 80V for 60-90 min. After migration of the DNA samples until a sufficient 
distance, the DNA bands were examined by UV Transilluminator or Gel 
Documentation machine 2000. 
 
3.2.2.6 Purification of the DNA fragments 
 
3.2.2.6.1 Purification of the PCR product 
 
Purification of PCR products was achieved using the QIAquick PCR 
Purification Kit (Qiagen) according to the manufacturer's instructions. The DNA 
fragments with a length of 100 bp up to 10 kb were isolated by binding to silica-
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3.2.2.6.2 Gel Extraction 
 
The DNA fragments were separated depending on their sizes using agarose 
gel electrophoresis (see 3.2.2.5). Upon the DNA fragment separation, the gel was 
placed on UV Transilluminator, and the target DNA bands were excised with a clean 
scalpel. The target DNA fragments were purified from agarose gels by applying the 
QIAquick Gel Extraction Kit according to the manufacturer's instructions by which the 
extracted gel was dissolved in a binding buffer at 50 °C and then DNA was bound to 
a silica gel membrane, washed and isolated by elution with 30 μl elution buffer EB or 




Digested DNAs were inserted into a digested DNA vector backbone to create 
a recombinant vector by T4 DNA ligase, which catalyzes the formation of 
phosphodiester bonds between the free 3’ hydroxyl end of one DNA terminus with 
the 5’ phosphate end of another one. The compositions of the ligation mixture are 
displayed in Table 25. 
 
Table 25: Ligation reaction 
Component Volume 
10x ligation Buffer 2 µl 
Insert X µl 
Vector X µl (40 ng – 100 ng) 
T4 DNA Ligase 1-2 µl 
Double distilled water To 20 µl 
 
The concentration of the DNA insert used was calculated according to the 
following equation: 
 
mass insert [ng] = 3 to 5 x mass vector [40 - 100 ng] x length insert [bp] / length vector [bp] 
 
The molar ratio of the insert to vector in this experiment was 3-5, while the 
quantities of the vector used for ligation were in between 40-100 ng. The ligation 
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mixture was incubated at room temperature/1 h, 4°C or 16 °C/overnight. The DNA 
ligate was then transformed into electro-competent or chemically-competent bacterial 




The bacterial transformation process was performed by gentle mixing of the 
ligates (recombinant plasmids) with chemically competent or electrically competent 
E.coli cells. For chemical transformation, the mixture was incubated on ice for 30 min 
followed by heat shock at 42 °C for 45 seconds and then the mixture was incubated 
on ice for 2 min. 500 μl SOC medium were added to the mixture and incubated at     
37 °C for 1h with gentle agitation. Transformation by electroporation was achieved by 
adding the DNA to electro-competent cells and transferred to an electroporation 
cuvette and pulsed at 2.5 kV, 25 μF and 200 Ohm using the Gene Pulser II (BioRad). 
Subsequently, 500 μL SOC medium were added immediately and the mixture were 
incubated at 37 °C for 1h. Upon transformation, the transformed cells were plated on 
LB agar plates containing Ampicillin or Kanamycin for selection of the target 
transformed bacterial colonies. The LB agar plates were incubated at 37 ºC for 24 
hours or room temperature for 48 hours. 
 
3.2.2.9 Plasmid Isolation 
 
Transformed cultured colonies were selected and grown in LB broth media 
with a selective antibiotic at 37ºC/overnight with shaking. 500 μl bacterial culture 
were added to 50% sterilized glycerol and stored at - 80 ºC as a glycerol stock. The 
plasmid DNA was purified using the QIAprep Spin Miniprep Kit or Endo-free Plasmid 
Maxi Kit according to the manufacturer’s instructions. The principle of these protocols 
is based on the alkaline lysis of bacterial cells. Since bacterial genomic DNA and 
plasmid DNA are similar in chemical nature, the only way to separate them is by 
physical mean; upon alkaline lysis of bacterial cell membrane, a bacterial genomic 
DNA remains attached and is precipitated with other cell debris while plasmid DNA is 
adsorbed onto silica membrane in presence of high salt. The prepared DNA was 
dissolved in 50 μl buffer EB by the QIAprep Spin Miniprep Kit or in 200-300 μl using 
the Endo-free Plasmid Maxi Kit. 
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3.2.2.10 Colony PCR 
 
This technique is designed to quickly detect the desired plasmid DNA directly 
from bacterial colonies growing on LB agar plates. This protocol was carried out by 
choosing the bacterial colonies and resuspending the bacterial cells in 10 μl double 
distilled water. For the colony PCR assay, 5 μl of the bacterial suspension were used 
as template DNA, while the rest was stored at 4 ºC for inoculation of overnight 
cultures. The components of the PCR reaction are listed Table 26. 
 
Table 26: The compositions of the colony PCR assay. 
Component Concentration Volume Final concentration 
 
PCR buffer/25 mM 
MgCl2 
10x 2.5 μl 1x 
DMSO 50% 2.5 μl 10% 
dNTPs 2.5 mM each 1 μl 1 mM each 
Forward primer 10 μM 0.5 μl 200 nM 
Reverse primer 10 μM 0.5 μl 200 nM 
Template DNA - 5 μl - 
Taq polymerase 250 U/μl 0.125 μl 1.25 μl 
Double distilled 
water 
- To 25 μl - 
 
Thermocycling conditions for the colony PCR assay are shown in Table 27. 
 
Table 27: Cycling parameters for the colony PCR assay 
Step Temperature Time Number of cycles 
Initial denaturation 95 °C 10 min 1 
Denaturation 95 °C 20 sec  
35 Annealing X °C 20 sec 
Extension 72 °C 1 min 
Final extension 72 °C 5 min 1 
 
To screen the desired DNA insert, part of the PCR products was loaded 
directly onto an agarose gel using an appropriate DNA ladder.  
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3.2.2.11 Sequencing PCR 
 
For sequencing reaction, BigDye 3.1 (ABI Terminator Chemie, Applied 
Biosystems) was utilized which contains AmpliTaq DNA polymerase 
and dNTPs and fluorescence-labeled 2', 3'-Didesoxynucleotrisphosphats 
(ddNTPs). Read-out of the sequencing PCR was performed by the RKI sequencing 
core facility. The analysis of sequence was performed by BioEdit and MegAlign 
Sequence program. The components and the cycling parameters for the sequencing 
PCR assay are included in Table 28 and Table 29 respectively. 
 
Table 28: The compositions of the sequencing PCR assay 
Component Concentration Volume Final 
concentration 
 
ABI buffer/25 mM 
MgCl2 
5x 1.5 μl 0.75x 
BigDye 3.1 - 1 μl - 
Template DNA - X µl (200 ng – 300 ng) - 
Sequencing 
primer 
10 μM 0.5 μl 500 nM 
Double distilled 
water 
- To 10 μl - 
 
Table 29: The cycling parameters of the sequencing PCR reaction 
Step Temperature Time Number of cycles 
Initial denaturation 95 °C 5 min 1 
Denaturation 95 °C 20 sec  
35 
 
Annealing X °C 20 sec 
Extension 72 °C 1 min 
Final extension 72 °C 5 min 1 
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SDS-PAGE (sodium dodecyl sulfate polyacrylamide gel electrophoresis) was 
achieved for separation of proteins based on their molecular weight under the effect 
of an applied electrical field. The electrophoretic analysis was performed in the Mini- 
Protean II Dual-Slab Cell, (BioRad, USA) using 12% acrylamide for resolving 
(separating) gel and 5% acrylamide for stacking gel. The components of SDS gels 
are shown in Table 30. 
 
Table 30: The components of SDS gels 
Component Resolving gel Stacking gel 
1.5M Tris-HCl Buffer pH 8.8 2.5 ml - 
0.5M Tris-HCl Buffer pH 6.8 - 2.5 ml 
Rotiphorese® Gel 30 (37.5:1) 4 ml 1.7 ml 
10% SDS 100 μl 100 μl 
APS 50 μl 50 μl 
TEMED 5 μl 10 μl 
Double distilled water 3.4 ml 5.7 ml 
 
The SDS-PAGE analysis was performed by dissolving samples in an 
appropriate volume of 4x Laemmli dissociation buffer and boiled at 95 °C for 5 min. 
Sample mixtures containing the HIV coRev or SIVmac coRev proteins were 
denatured at 60 °C for 5 min. The heating step is important for destruction of the 
protein tertiary structure and conversion of the target proteins into a linear form. The 
heated samples were carefully loaded under buffer on top of the gel. The 
electrophoresis was applied under a voltage of 100V for 10 min and later set to 180V 
for 60 min until the tracking dye was near the bottom of the gel. For determination of 
the size of the observed proteins, PageRuler Prestained Protein Ladder or 
PageRuler Plus Prestained Protein Ladder were loaded into the gel. Subsequently, 
the gels were stained with Coomassie Brilliant Blue G Concentrate or used for 
Western Blot analysis. 
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3.2.3.2 Western Blot Analysis 
 
Following the SDS-PAGE assay, Western blot was applied to transfer the 
separated proteins from the electrophoresis gel to a Polyvinylidene flouride (PVDF) 
or nitrocellulose membranes. First, the SDS gels were equilibrated in transfer buffer 
for 20 min. PVDF membranes were activated by methanol for 5 min followed by 
equilibration in transfer buffer for 10 min, whereas nitrocellulose membranes were 
directly equilibrated by transfer buffer. Western Blot assay was done based on semi-
dry blotting therefore; the gel was sandwiched between two filter papers moistened 
with transfer buffer. Immunoblotting was carried out at 10 - 20V for 40 min. Next, the 
membranes were blocked using blocking buffer for one hour at room temperature to 
inhibit the nonspecific binding of antibodies to the surface of the membrane. The 
transferred protein was incubated with a diluted primary antibody at 4 °C/overnight or 
at room temperature for one hour. Excessive washing with a washing buffer three 
times for 10 min was performed to remove unbound primary antibodies and then the 
membranes were incubated with the diluted horseradish peroxidase (HRP) 
conjugated secondary antibody at room temperature for one hour followed by 
washing of the membranes with a washing buffer three times for 10 min. Afterwards, 
the Super Signal West Dura Extended Duration Substrate was added to the 
membranes to detect the bound HRP labelled antibodies because the substrate 
combines with the enzyme producing light as a byproduct. The light output can be 
captured by the exposure of the membranes to X-ray film followed by the 
development of the film by a film processing machine. 
 
3.2.3.3 Protein Co-Immunoprecipitation 
 
Coimmunoprecipitation (co-IP) method was used in this work to study the 
protein-protein interaction and complex formation of various proteins as shown in 
Figure 13. 
 





Figure 13: Schematic representation of a conventional co-IP 
experiment. To assess the interaction between two 
proteins, cells were transfected with expression 
constructs for these proteins and after 48 hours, cells 
were lysed followed by incubation with agarose 
beads coated with an antibody specific for the first 
protein (Red color). The beads were precipitated and 
then washed. Western Blot analysis was achieved 
using antibody specific for the other protein (Blue 
color). The positive result indicates the successful 
binding between these proteins [148]. 
 
HEK 293T cells were seeded as previously described (see 3.2.1.3) in 100 mm 
dishes. The next day, the cells were transfected using calcium phosphate (see 
3.2.1.4). 48 hour post transfection, the supernatants were discarded, and 920 μl lysis 
buffer were added to each dish containing the transfected cells. By using a cell 
scraper, the cells were removed from the dishes followed by agitation at 4 °C for 30-
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45 min for complete lysis of the cells. To purify the cell lysate from the cell debris, 
centrifugation was performed at 13500g for 20 min at 4 °C and the supernatant was 
collected. 750 μl cell lysate was mixed with 30 μl of antibody-tagged agarose beads, 
completed with lysis buffer to a total amount of 1 ml and agitated at 4 °C/ overnight. 
After overnight incubation, the mixtures of the cell lysates were washed 10 times with 
lysis buffer. The mixtures in each washing step were centrifuged at 2000g at 4 °C for 
5 min. The agarose beads were resuspended in 40 μl 4x Laemmli sample buffer with 




Immunofluorescence was applied for examination of the intracellular antigens 
using fluorescence labeled antibodies. HEK-293T cells were cultured onto cover slips 
in 6-well plates and transfected as previously described (see 3.2.1.2, 3.2.1.3 and 
3.2.1.4). 48 h post transfection, cells were washed with 1x PBS and fixed with 2% 
paraformaldehyde (PFA) for 30 min at room temperature (RT). The cells were then 
washed with three times 1x PBS for 5 min to remove the excess of PFA. Afterwards, 
Cells were permeabilized by treatment with 0.5% Triton-X 100 for 30 min at room 
temperature and then washed three times with 1x PBS for 5 min. Subsequently, 1% 
skimmed milk powder in 1x PBS was added to the cells for one hour at RT to prevent 
nonspecific binding of antibodies. After that, the cells were incubated with the diluted 
specific primary antibody at 37 °C for one hour followed by washing with 1x PBS 
three times for 5 min. Thereafter, the diluted fluorescence labeled secondary 
antibody was added to the cells for one hour at RT. Next, the cells were again 
washed thoroughly. Cover slips were embedded in Mowiol or Mounting medium with 
Dapi and stored in dark conditions at 4 °C/overnight. The preparations were analyzed 
using a Zeiss confocal laser scanning microscope LSM780. 
 
3.2.3.5 CA-Antigen Capture ELISA 
 
The enzyme linked immunosorbent assay was applied for detection of HERV-
K113, HIV-1 and SIVmac viruses in cell culture supernatants and cell lysates. ELISA 
method is highly specific, and was achieved for measurement of the amount of viral 
Gag p24 and p27 particles. 96-well microtiter plates were coated with monoclonal α-
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HERV-K Gag Herma 7 (for HERV-K) or monoclonal α-SIV Gag AG3.0 (for HIV-1 or 
SIVmac) antibody diluted in carbonate bicarbonate buffer followed by incubation at                    
4 °C/overnight. Each well of antibody coated plates was washed three times with    
200 μl PBS/Tween-20/well and then the surface of plate wells were blocked with 200 
μl blocking buffer/well at 37 °C for one hour to prevent nonspecific interactions. The 
samples were inactivated by incubation with Tween-20 in a final concentration of 
0.02% at room temperature (RT) for 10 min. Thereafter, the blocking buffer was 
discarded, and the inactivated samples were added to the ELISA plate wells 
containing blocking buffer for the titration and incubated at 37 °C for one hour.  The 
sample solutions were removed and the wells were washed three times with 200 μl 
PBS/Tween-20. The primary antibody was added to each well either 50 μl HIV-1 
plasma pool/well diluted in PMT (1:1000) specific for HIV-1 and SIVmac or 50 μl rat 
α-HERV-K Gag/well diluted in PMT (1:5000) specific for HERV-K113. The plates 
were incubated at 37 °C for one hour and washed then three times with 200 μl  
PBS/Tween-20. 50 μl α-Human IgG-HRP diluted in PMT (1:1000) or 50 μl α-Rat IgG-
HRP diluted in PMT (1:2500)  were transferred to the wells and incubated at 37 °C 
for one hour followed by the step of washing with 200 μl PBS/Tween-20. For 
detection of the peroxidase conjugated antibody, substrate was prepared by 
dissolving 5 mg OPD in 12.4 ml phosphate citrate buffer pH 5.0 mixed with 12 μl 
H2O2. 
 
3.2.3.6 RT Activity Technique 
 
For detection and quantification of the retroviral reverse transcriptase activity 
in the sample, the Cavidi RT Activity assay was achieved for analysis of the virus 
infectivity according to the manufacturer’s instructions. This experiment is based on 
two steps, the DNA biosynthesis and the DNA quantifi cation. The RNA template is 
bound to the bottom of the plate. Next, primer, a nucleotide (BrdUTP) and the sample 
are added to the plate. The reverse transcriptase enzyme found in the sample will 
synthesise a DNA-strand. An alkaline phosphatase (AP) conjugated α-BrdU antibody 
specifically binds to the double stranded DNA/RNA molecule. Addition of a 
colorimetric AP substrate will result in quantifying the product. The AP activity is 
proportional to the RT activity in the sample. 
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3.2.3.7 Luciferase Reporter Assay 
 
The luciferase assay is employed as an indicator to assess the gene 
expression at the transcriptional level. This technique is depending on the luciferase 
enzyme which catalyzes the biochemical conversion of luciferin to oxyluciferin 
leading to light emission (e.g. firefly luciferase found in the firefly Photinus pyralisis).  
 
      luciferin + ATP                                              luciferyladenylate + PPi 
 
luciferyladenylate + O2                                       oxyluciferin + AMP + light 
 
The light output is associated with the amount of RNA exported into the 
cytoplasm for the luciferase enzyme biosynthesis. The firefly luciferase activity was 
evaluated by Dual-Glo® Luciferase Assay System or Luciferase 1000 Assay System 
according to the manufacturer’s instructions as follow: One day prior cell transfection, 
HEK-293T cells were seeded in 96-well plates (see 3.2.1.3). The next day, cells were 
transfected (see 3.2.1.4) with constructs containing genes of interest, shuttle vectors 
encoding for firefly luciferase as a reporter gene and with a vector encoding Renilla 
luciferase as internal control for normalization. 48 h post transfection, medium was 
removed and cells were washed once with 200 μl 1x PBS per well. Following 
washing, the cells were lysed with 20 μl 5 x passive lysis buffer per well and then the 
plates were rotated using shaker machine at room temperature for 15 min. After 
allowing the cell lysis, the cell lysates were transferred onto a white optical 96-well 
plate (Nunc) and then 100 μl the firefly luciferase reagent (LARII) was added to each 
well, followed by addition of 100 μl the Renilla luciferase reagent and firefly 
quenching (Stop & Glo buffer). The intensity of bioluminescence was measured using 
the Berthold Luminometer Centro LB 960. 




4.1 Effect of Staufen-1 overexpression on the retroviral particles production 
 
Staufen-1 is considered as one of cellular multifunctional proteins because 
some studies clarified its role in the nucleocytoplasmic RNA shuttling [128] [132], 
while others demonstrated the significance of Staufen-1 in mediating the rate of 
translation and viral RNA encapsidation [129] [139]. One of the objectives of this 
study was therefore to analyze the impact of Staufen-1 overexpression on the 
expression level of HERV-K113, HIV-1 and SIVmac239. 
 
4.1.1 Staufen-1 promotes the generation of HERV-K(HML-2) particles 
 
The expression level of Gag protein and viral like particles (VLPs) of the native 
HERV-K113 sequence is very low, causing difficulties in detection. This is attributed 
to mutations within the proviral DNA generated after the insertion into the human 
genome [144]. In earlier work, Hanke et al. indicated that the overexpressed Staufen-
1 elevated the level of oriHERV-K113 particles by an average of 20-fold [141]. Based 
on this finding, the aim of this experiment was to further investigate the dose-
dependent influence of Staufen-1 overexpression on viral particle production derived 
from the reconstituted oriHERV-K113 sequence. This was performed by transfection 
of HEK-293T cells with 1µg of the pBSK_oriHERV-K113 molecular clone and 
different concentrations of pCMV-FLAG-Staufen-1 DNA (0.125 µg, 0.5 µg, 2 µg). 
Control cells were transfected either with an empty pcDNA4-V5-His/B vector or 
pCMV-FLAG-Staufen-1 DNA alone as negative controls. Staufen-1 is necessary for 
viral replication by enhancing viral mRNA export, initiating the translation process and 
inducing virus packaging and release. The supernatants were therefore collected     
48 h post transfection to assess the Staufen-1 activities of RNA transportation and 
translation; cell lysates were also prepared to analyze the role of Staufen-1 in virus 
release. A CA-antigen capture ELISA was then carried out to determine the amount 
of viral Gag protein. 
 




Figure 14: Measurement of the Gag protein of HERV-K(HML-2) in the supernatants and 
the cell lysates. HEK-293T cells were cotransfected with HERV-K(HML-2) and 
Staufen-1 at different ratios. A CA-antigen capture ELISA was used to examine 
the level of viral Gag protein in the supernatants (A) and cell lysates (B). The 
experiment was repeated 6 times in HEK-293T cells. Data from one 
representative experiment performed in triplicate are displayed with standard 
error bars. The expression of ectopic Staufen-1 was demonstrated by Western 
blot assay using α-FLAG antibody. In addition, GAPDH detection was used as a 
loading control. 
 
As displayed in Figure 14, the ELISA demonstrates that Staufen-1 
overexpression elevates the concentration of the Gag protein in the supernatants 
(14A) and similarly in the cell lysates (14B). The most effective quantity of Staufen-1 
DNA introduced into the cells was 2 µg which showed that the maximum expression 
level of the viral Gag increase by an average of about 30-fold in the supernatants and 
nearly 24–fold increase in the cell lysates compared to the expression without 
Staufen-1. Additionally, no viral Gag protein was detected in the cells serving as a 
negative control. This result confirmed the critical role of Staufen-1 in oriHERV-K113 
propagation, probably through several mechanisms. 
For demonstration of the expressed Staufen-1 protein in the cell lysates, 
Western blot assay was performed using as primary antibody α-FLAG and as 
secondary antibody α-Rabbit IgG-HRP. In Figure 14, it can be observed that the 
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density of the positive examined Staufen-1 bands is directly proportional to Staufen-1 
DNA used for transfection. To ensure equal amounts of cell lysates loaded into SDS-
PAGE, the expression of GAPDH served as a loading control, and was observed 
using a primary antibody α-GAPDH and a secondary antibody α-Mouse IgG-HRP. 
 
4.1.2 Staufen-1 modulates the production of SIVmac virions 
 
To evaluate whether Staufen-1 positively affects the production of SIVmac 
particles as well as whether the Staufen-1 effect is dose dependent, HEK-293T cells 
were cotransfected with 1µg SIVmac molecular clone and pCMV-FLAG-Staufen-1 at 
different ratios (0.125 µg, 0.5 µg, 2 µg). Cells transfected with either empty vector or 
Staufen-1 only served as negative controls. The total concentrations of DNA were 
equalized with pcDNA4-V5-His/B vector to confirm that the variation in the titer of the 
viral capsid protein is not due to different DNA quantities used for transfection. After 2 
days incubation, supernatants were harvested and the cell lysates were prepared 
(see 3.2.1.5). Afterwards, a CA-antigen capture ELISA was performed to quantify the 
concentration of SIVmac Gag protein in the supernatants and cell lysates as 




Figure 15: Quantification of SIVmac Gag protein expression in the supernatants and 
the cell lysates. CA-antigen capture ELISA of the supernatants (A) and the cell 
lysates (B) was performed to measure the concentration of the viral Gag protein. 
The experiment was repeated 6 times in HEK-293T cells. Data from one 
representative experiment done in triplicate are shown with standard error bars. 
Overexpression of Staufen-1 in samples was shown by Western blotting using 
an α-FLAG primary antibody. A Western blot for GAPDH is shown from the same 
lysates as a loading control. 
Results  65 
 
As shown in Figure 15, overexpression of Staufen-1 increases the quantity of 
the viral Gag protein in the prepared supernatants (Figure 15A) and cell lysates 
(Figure 15B) and therefore enhances the production of the viral particles. The cells 
cotransfected with 2 µg of exogenous Staufen-1 DNA showed the highest Gag 
protein concentration, which is in the supernatants around 2.5-fold higher and in the 
cell lysates nearly 6-fold higher than in cells with only endogenous levels of     
Staufen-1. No viral Gag protein was observed in cells encoding only mock DNA or 
overexpressed Staufen-1. Therefore, this observation proved enhancement of the 
viral particle production by Staufen-1. 
The overexpression of Staufen-1 was confirmed by Western blotting using α-
FLAG as primary antibody (1:5000 dilution) due to the N-terminal FLAG tag of 
Staufen-1 and followed by incubation with a secondary antibody α-Rabbit IgG-HRP 
(1:5000 dilution). The expected molecular weight of Staufen-1 protein is 55 kDa as 
indicated in Figure 15. The abundant housekeeping protein GAPDH was used to 
demonstrate equal amounts of cell lysates loaded and was detected using a primary 
antibody α-GAPDH (1:1000 dilution) and α-Mouse IgG-HRP (1:5000 dilution) as a 
secondary antibody. As observed in Figure 15, the intensity of Staufen-1 protein was 
consistent with the concentration of pCMV-FLAG-Staufen-1 DNA used in the cell 
transfection assay. 
 
4.1.3 Time-dependent overexpression of ectopic Staufen-1 has a positive effect 
on the production of SIVmac 
 
The aim of this time-dependent course experiment was to identify whether 
production of new viral particles is associated with time based Staufen-1 
overexpression. HEK-293T cells were cotransfected with 1 µg SIVmac and 0.5 µg 
pCMV-FLAG-Staufen-1 as seen in Table 31. 
 
Table 31: displaying time dependent transfection. 
Sample Day 1 Day 2 Day 3 Day 4 
#1 SIVmac Staufen-1 Harvesting  
#2 Staufen-1 SIVmac  Harvesting 
#3 SIVmac + 
Staufen-1 
 Harvesting  
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The total concentrations of the transfected DNA were equalized using 
pcDNA4-V5-His/B vector to correctly assess the influence of the exogenous Staufen-
1 in the time-dependent experiment on the SIVmac production. The concentration of 
the viral Gag protein in the supernatants and in the cell lysates was quantified 48 h 




Figure 16: Expression of SIVmac Gag protein after time-dependent Staufen-1 
overexpression. The CA-antigen capture ELISA was used to determine the 
amount of viral Gag protein in the supernatants (A) and cell lysates of cells 
cotransfected with SIVmac and exogenous Staufen-1 in a time-dependent 
manner. Data from one representative experiment performed in duplicate are 
shown with standard error bars. Western blot analysis was applied to examine 
GAPDH expression in the cell lysates for confirmation that the same quantities 
were loaded into the gel. 
 
As seen in Figure 16, generation of the viral Gag appears to be directly 
dependent on the time of cell transfection with Staufen-1. Interestingly, whereas the 
lowest Gag protein yield was detected in the supernatants of cells cotransfected with 
Staufen-1 on the first day and SIVmac molecular clone on the second day, 
cotransfection of the cells with SIVmac and Staufen-1 at the same time induced the 
largest amount of the viral Gag protein observed in the supernatants (A) and cell 
lysates (B). Therefore, transfection of SIVmac and Staufen-1 at the same time 
exhibited the highest positive Staufen-1 effect on the virus production. 
To emphasize that equal quantities of the cell lysates were loaded into the gel, 
expression of GAPDH in cell lysates was evaluated by Western blot. GAPDH protein 
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was identified by a primary α-GAPDH antibody and a secondary α-Mouse IgG-HRP 
antibody. Bands corresponding to the protein of interest were displayed based on its 
size (37 kDa) as shown in Figure 16. The aim of GAPDH detection was to ensure 
that the differences in the virus production are dependent on the time of 
cotransfection with Staufen-1 and SIVmac. 
 
4.1.4 Downregulation of endogenous Staufen-1 has a negative effect on 
SIVmac particle production 
 
Further evaluation of the function of Staufen-1 protein can be performed by 
downregulation of endogenous Staufen-1 expression. It has been demonstrated that 
overexpression of ectopic Staufen-1 induces the production of HERV-K113 particles 
as performed in this study and by Hanke et al. [141], HIV-1 (mentioned later) and 
SIVmac as shown in the current study. In contrast, in earlier work, knockdown of 
endogenous Staufen-1 decrease the amount of HERV-K113 particles [145] so the 
aim of the protein downregulation was to analyze whether this process causes an 
adverse effect on the generation of SIVmac particles. The downregulation 
mechanism is carried out by gene silencing which is based on RNA mediated 
impairment of translation using short interfering RNAs (siRNA) consisting of around 
20 nucleotides formed by cleavage of long dsRNAs by the RNase III family member, 
Dicer. siRNAs are incorporated into the RNA Interference Specificity Complex (RISC) 
followed by binding of RISC to a complementary sequence in the mRNA causing the 
endonucleolytic degradation of the target mRNA and downregulation of the target 
protein. 
Therefore, four double-stranded 21-bp siRNAs to a selected region of Staufen 
cDNA were evaluated for Staufen knockdown efficiency in preliminary experiments. 
The duplex siRNA 3084 (5-AAATAGCACAGTTTGGAAACT-3) was assessed to 
generate the most significant knockdown of Staufen-1 gene expression [132]. This 
siRNA was cloned into shRNA vector and then used in this study. Staufen-1 silencing 
was performed by using Staufen-1 specific shRNA vectors that cleave several 
independent sites within Staufen-1 mRNA preventing the translation process (see 
Table 13). 
In a previous work, it was shown that downregulation of the endogenous 
Staufen-1 had a negative impact on production of new HERV-K(HML-2) particles 
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[145]. Therefore the effect of silencing the endogenous Staufen-1 on SIVmac 
expression could be evaluated in this study using expression DNA vectors containing 
Staufen-1 specific shRNA (short hairpin RNAs). The effect of endogenous Staufen-1 
downregulation on SIVmac production was tested by cotransfection of HEK-293T 
cells with equal DNA quantities of six Staufen-1 specific shRNAs. In addition, 
negative control cells were included in this experiment by transfecting cells with 
pLVTHM-shCofilin. After one day transfection, the same cells were transfected with   
1 µg of the SIVmac molecular clone. The cells were lysed 2 days post transfection. 
The level of viral Gag protein was measured in cell lysates by CA-antigen capture 
ELISA assay. Five shRNAs expressing DNA vectors were kindly provided by Jula 




Figure 17: Effect of silencing endogenous Staufen-1 on production of 
SIVmac Gag. Different types of Staufen-1 specific shRNAs 
were transfected into HEK-293T cells, and then the effect of 
Staufen-1 downregulation was evaluated by ELISA. The 
experiment was done in triplicate in HEK-293T cells and data 
are shown with standard error bars. 
 
As depicted in Figure 17, the reduced quantity of the viral Gag in the cell 
lysates of cells cotransfected with Staufen-1 shRNAs mixture was shown to be 
correlated with downregulation of the endogenous Staufen-1. Gag expression was 
markedly decreased after silencing endogenous Staufen-1 in cell lysates by factors of 
1.5, compared to that observed in cell lysates of cells cotransfected with pLVTHM-
shCofilin and the SIVmac molecular clone. Therefore, downregulation of endogenous 
Staufen-1 results in reduced SIVmac expression. 
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4.1.5 Staufen-1 has a positive effect on HIV-1 production  
 
Several studies previously described that Staufen-1 increased by 3-4-fold the 
production of HIV-1 [128] [149]; and another work suggested that Staufen-1 
interacted with the nucleocapsid region of pr55Gag resulting in the production of new 
infectious HIV-1 particles [132]. Consequently, the aim of this experiment was to 
investigate the dose-dependent impact of Staufen-1 overexpression on the levels of 
HIV-1 production. For this purpose, HEK-293T cells were cotransfected with 1µg of 
the HIV-1 pNL4-3 molecular clone and different amounts of pCMV-FLAG-Staufen-1 
DNA (0.125 µg, 0.5 µg, 2 µg). Mock-treated cells and cells expressing only the 
exogenous Staufen-1 DNA served as negative controls. Transfected cells were 
incubated for 48 h followed by lysis of the cells and harvesting the supernatants. 
Next, the amount of the viral Gag protein in the supernatants and cell lysates was 




Figure 18: Quantification of HIV-1 Gag protein in the supernatants and the cell lysates. 
Upon coexpression of HIV-1 and different concentrations of Staufen-1 in 
transfected HEK-293T cells, the CA-antigen capture ELISA was performed. The 
experiment was repeated 5 times in HEK-293T cells. Results from one 
representative experiment carried out in triplicate are shown with standard error 
bars. Overexpression of Staufen-1 was examined by Western blot using an α-
FLAG antibody. GAPDH expression was successfully detected in the same cell 
lysates. 
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The ELISA showed an 9-fold and 8.5-fold increase in expression of the viral 
Gag protein in the supernatants and cell lysates respectively, of cells transfected with 
0.5 µg Staufen-1 compared to that without exogenous Staufen-1. No Gag protein 
was observable in negative control cells transfected with either pcDNA4-V5-His/B or 
only Staufen-1 DNA. According to these data, a defined range of Staufen-1 
overexpression has a positive effect on virus production, whereas in contrast to that 
observed for SIVmac and oriHERV-K113, a higher concentration of transfected 
Staufen-1 DNA (2 µg) led to diminished viral expression. 
Western blot was used to test the overexpression and the signal intensity of 
Staufen-1 on whole cell lysates using an α-FLAG and an α-Rabbit IgG-HRP as 
primary antibody and secondary antibodies, respectively. As displayed in Figure 18, 
Western blot analysis shows a clear Staufen-1 signal at the expected protein size 
confirming the success of the cell transfection and expression of the target protein. 
The intensity of Staufen-1 protein bands appears to be associated with the quantity 
of pCMV-FLAG-Staufen-1 DNA added to the cells for transfection. For visualization of 
GAPDH (loading control), a primary α-GAPDH antibody and a secondary α-Mouse 
IgG-HRP antibody were used. 
 
4.1.6 Lower concentration of transfected HIV-1 DNA results in only slightly 
higher Staufen-1 enhancement 
 
In this study, Staufen-1 overexpression results in a stronger enhancement of 
oriHERV-K113 (low virus production after transfection of the full length molecular 
clone compared to that derived from the HIV-1 pNL4-3 or SIVmac molecular clones) 
than that measured for HIV-1 and SIVmac; Hanke et al. also showed an increase in 
the production of HERV-K113 particles by a factor of 20 upon Staufen-1 
overexpression [141] while other reports demonstrated that Staufen-1 led to a 3-4-
fold enhancement for HIV-1 [128] [149]. Therefore, the aim of this experiment was to 
assess whether the Staufen-1 enhancing effect on HIV-1 expression level is related 
to lower concentrations of HIV-1 DNA transfected into cells and therefore lower levels 
of virus production. For this purpose, HEK-293T cells were used for transfection with 
0.5 µg pCMV-FLAG-Staufen-1 DNA and full length HIV-1 DNA at different ratios 
(2000 ng, 666.6 ng, 222.2 ng, 74 ng). Cells were also transfected with HIV-1 DNA 
alone at the different concentrations mentioned above. Cells transfected with mock 
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DNA served as a negative control. After incubation of the transfected cells for 48 h, 
the harvested supernatants were tested by CA-antigen capture ELISA to quantify the 




Figure 19: Viral Gag production upon cotransfection with HIV-1 either in the presence 
or absence of exogenous Staufen-1. HEK-293T cells were cotransfected with 
0.5 µg pCMV-FLAG-Staufen-1 DNA and different amounts of full length HIV-1 
DNA, and the same amounts of HIV-1 DNA alone were transfected separately 
into other cells. The experiment was repeated 3 times and data from one 
representative experiment done in triplicate are shown with standard error bars. 
 
HIV-1 Gag protein was successfully detected in the supernatants from cells 
transfected either with the virus alone or with the virus plus Staufen-1. Negative 
control cells (mock) did not produce any viral particles. As depicted in Figure 19, 
Staufen-1 stimulates an increase in viral particles by an average of approximately       
2-fold, 2.4-fold, 2-fold and 3.5-fold for 2000 ng, 666.6 ng, 222.2 ng and 74 ng, 
respectively, compared to cells not expressing the ectopic Staufen-1. These data 
indicated that the lowest HIV-1 DNA concentration transfected into the cells allowed a 
slightly stronger effect of Staufen-1; therefore the lower virus production derived from 
virus DNA maintains higher Staufen-1 enhancement. Also, these data showed that 
lower HERV-K(HML-2) expression levels do not explain the stronger Staufen-1 
enhancement. 
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4.1.7 Staufen-1 overexpression stimulates the production of pseudotyped 
SHIV-luci construct only in the presence of HIV-1 Rev 
 
In this experiment, pSHIV-luci was used, which is composed of the 
SIVmac239 genome carrying the SalI/XhoI fragment of HIV-1 HXB2 (containing tat); 
as well as the luciferase gene in place of env/rev). This construct can be used as 
model for a lentivirus with a Rev deletion. In this experiment the dependency of 
enhanced viral particle production by Staufen-1 overexpression on the HIV-1 Rev 
protein was investigated and the aim was to analyze how the virus replicates in the 
presence of Staufen-1 when the gag-pro-pol sequence is obtained from SIVmac and 




Figure 20: Genomic organization of SHIV-luci construct. The SHIV-luci is composed of 
two long-terminal repeats (LTR), gag-pro-pol genes from SIVmac239 and the 
accessory genes vif, vpr, tat, nef plus, the HIV-1 Rev-response element (RRE) 
and the luciferase gene in place of env/rev. 
 
Therefore, 0.5µg pCMV-FLAG-Staufen-1 DNA and 0.7µg of the SHIV-luci 
construct plus 0.1 µg pVSV-G either in the presence or absence of 0.2 µg HIV-1 Rev 
were transfected into HEK-293T cells. Also, cells were transfected with either 
pcDNA4-V5-His/B or exogenous Staufen-1 DNA only were used as negative controls. 
After incubation for 48 h, the supernatants were collected and the transfected cells 
were lysed. Thereafter, the efficiency of Staufen-1 enhancement was assessed by 
measuring the viral Gag protein in the supernatants and the prepared cell lysates 
using the CA-antigen capture ELISA. 
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Figure 21: Investigation of the virus production of pseudotyped SHIV-luci upon 
overexpression of Staufen-1. HEK-293T cells were cotransfected with pCMV-
FLAG-Staufen-1 DNA and SHIV-luci construct and pVSV-G either with or 
without the addition of HIV-1 Rev, followed by analysis in CA-antigen capture 
ELISA. Data from one representative experiment performed in triplicate are 
displayed with standard error bars. 
 
As indicated in Figure 21 Staufen-1 contributes strongly to production of new 
virions by increasing the quantity of viral Gag protein only in cells transfected with 
HIV-1 Rev DNA, whereas no virus production was observable in cells lacking HIV-1 
Rev (data not shown). Also, Figure 21 shows that 0.5 µg Staufen-1 DNA introduced 
into the cells results in the highest yield viral Gag protein in the supernatants and cell 
lysates with increases of about 3-fold and 8-fold, respectively, compared to cells not 
expressing exogenous Staufen-1 DNA. In addition, no viral Gag protein was detected 
in the control cells. 
In conclusion, this result demonstrated that Staufen-1 cannot stimulate the 
biosynthesis of SHIV-luci Gag protein without HIV-1 Rev. In addition, it indicates that 
the highest quantity of Staufen-1 DNA (2 µg) caused a reduction in the viral Gag 
protein production as shown before for the impact of Staufen-1 on HIV-1 production. 
 
4.2 Evaluation of the influence of Rev modulation on virus production with 
respect to Staufen-1 overexpression  
 
4.2.1 Overexpression of HIV-1 Rev in the presence of exogenous Staufen-1 
inhibits the production of virus particles 
 
In this work, it was important to study whether HIV-1 Rev overexpression 
hinders the expression of viral particles. To achieve this, HEK-293T cells were 
Results  74 
 
cotransfected with 1µg the HIV-1 pNL4-3 molecular clone expressing Rev, 0.5 µg 
Staufen-1 DNA and different ratios of Rev DNA (0.25 µg, 0.5 µg, 0.75 µg, 1 µg). 
Other cells were transfected with the HIV-1 pNL4-3 molecular clone alone without 
additional Rev. The supernatants were harvested 48 post transfection, and the level 
of Gag protein was determined by CA-antigen capture ELISA and compared for cells 
cotransfected with HIV-1, Staufen-1 and the highest amounts of Rev DNA and those 




Figure 22: Determination of the effect of HIV-1 Rev and Staufen-1 
overexpression on the formation of viral Gag protein. 
Cells were cotransfected with HIV-1, Staufen-1 and Rev at 
different concentrations. CA-antigen capture ELISA assay 
was then carried out to determine the level of viral Gag 
protein in the supernatants. The experiment was repeated 
twice in HEK-293T cells. Data from one representative 
experiment are shown. The α-V5-Tag antibody was used to 
visualize the Rev and Staufen-1 proteins by Western 
blotting. Furthermore, α-GAPDH antibody was used to 
confirm that equal quantities of proteins were loaded. 
 
Notably, the degree of Gag protein expression was reduced by overexpression 
of Rev as displayed in Figure 22. The lowest amount of Gag protein in the 
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supernatants was seen with cells transfected with 1 µg and 0.75 µg HIV-1 Rev, with 
viral particle production impaired by a factor of 2 when compared to that in cells 
transfected with HIV-1 molecular clone and exogenous Staufen-1 alone. Therefore, 
cotransfection with HIV-1 Rev had an adverse impact on the generation of new HIV-1 
particles. 
Expression of HIV-1 Rev and Staufen-1 in the transfected cells was evaluated 
by Western blotting. As shown in Figure 22, protein bands of 15 kDa, 55 kDa, the 
expected molecular weight of V5 tagged Rev and V5 tagged Staufen-1 respectively, 
were visualized by using a primary mouse α-V5-Tag antibody and a secondary α-
Mouse IgG-HRP antibody. Additionally, it has been found that higher DNA amounts 
of pCDNA3-V5-HIV-1-coRev transfected into the cells resulted in an increase in the 
expression level of Rev protein. Expression of loading control GAPDH as 
housekeeping protein was assessed using a primary α-GAPDH antibody and a 
secondary α-Mouse IgG-HRP antibody. It was also shown that transfection of cells 
with the virus alone resulted in a higher signal than with HIV-1 Rev overexpression. 
 
4.2.2 Overexpression of SIVmac Rev reduces viral particle production 
 
To increase the efficiency of SIVmac251coRev expression, Rev was codon 
optimized (named SIVmac251 coRev), and cloned into pCMV-FLAG or the pCDNA4-
V5 expression vector to produce pCMV-FLAG-SIVmac-coRev or pCDNA4-V5-
SIVmac-coRev respectively. The expression of SIVmac coRev protein could then be 
evaluated using anti-FLAG or anti-V5 antibodies. Based on the significant role of 
retroviral Rev/Rec protein in the nuclear transportation of unspliced and incompletely 
spliced RNA transcripts [108] [150], it has been shown by Hanke et al. and another 
work that overexpression of HERV-K(HML-2) Rec appeared to be involved in 
increasing the yield of virus particles [141] [145]. Therefore, it was vital to analyze the 
effect of SIVmac Rev overexpression on the virus production. In this regard,       
HEK-293T cells were cotransfected with 1µg of the SIVmac molecular clone 
expressing Rev and SIVmac Rev DNA at different ratios (0.125 µg, 0.25 µg, 0.5 µg, 
0.75 µg, 1 µg). As control, cells were transfected with SIVmac molecular clone alone 
without exogenous Rev. The supernatants and the cell lysates were then prepared 
and subjected to CA-antigen capture ELISA for measuring the amount of SIVmac 
Gag protein upon SIVmac Rev overexpression. 





Figure 23: The effect of SIVmac Rev overexpression on viral Gag production. 
After transfection of the cells with SIVmac and Rev at different 
concentrations, the amount of the viral Gag protein in the cell lysates 
was determined using the CA-antigen capture ELISA. The experiment 
was repeated twice in HEK-293T cells and the results from one 
representative experiment are shown without standard error bars. 
Expression of GAPDH was analyzed by Western blotting in lysates from 
HEK-293T cells transfected with the SIVmac molecular clone and 
pCDNA4-V5-SIVmac-coRev DNA at different ratios. GAPDH protein 
used as a loading control was visualized using an α-GAPDH antibody. 
 
The ELISA displayed in Figure 23 suggests that the overexpressed SIVmac 
Rev has an inhibitory effect on virus production. Moreover, increasing the amount of 
Rev DNA transfected into the cells leads to a decrease in the yield of viral Gag in the 
cell lysates. The maximum inhibitory effect of Rev was seen with cotransfection of the 
cells with the highest amount used of (1µg) Rev DNA. 
Expression of GAPDH protein was determined by SDS-PAGE and Western 
blot analysis of the cell lysates. As a loading control, the blot was incubated with a 
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primary α-GAPDH antibody and a secondary α-Mouse IgG-HRP antibody. Western 
blotting detected GAPDH in all cell lysates, confirming that the same quantities of the 
cell lysates were loaded on to the gel, ensuring that the differences in the quantity of 
viral Gag protein detected in the ELISA was due to the inhibitory effect of Rev 
overexpression and did not involve in disturbance of the cellular metabolism. 
 
4.2.3 Overexpression of SIVmac Rev in the presence of exogenous Staufen-1 
decreases the production of viral Gag protein 
 
In order to establish whether the SIVmac Rev negatively affects the generation 
of new SIVmac virions in the presence of exogenous Staufen-1, HEK-293T cells 
were cotransfected with 1µg of SIVmac molecular clone (which produces the Rev 
protein), a constant concentration of Staufen-1 (0.5 µg) and different concentrations 
of Rev DNA. Cells were also transfected with SIVmac and Staufen-1 without coRev. 
After collecting the supernatants and lysing the cells 48 post transfection, CA-antigen 




Figure 24: Analysis of the impact of coexpression of SIVmac Rev and Staufen-1 on 
viral Gag production. Cells were cotransfected with SIVmac, Staufen-1 and 
Rev at different ratios, followed by ELISA to measure the levels of viral Gag in 
the supernatants (A) and cell lysates (B). The experiment was repeated and data 
from one representative experiment are displayed above. To confirm that the 
amounts of cell lysates loaded were the same, expression of the loading control 
GAPDH was visualized by Western blot using an α-GAPDH antibody. 
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The ELISA shown in Figure 24 revealed that the decreased level of viral Gag 
protein in the supernatants (A) and cell lysates (B) appears to be associated with 
increasing the amounts of Rev used for transfection. Also, Figure 24 shows that viral 
particle production upon transfection with 0.25 µg and 0.5 µg Rev with coexpression 
of exogenous Staufen-1 is higher than that detected after transfection of cells with 
SIVmac and 0.75 µg or 1 µg Rev. In addition, Figure 24 shows that the highest 
amount of Gag protein was seen in supernatants and cell lysates of cells transfected 
with the virus and Staufen-1 alone. 
GAPDH Western blotting of cell lysates was performed to ensure that the 
same amounts were loaded on to the gel. GAPDH expression was detected using a 
primary α-GAPDH antibody and a secondary α-mouse IgG-HRP antibody. 
In conclusion, in contrast to the positive influence of Rec on HERV-K113 
production, SIVmac Rev overexpression either with or without expressing exogenous 
Staufen-1 appears to be associated with the decreased concentration of SIVmac 
Gag protein. 
 
4.3 Investigation of the interacting functional domains within SIVmac Rev and 
Staufen-1 
 
4.3.1.1 Site directed mutagenesis of SIVmac Rev  
 
The retroviral Rev trans-activator plays an important role in the regulation of 
retroviral mRNA expression [151] [152]. To investigate the function of the SIVmac 
Rev domains necessary for Rev-mediated nucleocytoplasmic RNA shuttling and 
responsible for binding to Staufen-1, mutations were introduced into the SIVmac Rev 
DNA sequence. The SIVmac251 Rev amino acid sequence was first aligned with the 
functional coding sequence of HIV-1 Rev as illustrated in Figure 25. The aim of this 
alignment was to identify, based on the known domains within HIV Rev, the important 
domains within SIV Rev to target for mutation. 
 




Figure 25: Alignment of SIVmac and HIV-1 Rev sequences. The functional amino acid 
coding sequence domains of SIVmac Rev were aligned with the amino acid 
sequences of HIV-1 Rev. 
 
pCMV-FLAG-SIVmac-coRev was subjected to either deletion mutations or 
substitution mutations. The deletion mutation was created by removal of N-terminal 
amino acids by PCR using specific primers as shown in Figure 26, and the amplified 
PCR products were then double digested using particular restriction enzymes. The 
DNA digests were next ligated with the pCMV-FLAG expression vector. In addition, 
nucleotide substitution mutations were generated by oligonucleotide site directed 
mutagenesis (see 3.2.2.3). These constructs were generated to be analogous to 
known mutants of HIV-1 Rev. For example, HIV-1 Rev M5 and SLT40 fails to 
transport viral mRNAs from the nucleus into the cytoplasm [142]. 
 




Figure 26: SIVmac Rev mutagenesis by amino acids deletions and substitutions. 
SIVmac Rev contains 100 amino acids and is composed of many functional 
domains: Nuclear localization domain (NLS) overlapping with RNA binding 
domain (RBD) in aquamarine color, and two multimerization domains displayed 
in red. Rev mutants produced by N-terminal amino acid deletions are Δ31 (1-
31), Δ59 (1-59), while mutants with substitution of amino acids M5 (R37D, 




Figure 27: Amino acids alignment of SIVmac Rev with its mutants. The deletion mutants 
were formed by elimination of 31 or 59 N-terminal amino acids (SIVmac Δ31 and 
Δ59 respectively), whereas the substitution mutants (SIVmac M5 and SLT40) 
were created by single amino substitution as indicated in blue and green color. 
DNASTAR MegAlign was used to produce the alignments. 
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The SIVmac Rev mutants (see 3.2.2.11) were subsequently sequenced and 
the success of the mutation process checked by alignment of the amino acid 
sequences with that of SIVmac251 Rev as displayed in Figure 27. 
 
4.3.1.2 Subcellular localization of SIVmac Rev, HIV-1 Rev, HERV-K(HML-2) Rec 
and SIVmac Rev mutants 
 
Study of the subcellular localization of retroviral proteins (e.g. Rev) plays a role 
in examining viral pathogenesis and investigating potential targets for efficient drugs. 
The Rev protein mediates the nuclear RNA export and is characterized by a 
cytoplasmic and nuclear subcellular localization in several cell lines [153]. Based on 
these findings, the expression of SIVmac Rev, as detected by Western blot analysis, 
was affirmed via immunofluorescence by transfecting HEK-293T cells with 2 µg 
pCDNA4-V5-SIVmac-coRev. In addition, cells were transfected with pCDNA3-V5-
HIV-1-coRev, pCDNA3-V5-HERV-K113-oricoRec or the ovalbumin expression vector 
(pTH-OVA). The latter was included because it has a high level of expression in the 
cytoplasm. Naïve cells served as a negative control. After incubation for 48h, the 
cells were prepared for cLSM analysis as previously described (see 3.2.3.4). 
Expressed proteins were visualized using the mouse monoclonal α-V5-Cy3 (1:750) 
and immunofluorescence CLSM imaging. 
As seen in Figure 28, the expressed SIVmac Rev appears to be mainly 
located in the cytoplasm. In addition the expression of HIV-1 Rev by confocal laser 
scanning microscope was found mostly in the cytoplasm. Also, the 
immunofluorescence assay demonstrated that ovalbumin and Rec proteins were 
successfully expressed and mainly found within the cytoplasm. The expression level 
of all proteins appeared to be similar. 




Figure 28: Protein localization and immunofluorescence analysis of SIVmac 
Rev, HIV-1 Rev and HERV-K(HML-2) Rec. For the localization assay, 
HEK-293T cells were transfected with plasmids producing either 
SIVmac Rev, HIV-1 Rev, HERV-K(HML-2) Rec or ovalbumin using 2 
µg of each DNA construct. 48 h post transfection, cells were 
immunostained with a mouse monoclonal α-V5-Cy3. The right hand 
panel shows the cytoplasmic localization of the expressed proteins (red 
fluorescence) in the merged images while the blue fluorescence 
indicated Staining of the nucleus with DAPI dye. Scale bar, 10 µm. 
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Furthermore, immunofluorescence assays was carried out to determine 
whether SIVmac Rev mutants were expressed in plasmid treated cells. The cellular 
and nuclear localizations of the target proteins were investigated using HEK-293T 
cells transfected either with SIVmac Rev, SIVmac RevΔ31, SIVmac RevΔ59, SIVmac 
Rev M5, or SIVmac Rev SLT40. At 48 h after cell transfection, cells were subjected 
to cLSM analysis as previously described (see 3.2.3.4). The expression of SIVmac 
Rev mutants was shown by incubation of the transfected cells after permeabilization 
with an α-FLAG-Tag primary antibody and AlexaFluor 568 α-mouse-IgG secondary 
antibody at a dilution of 1:5000 and 1:2000, respectively. Images were then obtained 
using confocal laser scanning microscopy. 
Notably, confocal laser-scanning microscopy revealed a predominantly 
cytoplasmic distribution of the SIVmac Rev (green) mutant proteins (Figure 29). The 
expression of SIVmac RevΔ31 in the cytoplasm was not adversely influenced by 
deletion of the first loop. In addition, the SIVmac RevΔ59 and SIVmac Rev M5 
mutants were expected to be detectable only within the cytoplasm due to deletion of 
the NLS amino acids (RevΔ59) or inactivation of the NLS by amino acids substitution 
(Rev M5). Moreover, expression of SIVmac Rev SLT40 mutant within the cytoplasm 










Figure 29: Intracellular localization of SIVmac Rev mutants. 
Transfection of SIVmac Rev or each Rev mutant (Δ31, Δ59, 
M5, SLT40) into HEK-293T cells resulted in cytoplasmic 
staining of the expressed Rev and its mutants using an α-
FLAG-Tag primary antibody and AlexaFluor 568 α- mouse-
IgG secondary antibody. The right-hand panel shows green 
fluorescent Rev mutants displayed within the cytoplasm in 
the merged images, whereas staining of the nucleus with 
DAPI is indicated in blue. Scale bar, 10 µm. 
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4.3.1.3 The binding of Staufen-1 to SIVmac Rev or Rev SLT40 is indicated by 
CoIP and Western blotting while other mutations (RevΔ31, RevΔ59, Rev 
M5) fail to show interaction with Staufen-1 
 
One of the objectives of this study was to determine which functional domains 
within SIVmac Rev are responsible for the binding of Rev to Staufen-1. In earlier 
work, it was shown that the generation of HIV-1 Rev NLS mutants impaired the 
attachment of Rev to Staufen-1 [142]. For this, the interaction of Staufen-1 and 
SIVmac Rev mutants was investigated by co-immunoprecipitation experiments and 
Western blot analysis. In this regard, HEK-293T cells were cotransfected with 15 µg 
pCDNA3-V5-Staufen-1 and either 15 µg pCMV-FLAG-SIVmac-coRev, RevΔ31, 
RevΔ59, Rev M5 or Rev SLT40. Western blotting using a primary α-FLAG antibody 
and a secondary α-rabbit IgG-HRP antibody revealed FLAG-SIVmac-coRev and 
FLAG-coRev SLT40 bands, corresponding to 15 kDa. The Western blot therefore 
indicated that deletion of 31 or 59 amino acids (RevΔ31, RevΔ59) and mutation of 
the NLS domain by amino acid substitution (Rev M5) abrogates Rev-Staufen-1 
interaction whereas mutation by amino acid substitution in the multimerization 
domain (SLT40) does not have this effect. Furthermore, expression of V5-Staufen-1 




















Figure 30: Analysis of the binding between Staufen-1 and SIVmac Rev mutants by 
CoIP and Western blotting. HEK-293T cells were cotransfected with pCDNA3-
V5-Staufen-1 and either pCMV-FLAG-SIVmac-coRev, RevΔ31, RevΔ59, Rev 
M5 or Rev SLT40. The cell lysates were next treated with anti-V5 tagged 
agarose beads. Western blot analysis demonstrated a positive interaction 
between Staufen-1 and Rev/Rev SLT40. V5-Staufen-1 was detected in the cell 
lysates using α-V5-HRP. Also, cells were cotransfected with an empty pcDNA4-
V5-His/B vector alone or in combination with pCMV-FLAG-SIVmac-coRev as a 
negative control. 
 
In conclusion, these experiments revealed binding of Staufen-1 to SIVmac 
Rev and, to an enhanced degree, to the SLT40 mutant. 
 
4.3.1.4 Mutation in SIVmac Rev decreases the amount of SIVmac particle 
production 
 
The results above show that overexpression of SIVmac Rev diminished the 
yield of viral Gag protein. The effect of overexpression of SIVmac Rev mutants on the 
virus production was therefore analyzed to determine whether mutation of the 
functional domains within SIVmac Rev abrogates the negative influence of Rev on 
viral expression. In recent work, it has been reported that overexpression of HIV-2 
Rev mutants did not cause an increase or decrease in the level of the viral Gag 
protein [143]. Consequently, in this study, HEK-293T cells were cotransfected with 
1µg of the SIVmac molecular clone (producing Rev protein) and either 1 µg Rev or 
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each Rev mutant (Δ31, Δ59, M5, or SLT40). Cells were also transfected with 
pcDNA4-V5-His/B vector as a negative control or with the virus alone. Supernatants 
and the cell lysates prepared 48 h post transfection were analyzed for viral Gag 




Figure 31: Demonstration of the adverse influence of SIVmac Rev mutant 
overexpression on the formation of virus particles. Transfection of HEK-
293T cells was carried out with SIVmac molecular clone, and 1µg of each Rev 
DNA mutant. The amount of the viral Gag protein in the supernatants (A) and 
in the cell lysates (B) was then measured by CA-antigen capture ELISA. 
Results from one representative experiment performed in triplicate are shown 
with standard error bars.  
 
As shown in Figure 31, Rev, whether mutated or not, was found to effectively 
diminish the yield of Gag protein by approximately a factor of approximately 2.5 
compared to cells transfected with the SIVmac molecular clone alone. 
In conclusion, deletions of the first loop/NLS domain or inactivation of 
NLS/multimerization domains did not abrogate the inhibitory effect on virus 
generation seen with non-mutated SIVmac Rev. 
 
4.3.1.5 Overexpression of SIVmac Rev mutants in the presence of an ectopic 
Staufen-1 DNA impairs the production of new viral particles 
 
In this experiment, the effect of the SIVmac Rev mutants and Staufen-1 was 
addressed by cotransfection of HEK-293T cells with 1µg of the SIVmac molecular 
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clone, 0.25 µg of each SIVmac Rev mutant and 0.5 µg Staufen-1 DNA. Furthermore, 
cells were transfected either with the virus alone or with the virus plus Staufen-1 
DNA. Mock-transfected cells served as a negative control. The transfected cells were 
incubated for 48 hours before lysing the cells. The CA-antigen capture ELISA was 




Figure 32: Effect of coexpressing SIVmac Rev mutants and Staufen-1 on the 
production of the SIVmac Gag protein. The SIVmac molecular clone was 
cotransfected with each Rev mutant and Staufen-1 DNA into HEK-293T cells 
and the quantity of Gag protein in the cell lysates subsequently measured by 
CA-antigen capture ELISA. The experiment was carried out in triplicate and 
data are shown with standard error bars. 
 
As shown in Figure 32, the levels of the expressed viral Gag protein were 
diminished in the lysates of cells transfected with the virus, plus Staufen-1 and Rev 
mutants, compared to that in cells expressing only virus plus Staufen-1, suggesting 
that the overexpressed SIVmac Rev and SLT40 mutant were responsible for 
inhibition of the Staufen-1 enhancement, while Δ31, Δ59, M5 do not have a clear 
negative effect. No viral Gag was detected in the lysate of the negative control cells. 
Based on this result, cotransfection of Staufen-1 and SIVmac Rev mutants had the 
same adverse effect on virus production as that seen with non-mutated SIVmac Rev. 
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In conclusion, mutations in SIVmac Rev did not alter the inhibitory effect of 
SIVmac Rev, regardless of their ability to interact with Staufen-1 (Rev, SLT40) or not 
(M5, Δ31, Δ59). This finding demonstrated a reduced negative effect on virus 
production in the presence of exogenous Staufen-1. 
 
4.3.2.1 Exogenous Staufen-1, Staufen-1_ΔRBD4 and Staufen-1_ΔTBD/RBD5 
elevate the quantity of SIVmac Gag protein produced, whereas Staufen-
1_F135A/Staufen-1_ΔRBD3 do not 
 
Staufen-1 is composed of several functional double-stranded RNA binding 
domains (dsRBD2 to dsRBD5) and a tubulin binding domain (TBD) (see Figure 12). 
Staufen-1 mutants were produced and kindly provided by Jula Wamara, (a co-worker 
in the laboratory) to determine which domains within Staufen-1 protein are essential 
for interaction with SIVmac Rev and promotion of virus production. Mutations were 
introduced by deletion of RBD3, RBD4, or TBD/RBD5 (termed ΔRBD3, ΔRBD4 and 
ΔTBD/RBD5, respectively) and a Staufen-1_F135A mutant was generated by 
inactivation of RBD3 via a single point mutation. 
A previous study indicated that Staufen-1_F135A and, ΔRBD3 overexpression 
resulted in lower virus expression levels than those induced by Staufen-1, ΔRBD4 
and ΔTBD/RBD5 [143]; Hanke et al. also demonstrated that overexpression of 
Staufen-1 increased the amount of viral Gag protein by a factor 20 [141]. The main 
purpose of this experiment was therefore to determine the exact domain in Staufen-1 
responsible for enhancing the production of SIVmac particles. 1µg SIVmac molecular 
clone and 0.5µg of either FLAG-Staufen-1, Staufen-1_F135A, Staufen-1_ΔRBD3, 
Staufen-1_ΔRBD4 or Staufen-1_ΔTBD/RBD5 were cotransfected into HEK-293T 
cells that were then incubated for 48 h. Cells transfected with pcDNA4-V5-His/B as a 
mock DNA served as a negative control. Cell lysates were then prepared for 
measuring the quantities of viral Gag protein using the CA-antigen capture ELISA. 
 




Figure 33: Impact of overexpressing Staufen-1 mutants on the production of SIVmac 
Gag protein. Lysates of HEK-293T cells cotransfected with SIVmac and each 
Staufen-1 mutant were subjected to CA-antigen capture ELISA to determine the 
concentration of Gag protein. Data from one representative experiment done in 
triplicate are shown with standard error bars. Western blotting as indicated by 
red arrows confirmed the expression of Staufen-1 mutants at their expected 
sizes in the cell lysates. 
 
The ELISA shown in Figure 33 demonstrated higher expression levels of the 
viral Gag protein in lysates of cells overexpressing Staufen-1, Staufen-1_ΔRBD4 or 
Staufen-1_ΔTBD/RBD5 by factors of 1.5, 2 or 1.5, respectively compared cells 
cotransfected with only the virus or with the virus plus Staufen-1_F135A/Staufen-
1_ΔRBD3. No viral Gag protein was produced in the negative control cells. 
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Therefore, deletion of the RBD4 or TBD/RBD5 domains did not abolish the 
generation of SIVmac mediated by Staufen-1, while Staufen-1_F135A/Staufen-
1_ΔRBD3 mutants inhibited the positive role of Staufen-1 on viral particle production. 
Equal amounts of protein from the cell lysates were subjected to SDS-PAGE 
and Western blotting to determine the expression of the Staufen-1 mutants. Staufen-
1 mutants carrying FLAG tag were detected by a primary α-FLAG antibody and a 
secondary α-rabbit IgG-HRP antibody. As shown in Figure 33, the 55-kDa band size 
corresponds to the non-mutated Staufen-1 and Staufen-1_F135A (weak signal 
indicated with a red arrow between the two dark bands), whereas the Western blot 
for Staufen-1 ΔRBD3 and Staufen-1 ΔRBD4 confirms their expected molecular 
masses of 47 kDa. Additionally, expression of Staufen-1 ΔTBD/RBD5 at the expected 
molecular weight of, approximately 33 kDa was seen by immunoblotting. 
 
4.3.2.2 SIVmac Rev binds to Staufen-1 and its mutants but with lower 
interaction efficacy to Staufen-1_F135A, ΔRBD3 
 
In a previous publication, Hanke et al. confirmed that RBD4 promotes HERV-
K(HML-2) Rec/Staufen-1 interaction [141], and in the present study, a co-
immunoprecipitation assay was therefore performed to determine which Staufen-1 
subdomain plays a significant role in interacting with SIVmac Rev in an RNA- 
independent manner. HEK-293T cells were therefore cotransfected with pCDNA4-
V5-SIVmac-coRev and either pCMV-FLAG-Staufen-1, FLAG-Staufen-1_F135A, 
ΔRBD3, ΔRBD4 or ΔTBD/RBD5. Cell lysates were prepared 48 h post transfection 
and 750 µl incubated with anti-V5 agarose beads (see 3.2.3.3). Following co-
immunoprecipitation, FLAG-tagged Staufen-1 and its mutants were examined by 
Western blot using a primary α-FLAG antibody and a secondary α-rabbit IgG-HRP 
antibody. As shown in Figure 34, the Western blot provides evidence that the 
expressed FLAG-Staufen-1 (and its mutants) bands co-sedimented with the 
expressed V5-Rev. This strongly indicates a binding between these proteins but a 
dramatically with lower efficacy of Rev binding to Staufen-1 ΔRBD3 and Staufen-1 
F135A. Western blotting for Staufen-1 and Staufen-1_F135A indicated a molecular 
weight of 55 kDa, whereas, the size of Staufen-1 ΔRBD3 and Staufen-1 ΔRBD4 was 
47 kDa and Staufen-1 ΔTBD/RBD5 was approximately 33 kDa. 
 




Figure 34: Analysis of the interaction between SIVmac Rev and 
Staufen-1 mutants by CoIP and Western blot. HEK-293T 
cells were cotransfected with V5-SIVmac-coRev and either 
FLAG-Staufen-1, FLAG-Staufen-1_F135A, ΔRBD3, ΔRBD4 or 
ΔTBD/RBD5. Cell lysates were then analyzed by CoIP using 
anti-V5 agarose beads followed by Western blotting using 
anti-FLAG. Interactions between the Rev protein and the 
Staufen-1 mutants are indicated by red arrows. As a negative 
control, cells were cotransfected with an empty pcDNA4-V5-
His/B vector and either pCDNA4-V5-SIVmac-coRev or pCMV-
FLAG-Staufen-1. 
 
 This finding demonstrated that inactivation or deletion of dsRBD3 negatively 
influenced the binding between Staufen-1 and SIVmac Rev. 
 
4.3.3.1 SIVmac Rev and its mutants induce mRNA transport in the presence of 
HIV-2 RRE while Staufen-1 decreases the efficiency of RNA export 
 
The retroviral Rev/Rec proteins attach to the Rev Responsive Element (RRE) 
located within the unspliced and incompletely spliced viral mRNAs and then initiate 
nuclear transportation for protein biosynthesis [154]. The aim of this study was 
therefore to study SIVmac Rev-dependent transport of viral mRNA, for which two 
constructs, termed as Shuttle and Shuttle HIV-2 RRE, were used. As shown in Figure 
35, each construct is composed of pCDNA4 as a DNA vector backbone, HERV-K113 
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5´UTR with donor site (SD), a firefly luciferase encoding gene (reporter gene), HERV-
K113 Gag and an env gene with acceptor site (SA). Four stop codons were 
introduced into the open reading frame of the rec gene to inhibit transcription. To 
investigate whether the transport of the viral mRNA is dependent on the Rev protein, 
Shuttle HIV-2 RRE was designed to contain a C-terminal Rev-responsive element 
(RRE). Shuttle and Shuttle HIV-2 RRE constructs were kindly provided by Anna Klara 
Amler, a co-worker in the laboratory. HIV-2 RRE was used in this experiment 
because it is known that both HIV-2 and SIVmac originated from SIVsm and there is 
therefore a high homology between their DNA sequences. It was shown by Hanke et 
al. that cotransfection of shuttle RcRE and oricoRec increased nucleocytoplasmic 
shuttling but that when Rec and shuttle lacking RcRE were cotransfected into cells, 




Figure 35: Schematic representation showing the structure of Shuttle and Shuttle HIV-
2 RRE constructs. Each DNA construct consists of HERV-K113 5´UTR, a firefly 
luciferase expressing gene as a reporter gene, HERV-K113 Gag and an env 
gene. To suppress the expression of Rec, four stop codons were introduced into 
rec. To determining transport of only the viral unspliced RNAs, the luciferase 
gene was introduced between the 5’UTR and the Gag ORF. Additionally, Shuttle 
HIV-2 RRE comprises an RRE specific for SIVmac and HIV-2 Rev-based RNA 
transport. 
 
In this regard, the influence of SIVmac Rev and its mutants on the viral RNA 
transport was assessed by cotransfection of HEK-293T cells (see 3.2.1.4) with 
Shuttle HIV-2 RRE and SIVmac Rev or each Rev mutant (Δ31, M5, or SLT40) either 
with or without expressing Staufen-1. Cells were also cotransfected with Shuttle HIV-
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2 RRE and HIV-2 Rev as a positive control. To enable normalization of the firefly 
luciferase data, the cells were cotransfected with a DNA vector encoding Renilla 
luciferase as an internal control. Moreover, cells transfected with either SIVmac Rev 
or HIV-2 Rev alone were tested. As a negative control, cells were transfected with the 





Figure 36: SIVmac Rev-dependent RNA transport in the presence of RRE. Shuttle HIV-2 
RRE and SIVmac Rev or Rev mutants were co-expressed in HEK-293T cells. + 
indicates that the cells express an exogenous Staufen-1. The results were 
normalized to the activity of the expressed Renilla luciferase as an internal 
control. The green line marks the threshold (average luciferase activity measured 
for non-specific transport of the construct Shuttle plus three times the standard 
deviation). The experiment was repeated three times in HEK-293T cells. Data 
from one representative experiment done with 8 replicates are shown with 
standard error bars. 
 
As displayed in Figure 36, Shuttle HIV-2 RRE alone induces low luciferase 
activity in the transfected cells (RLU = 8.36). In addition, SIVmac Rev or Rev mutants 
and the Shuttle HIV-2 RRE construct cotransfected into cells results a significant 
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elevation in luciferase activity mediated by SIVmac Rev and Rev-ΔSLT40. In 
contrast, in cells coding for an exogenous Staufen-1, Shuttle HIV-2 RRE and Rev 
diminishes the activity of the Rev-dependent RNA export from the nucleus to the 
cytoplasm compared to that in absence of an ectopic Staufen-1. Also, luciferase 
activity was observed when cells were cotransfected with Shuttle HIV-2 RRE and 
HIV-2 Rev, especially without overexpression of Staufen-1. No luciferase activity was 
detectable in cells transfected with either mock DNA, SIVmac Rev or HIV-2 Rev 
alone. 
In conclusion, SIVmac Rev activates nuclear RNA export and inactivation of 
the multimerization domain did not lead to inhibition of RNA transport, whereas  
RevΔ31 and M5 (NLS-deficient) prevented luciferase biosynthesis. Furthermore, 
SIVmac Rev demonstrated stronger RNA transport activity than that mediated by 
HIV-2 Re and Staufen-1 impaired Rev-based RNA export. 
 
4.3.3.2 SIVmac Rev, its mutants and Staufen-1 do not affect mRNA export in the 
absence of HIV-2 RRE 
 
To analyze the non-specific RNA transport without using RRE, HEK-293T cells 
were cotransfected with equal concentrations of the Shuttle construct, and SIVmac 
Rev, its mutants (Δ31, M5, or SLT40) or HIV-2 Rev. Cells transfected with a mock 
DNA vector served as a negative control and cells transfected with SIVmac Rev or 
HIV-2 Rev alone were also evaluated. As shown in Figure 37, only very low 
luciferase activity was observed upon transfection of cells with the Shuttle construct 
lacking RRE, with SIVmac Rev or its mutants, or with HIV-2 Rev, either with or 
without overexpression of an exogenous Staufen-1. Therefore, coexpression of 
Staufen-1 and SIVmac Rev mutants had no significant effect on Shuttle reporter 
expression levels and unspecific Shuttle RNA export from the nucleus into the 
cytoplasm was not detected with Rev mutants. Also, no luciferase activity was 
detected when HIV-2 Rev, SIVmac Rev or mock DNA was transfected into the cells. 
 




Figure 37: SIVmac-Rev dependent RNA transport in the absence of RRE. To assess 
non-specific RNA transport using the Shuttle construct lacking RRE, SIVmac 
Rev, its mutants or HIV-2 Rev plus the Shuttle construct were cotransfected into 
cells. + indicates coexpression of Staufen-1 in the cells. In addition, values were 
normalized to the activity of the cotransfected Renilla luciferase as an internal 
control. The experiment was repeated three times in HEK-293T cells. Data from 
one representative experiment done with eight replicates are displayed with 
standard error bars. 
 
4.3.3.3 Staufen-1 and particular mutants have an adverse influence on mRNA 
transport in the presence of RRE 
 
The objective of this experiment was to determine which of the Staufen-1 
functional domains cause the inhibitory effect on Rev-dependent RNA transport. 
Therefore, the impact of Staufen-1 and its mutants (Staufen-1_F135A, Staufen-
1_ΔRBD3, Staufen-1_ΔRBD4 or Staufen-1_ΔTBD/RBD5) on Rev based mRNA 
export was determined by adding equal quantities of Shuttle HIV-2 RRE, SIVmac 
Rev and Staufen-1 or its mutants to HEK-293T cells for transfection. Also, Shuttle 
HIV-2 RRE and Staufen-1 or its mutants were transfected into cells to examine the 
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effect of Staufen-1 and its mutants on Rev independent mRNA transport. As controls, 
cells were transfected with Shuttle HIV-2 RRE with and without SIVmac Rev. The 
values from the firefly luciferase assay were normalized by expressing Renilla 




Figure 38: The effectiveness of Staufen-1 and its mutants on mRNA transport using 
RRE. Cells were cotransfected with Staufen-1 mutants, SIVmac Rev and Shuttle 
HIV-2 RRE either with or without SIVmac Rev; SIVmac Rev alone and Shuttle 
HIV-2 RRE were also transfected. The + sign indicates overexpression of Rev in 
the cells. Values were normalized to the activity of the expressed Renilla 
luciferase as an internal control. The green line refers to the threshold, i.e. the 
average luciferase activity associated with non-specific transport of the Shuttle 
construct. Results from one representative experiment performed in 
quadruplicate are shown with standard error bars. 
 
SIVmac Rev in combination with Shuttle HIV-2 RRE was found to markedly 
enhance luciferase activity as depicted in Figure 38 compared to activity following 
Results  98 
 
cotransfection of Rev and Staufen-1, which showed no RNA transport activity. 
Furthermore, luciferase activity was observed upon cotransfection of Rev and 
Staufen-1_F135A or Staufen-1_ΔRBD3 but was reduced after cotransfection with 
Rev and Staufen-1_ΔRBD4 or Staufen-1_ΔRBD5. Conversely, only overexpression 
of Staufen-1 and Shuttle HIV-2 RRE led to a clear reduction in luciferase activity, 
particularly the lowest promotion of RNA transport was seen after cotransfection of 
Staufen-1, Staufen-1_ΔRBD4 or Staufen-1_ΔTBD/RBD5. In addition, Shuttle HIV-2 
RRE transfected alone resulted in decreased luciferase activity. Therefore, Staufen-
1, Staufen-1_ΔRBD4 and ΔTBD/RBD5 reduced Rev-dependent RNA export, 
whereas Staufen-1_F135A and ΔRBD3 with a non-functional dsRBD3 domain 
increased the luciferase expression level. 
In conclusion, Staufen-1 overexpression prevents Rev-mediated mRNAs 
transportation from the nucleus into the cytoplasm and the positive influence of 
Staufen-1 on the virus production is thereby independent of nucleocytoplasmic RNA 
shuttling. 
 
4.3.3.4 Staufen-1 and its mutants have no impact on mRNA transport in the 
absence of RRE 
 
To study the effect of Staufen-1 mutants (Staufen-1_F135A, Staufen-
1_ΔRBD3, Staufen-1_ΔRBD4 or Staufen-1_ΔTBD/RBD5) on the non-specific RNA 
transport without using RRE, equal amounts of the Shuttle construct and Staufen-1 or 
each mutant were cotransfected into HEK-293T cells. Cells were also transfected 
with equal quantities of the Shuttle construct, SIVmac Rev and each Staufen-1 
mutant and cells transfected either with Shuttle construct or with SIVmac Rev alone 
were examined. 
 




Figure 39: RNA export upon coexpression of Staufen-1 mutants and SIVmac Rev with 
the Shuttle construct lacking RRE. Cotransfection of cells was performed with 
the Shuttle construct and with either Staufen-1 mutants alone or with SIVmac 
Rev together with the Staufen-1 mutants. SIVmac Rev or the Shuttle construct 
transfected into cells were also included. Cotransfection of the cells with Staufen-
1 mutants is indicated with +. Values were normalized to the activity of the 
expressed Renilla luciferase as an internal control. Results from one 
representative experiment performed in quadruplicate are shown with standard 
error bars. 
 
Figure 39 demonstrates that cells coexpressing Staufen-1 mutants and 
SIVmac Rev showed only low levels of luciferase activity due to the lack of an RRE in 
the Shuttle construct. In addition, Staufen-1 or its mutants overexpressed alone with 
Shuttle construct resulted in lower levels of luciferase activity than those achieved by 
using Rev. Furthermore, overexpression of Rev with the Shuttle construct alone 
appears to slightly increase RNA transport. Finally, transfection of cells with Shuttle 
construct alone resulted in background luciferase activity. 
Luciferase activity was therefore not associated with cotransfection of Staufen-
1 mutants and Rev but was also influenced by the presence of an RRE, because 
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only background levels were seen after cotransfection of only Staufen-1 mutants and 
Rev. 
 
4.4 Analysis of a Rec-deficient mutant of a reconstituted HERV-K (HML-2) 
 
4.4.1 Generation of pBSK ori HERV-K113 ΔRec 
 
 It has been shown that HERV-K(HML-2) genes express an accessory protein, 
known as Rec which is functionally similar to the HIV-1 Rev and HTLV Rex proteins. 
The HERV-K113 molecular clone was generated by cloning the entire sequence 
coding for the reconstituted proteins into the pBSK plasmid vector [144]. This 
construct expresses Env, Rec and Gag-Pro-Pol. Production from the Gag protein and 
virus-like particles of the native HERV-K113 sequence in transfected cells is very low 
causing difficulties in detection due to mutations in the proviral DNA that occurred 
after insertion into the host’s genome. For this purpose, the original envelope protein 
of HERV-K113 was reconstituted and expressed at high levels. After the insertional 
mutation, the amino acid sequence of HERV-K113 gag-pro-pol region was aligned 
with those of 10 well-preserved human specific HERV-K(HML-2) viruses [144]. The 
HERV-K(HML-2) Rec protein is required to transport introns containing partially 
spliced or unspliced viral mRNA transcripts from the nucleus into the cytoplasm for 
translation. Several investigators provide evidence that HERV-K(HML-2) Rec 
overexpression results in an increase in the quantity of the viral Gag protein [141], 
while overexpression of SIVmac Rev diminishes the viral particle production, similar 
to the results in the present study. The aim of this study was therefore to evaluate the 
effect of Rec mutation on the level of viral expression. pBSK ori HERV-K113 ΔRec 
was generated using the pBSK ori BCD vector which consists of pBSK ori HERV-
K113 lacking an 5´ LTR ApaI/SalI fragment (composed of 1221 bp bordered by 
ApaI/SalI restriction sites). Mutations preventing Rec splicing were introduced into the 
pBSK ori BCD vector by deletion of nucleutides within the SD2 regions using multi-
Site-directed mutagenesis. In the ori HERV-K113 sequence published by Chudak et 
al., 2013 [147], nine nucleotides at position 6708-6716 (numbered according to the 
HERV-K113 sequence Genbank Acc. Number AY037928) were deleted without any 
inhibitory influence on the open reading frame of the env gene as indicated in Figure 
40. To clone back the mutated Rec into the pBSK ori HERV-K113, the strategy 
Results  101 
 
performed was based on PCR amplification of the mutated Rec sequence within 
pBSK ori BCD vector followed by another PCR assay in which the amplified fragment 




Figure 40: Location of rec mutagenesis in pBSK ori HERV-K113 DNA sequence. Site-
directed mutagenesis was used to remove nine nucleotides (three amino acids) 
within the rec SD2 region of the pBSK ori BCD vector followed by ligation with a 
5´LTR ApaI/SalI fragment using PCR for the formation of the pBSK ori HERV-
K113 ΔRec molecular clone. 
 
4.4.2 Deletion of Rec results in undetectable levels of viral Gag protein 
production 
 
The objective of this experiment was to determine the effect on virus 
production of preventing pBSK ori HERV-K113 Rec expression. In addition, it could 
be investigated in this study and earlier work that cotransfection of Staufen-1 
enhanced the HERV-K(HML-2) particle production by up to 30-fold [141] so it would 
be interesting to examine the impact of Staufen-1 modulation on the expression level 
of ori HERV-K113 ΔRec. For this, HEK-293T cells were cotransfected with 1 µg ori 
HERV-K113 ΔRec with or without 1.5 µg Staufen-1. Cells were also cotransfected 
with either 1 µg ori HERV-K113 ΔRec, 0.5 µg oricoRec or a combination together 
with different amounts of Staufen-1 (0.018 µg, 0.05 µg, 0.16 µg, 0.5 µg, 1.5 µg). In 
addition, ori HERV-K(HML-2) with or without Staufen-1 was transfected into cells as a 
control. Cells transfected with the pCDNA4-V5-His/B vector served as a negative 
control. The supernatants were harvested and cell lysates were prepared 48 h post 
transfection. The CA-antigen capture ELISA of the supernatants and cell lysates was 
used to measure the levels of viral Gag protein. 
 




Figure 41: Evaluation of the yield of viral Gag protein after ori HERV-K(HML-2) Rec 
mutation. The ELISA demonstrated that in the supernatants (A) and cell 
lysates (B), viral Gag expression was inhibited by blocking Rec production, 
whereas viral Gag protein could be demonstrated in cells encoding Rec. In 
addition, level of the viral Gag protein was markedly increased when Staufen-1 
was overexpressed. The experiment was repeated four times in HEK-293T 
cells. Results from one representative experiment carried out in triplicate are 
indicated with standard error bars. 
 
Figure 41A shows that no viral Gag protein was detectable in the supernatants 
of cells transfected with ori HERV-K113 ΔRec alone and that Staufen-1 did not 
induce virus production in the absence of Rec expression. In contrast, viral Gag 
protein was clearly produced after cotransfection with oricoRec and Staufen-1 
overexpression increased viral expression in the presence of Rec. It was observed 
that higher concentrations of Staufen-1 DNA transfected into cells led to increased 
production of new virions and the most effective Staufen-1 concentration was 0.5 µg 
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DNA which enhanced viral Gag expression an approximate factor of 19. Furthermore, 
cells transfected with ori HERV-K(HML-2) showed virus production that was 
significantly elevated by Staufen-1 overexpression. In addition, the concentration of 
viral Gag protein was elevated about 4-fold after cotransfection of 1.5 µg Staufen-1 
and ori HERV-K113 ΔRec compared to that for HERV-K(HML-2) and Staufen-1 
cotransfection. No virus production was detected by ELISA in the negative control 
cells. 
Similar result was also obtained with the cell lysates as shown in Figure 41B. It 
has been shown that impairment of Rec expression is linked to inhibition of virus 
production. In contrast, lysates of cells transfected with ori HERV-K113 ΔRec and 
Rec produced viral Gag protein in particular the highest level was seen after 
cotransfection with 0.16 µg Staufen-1 DNA, a 13-fold increase compared to those not 
expressing ectopic Staufen-1. Moreover, cells transfected with oriHERV-K113 
exhibited viral Gag protein production either with or without encoding Staufen-1. 
Finally, the level of viral Gag protein was increased by about 3-fold after 
coexpression of 0.166 µg Staufen-1 and ori HERV-K113 ΔRec compared to that for 
ori HERV-K113 and overexpressed Staufen-1. 
In conclusion, inhibiting Rec expression resulted in undetectable levels of viral 
Gag protein in the supernatants and cell lysates, either in the presence or absence of 
exogenous Staufen-1. These data also show that an increase in the amount of 
exogenous Staufen-1 while expressing Rec resulted in higher levels of virus 
expression. 
 
4.4.3 Effect of Rec titration on HERV-K(HML-2) particle production 
 
The aim of this experiment was to study the influence of increasing the 
amounts of transfected oricoRec DNA on ori HERV-K113 ΔRec production. For this 
purpose, 1 µg ori HERV-K113 ΔRec, 0.5 µg Staufen-1 and different quantities of Rec 
(0.05 µg, 0.166 µg, 0.5 µg, 1.5 µg) were transfected into HEK-293T cells. Cells were 
also cotransfected with ori HERV-K113 ΔRec and Staufen-1. Cells transfected with 
mock DNA served as a negative control. The supernatants collected 48 h post 
transfection were subjected to CA-antigen capture ELISA to quantify the yield of viral 
Gag protein. 
 




Figure 42: Viral Gag protein production after titration of Rec. The supernatants of cells 
cotransfected with ori HERV-K113 ΔRec, Staufen-1 and Rec at different ratios 
were subjected to ELISA analysis. The ELISA demonstrated that Rec expression 
resulted in remarkably higher levels of the viral particles. The experiment was 
repeated twice and data from one representative experiment performed in 
triplicate are shown with standard error bars. 
 
Figure 42 shows that increasing the Rec DNA concentration transfected into 
cells led to increases in the level of viral expression with a maximum enhancement at 
1.5 µg Rec DNA. In contrast, production of new virions was not observed in the 
supernatants of cells not encoding oricoRec. 
Higher concentrations of Rec DNA transfected into the cells therefore have an 
increasing positive influence on ori HERV-K113 ΔRec production. 
 
4.4.4 Viral Gag protein production in the absence of Rec after transfection with 
higher quantities of oriHERV-K113 ΔRec 
 
It was previously shown, that ori HERV-K113 ΔRec with or without Staufen-1 
produced undetectable levels of Gag protein (see Fig. 41). The viral genes may be 
expressed after Rec mutation, probably due to cellular mechanisms and/or by the 
endogenous Rec. Further investigations were therefore performed to evaluate the 
impact of mutations that prevent Rec splicing on the generation of new infectious viral 
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particles by increasing the number of transfected cells and the concentrations of 
oriHERV-K113 Δrec used for the cell transfection. In addition, the effect on the 
promotion of virus production of adding Rec in trans with or without Staufen-1 was 
analyzed. For this purpose, 80 µg ori HERV-K113 ΔRec/40 µg Rec either with/or 
without 40 µg ectopic Staufen-1 DNA were cotransfected into cells. Furthermore, 80 




Figure 43: Viral Gag protein after transfection with a large amount of ori HERV-K113 
ΔRec alone or ori HERV-K113 ΔRec/Rec/Staufen-1. ELISA of ultracentrifuged 
supernatants revealed that the Rec mutation significantly diminished the 
formation of the new virus compared to non-mutated Rec expression. Data of this 
experiment are shown without standard error bars. 
 
It was shown in Figure 43 that expression of ori HERV-K113 ΔRec and of ori 
HERV-K113 ΔRec/Rec in HEK-293T cells resulted in remarkable differences in virion 
production. Substitution of Rec in trans resulted in an approximately 11-fold decrease 
in particle production in cells transfected with ori HERV-K113 ΔRec alone compared 
to that in cells cotransfected with ori HERV-K113 ΔRec and Rec. Furthermore, an 
increase of the yield of new virions was observed with the Rec-dependent 
enhancement of Staufen-1 overexpression by a factor of 6 compared to cells not 
expressing exogenous Staufen-1. 
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In conclusion, deletion of Rec nevertheless resulted in the detectable 
production of viral particles when using very large quantities of ori HERV-K113 ΔRec 
and increasing the number of the cells transfected. However, providing Rec in trans 
enhanced the level of viral Gag protein 11-fold. Moreover, Staufen-1 overexpression 
increased the yield of viral Gag in the concentrated supernatants of cells with ori 
HERV-K113 ΔRec and Rec by a factor of 6 when compared in cells not producing 
exogenous Staufen-1. 
Further studies were performed to evaluate the influence of Rec deletion and 
residual expression of ori HERV-K113 ΔRec. The quantity of ori HERV-K113 ΔRec 
DNA cotransfected into the cells was elevated and high numbers of cells were used 
to aid in detecting very low levels of viral Gag protein. 80 µg ori HERV-K113 ΔRec 
DNAs were mixed with 40 µg pcDNA4-V5-His/B vector or with 40 µg exogenous 
Staufen-1 DNA. Negative control cells were transfected with the pcDNA4-V5-His/B 




Figure 44: Analysis of the virus production after cotransfection with high quantities of 
ori HERV-K113 ΔRec and Staufen-1. The supernatants of cells cotransfected 
with high amounts of ori HERV-K113 ΔRec alone or in combination with Staufen-
1 were analyzed by ELISA. Data of this experiment are presented without 
standard error bars. 
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In Figure 44, shows that higher amounts of transfected ori HERV-K113 ΔRec 
DNA clearly resulted in viral expression and that coexpression of Staufen-1 positively 
enhanced virus production by a factor of approximately six compared to cells not 
expressing Staufen-1. As expected, viral Gag protein was not detected in the 
supernatants of negative control cells. 
In conclusion, using high quantities of cells, a weak expression of viral Gag 
protein derived from the ori HERV-K113 ΔRec molecular clone could be detected. 
Furthermore, cotransfection of Staufen-1 resulted in an approximately 6-fold 
enhancement of this expression, previously demonstrated.  
 
4.4.5 HIV-1 Rev, SIVmac Rev, HTLV Rex, Np9 positively support the expression 
of ori HERV-K113 ΔRec whereas NP9 does not have a positive influence 
 
It has been confirmed that HERV-K Rec, which transports unspliced viral 
mRNAs into the cytoplasm, is functionally similar to HIV-1 Rev, SIVmac Rev and, 
HTLV Rex. A previous study reported that the HERV-K RNA sequence is recognized 
by HIV-1 Rev. Also, a notable elevation in the level of HERV-W and HERV-K RNA 
during HIV-1 infection has been demonstrated [155] and a previous work proved that 
HIV Rev was able to interact functionally with HERV-K-RRE leading to nuclear RNA 
export [156]. Consequently, one of our goals in this study was to investigate the 
effect of expression of HIV-1 Rev, SIVmac Rev, HTLV Rex and Np9 on the formation 
of new oriHERV-K113 ΔRec particles. For this purpose, HEK-293T cells were 
cotransfected with ori HERV-K113 ΔRec alone or in combination with Rec, Np9, HIV-
1 Rev, SIVmac Rev or HTLV Rex either with or without exogenous Staufen-1. 
Following incubation for 48 hours, the supernatants were harvested and centrifuged 
at 27410g and 4°C for three hours to pellet the virus. The supernatants were carefully 
discarded and the virus pellets resuspended in 40 μl PBS. The Cavidi RT Activity 
assay was then used to demonstrate that all proteins with the exception of Np9 
caused a Staufen-1 mediated increase in viral RT activity (Figure 45). 
 




Figure 45: Rescue of particle production by a Rec-deficient HERV-K(HML-2) mutant by 
Rev and Rex. HEK-293T cells were transfected as indicated   (A, without 
Staufen-1 overexpression, B, with Staufen-1). Particle production was assessed 
using a sensitive RT-Assay (Cavidi) two days post transfection. The experiment 
was repeated 6 times in HEK-293T cells. Data from one representative 
experiment performed in duplicate are displayed with standard error bars.  
 
In the absence of the ectopic Staufen-1 (Figure 45A), cotransfection with Rec, 
HIV-1 Rev or SIVmac Rev appear to be associated with the highest viral RT activity, 
whereas expression of Rex and Np9 resulted in viral RT activity lower than that 
obtained when ori HERV-K113 ΔRec was transfected alone into the cells. Moreover, 
as shown in Figure 45B, Staufen-1 coexpression with ori HERV-K113 ΔRec alone or 
in combination with Rec, HIV-1 Rev, SIVmac Rev, or Rex positively contributed to the 
enhancement of the viral reverse transcriptase activation by factors of 5, 6.5, 5.5, 3, 
or 26 respectively. Conversely, expression of Np9 showed no a viral RT activity either 
with or without exogenous Staufen-1. 
This study therefore indicates that HIV-1 Rev, SIVmac Rev, HTLV Rex are 
able to successfully bind to the RcRE of unspliced HERV-K mRNA transcripts leading 
to nucleocytoplasmic RNA shuttling and thereby significantly increased virion 
production. Rec coexpression resulted in the most profound enhancement while NP9 
cannot functionally substitute Rec and did not facilitate nuclear RNA transportation.




5.1 The influence of Staufen-1 on retroviral particle production 
 
Human cellular Staufen-1 protein is considered as a double stranded RNA 
binding protein, first found in Drosophila [157]. It is composed of five functional sub 
domains dsRBD2 to dsRBD5 and a tubulin binding domain (TBD) found between 
dsRBD4 and dsRBD5 [123]. Mammalian cells have two Staufen homologs, Staufen-1 
and Staufen-2, each with multiple isoforms [158]. The interaction between Staufen-1 
and retroviruses (HIV-1, HIV-2, and HERV-K113) was studied in our group. The 
impact of Staufen-1 coexpression on SIVmac239 molecular clone was not evaluated 
therefore this was analyzed in the current work as well as further investigations 
regarding the relation between Staufen-1 and HERV-K113/HIV-1 were done. This 
study describes the aspects of human Staufen-1 in retroviruses pathogenesis. The 
dose dependent effectiveness of Staufen-1 overexpression on the expression levels 
of viral Gag protein could be demonstrated by cotransfection of HEK-293T cells with 
HIV-1 /SIVmac239/or HERV-K113 and Staufen-1 at different ratios. The most influent 
Staufen-1 concentration exhibited increase of the viral Gag protein yield in the 
supernatants and the cell lysates for HIV-1 by an average of 9-fold and 8.5-fold 
respectively. Also, Staufen-1 supported production of the viral SIVmac Gag protein in 
the supernatants and the cell lysates by a factor of 2.5-fold and 6-fold respectively. 
Furthermore, overexpression of Staufen-1 positively affected the expression level of 
HERV-K Gag protein in the supernatants by an average of 30-fold and in the cell 
lysates by a factor of 24-fold. The different impact of Staufen-1 overexpression on 
various retroviruses was shown earlier using different kinds of assays. A previous 
work published by Hanke et al. showed that the overexpressed Staufen-1 was 
involved in increasing the viral particle generation by a factor of 20 [141]. The positive 
influence of Staufen-1 on HIV-1 and SIVmac239 was the same probably attributed to 
the similarity of HIV-1 Rev to SIVmac Rev but this Staufen-1 effect was different from 
that on oriHERV-K113 probably because HERV-K Rec appears to be older than 
lentiviral Rev. 
Previous studies were accomplished to assess the aspects of Staufen protein 
in the retroviruses propagation. One of these studies revealed that human Staufen-1 
interacts with HIV-1 genomic RNA and thereby is involved in promoting the HIV-1 
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genomic RNA packaging into the new virions by a factor of 3 but it was shown that 
this process abrogates the virus infectivity due to incorporation of the human Staufen-
1 in HIV-1 [128].In addition, Staufen-1 has a positive effect on encapsidation through 
its association to dimeric viral RNAs [139]. Previous reports demonstrated that 
overexpression or silencing Staufen-1 adversely affected the virus infectivity during 
the reverse transcription, the integration step or the efficiency of encapsidation [128] 
[140]. 
The retroviral 9-kb mRNA transcripts biosynthesized in the infected cells are 
unspliced mRNAs, partially spliced mRNAs 4-kb or completely spliced 2-kb mRNAs 
[159] [160] [161] [162]. The 9-kb mRNAs and singly spliced transcripts 4-kb are 
transported from the nucleus into the cytoplasm in case of HIV-1 by the viral Rev 
[163] [164] via interaction of Rev to cis-acting RRE present within all 9-kb and 4-kb 
mRNAs leading to packaging of the full length viral genome and translation into viral 
proteins [165] [166]. Thus, in absence of Rev, the viral mRNAs are retained in the 
nucleus until subjecting to further splicing or degradation. Hence, one of our 
objectives in the current study was to evaluate the influence of Staufen-1 
overexpression on SHIV-luci (a SIV/HIV hybrid virus) (SHIV) which is rev deficient 
because of the insertion of a reporter gene at the site of env gene either HIV-1 coRev 
is expressed or not. It has been indicated that no viral Gag protein was detectable in 
the supernatants and the cell lysates of cells not encoding viral Rev but on the other 
hand, new viral Gag protein could be demonstrated in the supernatants and in the 
cell lysates when cells expressing HIV-1 coRev. Based on this finding, it has been 
confirmed in the present study that viral Rev protein is necessary for regulation of the 
retroviral gene expression. 
In light of the positive Staufen-1 effect on the retroviruses production, support 
for these data is found in previous work done in our group that showed that the 
overexpressed Staufen-1 induced stronger generation of oriHERV-K113 and HIV-1 
particles, respectively [142] [145]. Also, earlier studies indicated that consistent 
Staufen-1 dependent activation of HIV-1 production [128] [132] [167]. In addition, 
Staufen-1 enhancement of the retroviral expression level indicated in the present 
study was in agreement with the positive impact of Staufen-1 on production of HIV-2 
particles shown by another Master’s thesis [143] who displayed that Staufen-1 
cotransfection into HEK-293T cells caused a significant elevation of the quantity of 
the viral Gag protein by a factor of 6 in the supernatants when compared with that in 
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cells not encoding the exogenous Staufen-1. The positive impact of Staufen proteins 
was emphasized by a certain study which suggested that overexpression of Staufen-
2 led to increasing in the formation of new HIV-1 particles [149]. Therefore, Staufen-1 
effect reflects its vital biological function in the retroviral life cycles. This effect caused 
by Staufen-1 might be attributed to enhancing Staufen-1 dependent nuclear export of 
the viral mRNAs for protein biosynthesis by binding to viral Rev/Rec/Rex proteins; 
also eliciting the translation rate of the viral proteins [128] [132] [141] [138]. This 
hypothesis was confirmed by previous data investigating that human Staufen-2 
protein specifically interacts with HIV-1 Rev protein stimulating the viral unspliced or 
partially spliced mRNAs transportation form the nucleus to the cytoplasm, thereby 
mediating the propagation of HIV-1 as well as it has been examined that Staufen-2 
expression level is higher in HIV-1 infected human T-lymphocyte and astrocyte cell 
lines, consequently this proves the importance of human Staufen proteins in the viral 
replication cycles [149]. 
Earlier work indicated that Staufen-1 protein is associated with mediating the 
mRNAs export from the nucleus into the cytoplasm for the efficient translation as well 
as Staufen-1 particles in previous publication is described as one of the components 
of the ribonucleoproteins that demonstrated 15-fold enrichment of mRNAs [168] 
[169]. Additionally, previous finding provided evidence that dmStaufen protein 
(expressed by Drosophila melanogaster) specifically attach to oskar mRNA of 
Drosophila melanogaster followed by localization in certain site for gene expression 
[170]. This was confirmed by another study which suggested by immunofluorescence 
that human Staufen is colocalized with the rough endoplasmic reticulum as well as 
human Staufen is linked to ribosomes and polysomes so it transport mRNAs into the 
translation sites [120]. 
Moreover, another trial reported that transport of HIV-1 RNA transcripts to 
ribosomes could be activated by Staufen protein followed by stimulating the viral 
mRNA binding to the translation initiation factor termed as elF4E resulting in coding 
for the viral genes [129].  
Also, other investigators suggested that Drosophila Staufen has amino acid 
sequences homology to those of human cellular protein sequence, TRBP [170]. This 
region can attach specifically to TAR containing viral RNA transcripts and thereby 
mediating the translation process and producing new virions [137]. In contrast, 
Staufen-1 did not positively affect the expression of the translated mRNAs lacking an 
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apparent structured 5' end, so the interaction of Staufen-1 with the 5' end of the 
mRNA transcripts is essential for their transport into ribosomes [122] and 
enhancement of the translation process as well as Staufen-1 blocks PKR binding site 
so no repression of the luciferase translation by activated PKR occurs [138]. 
Additionally, several proteomic [171] [172] [173] and cell biology [168] [169] [174] 
[175] [176] studies revealed that Staufen-1 plays a role in the mRNAs export. For 
examples, Staufen-1 might be involved in mRNA transport in neurons because RNAs 
were observed within Staufen-1 granules and move in dendrites on microtubules 
[168] [175]. This finding is supported by decreasing the concentrations of HIV-1 RNA 
in dendrites of neurons upon silencing of Staufen-1 [171]. On the nuclear level, it has 
been revealed that Staufen-1 is linked to telomerase and/or telomeric RNA in the 
nucleolus [177] [178]. In the cytoplasm, the function of Staufen-1 is to stabilize RNAs 
causing 5-fold elevation in the translation process for biosynthesis of proteins belong 
to the cell metabolism and/or cell growth. These functions are considered as 
complementary to its role in RNA transport and translation following localization 
[179][180]. These reports prove that Staufen-1 is a critical multifunctional protein; 
therefore, more studies are required for understanding mechanism of Staufen action 
and its function in synthesizing new infectious virions as well as to analyze the role of 
host cellular proteins in the replication of retroviruses. 
Obviously, it has been proved in this study and another article that the 
expression level of HERV-K(HML-2) is less than that for HIV-1 [141], it could be 
found that Staufen-1 enhancement of the generation of HERV-K(HML-2) and HIV-1 
particles in the supernatants was 30-fold and 9-fold respectively; also Hanke et al., 
showed increase in the yield of HERV-K(HML-2) particles by a factor of 20 upon 
Staufen-1 overexpression [141] while attempts by other investigators revealed that 
Staufen-1 caused 3-4-fold enhancement for HIV-1 [128] [149]. Thus, based on these 
observations, one of our aims in this work was to evaluate the correlation between 
Staufen-1 enhancement and the viral expression level. This was performed by 
cotransfection of HEK-293T cells with constant concentration of Staufen-1 DNA and 
different amounts of full length HIV-1 DNA (about 2000 ng, 666.6 ng, 222.2 ng, 74 
ng). The results described that lower quantity of HIV-1 DNA introduced into the cells 
for transfection led to higher Staufen-1 enhancement; consequently these data 
suggested that Staufen-1 effect is only slightly increased with decreasing in the 
quantities of the virus DNAs introduced into the cells for transfection. Probably the 
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viruses with lower expression levels are characterized with lower capabilities of using 
the cellular replication machines and subsequently this may support the important 
role of Staufen-1 in the virus propagation. 
Furthermore, it would be interesting to study whether Staufen-1 and 
SIVmac239 are cotransfected on the same time or at different times alters the 
amounts of the viral Gag protein in the supernatants and the cell lysates. For this 
regard, HEK-293T cells were cotransfected with Staufen-1 and SIVmac239 on the 
same time or at various times (see Table 31). The result displayed that the largest 
amount of the viral Gag protein was detectable when both Staufen-1 and the virus 
were cotransfected on the same day while the lowest Gag protein quantity in the 
supernatants was observable when cells were cotransfected first with Staufen-1 then 
with the virus on the second day. From this finding, it has been assessed that the titer 
of the viral Gag protein appears to be directly associated with the time course of cell 
transfection with Staufen-1. 
 
5.2 Effect of Staufen-1 mutants on the virus production 
 
The essentiality of SIVmac251 Rev-Staufen-1 interaction was assessed in this 
study by using Staufen-1 mutants. Mutations were introduced into Staufen-1 DNA 
sequence by deletion of dsRBD3, dsRBD4, or dsRBD5/TBD known as ΔRBD3, 
ΔRBD4 or ΔTBD/RBD5 respectively as well as dsRBD3 domain was mutated and 
inactivated by single point mutation in dsRBD3 called Staufen-1-F135A which 
abrogated the double stranded RNA binding efficacy of Staufen-1 as previously 
reported in a certain work [132]. Examining which Staufen-1 domains mediate the 
viral Gag protein production was done by transfection of HEK-293T cells with either 
only SIVmac239 molecular clone or the virus and Staufen-1/or each Staufen-1 
mutant. It was shown that generating Staufen-1-F135A and Staufen-1 ΔRBD3 
mutants did not support the Staufen-1 dependent enhancement of the expression 
level of the viral proteins, and thereby the final virus yield, while deletion of dsRBD4 
or dsRBD5/TBD domains within Staufen-1 had no a negative influence on Staufen-1 
mediated production of SIVmac Gag protein. It was determined that dsRBD3 region 
is specifically bound to SIVmac251 coRev by CoIP in the present study and indicated 
by our group for HIV-1 and HIV-2 [142] [143]; therefore, inactivation of this domain 
inhibits the binding to viral Rev and thereby might reduce the Rev dependent mRNAs 
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export activity and the virus replication. The negative impact of some Staufen-1 
mutations assessed in this study was in agreement with another work which 
explained that deletion or inactivation of dsRBD3 region strongly contributed to 
decreasing the concentration of the HIV-2 particles when compared to that displayed 
in presence of Staufen-1 or the other mutants [143]. Moreover, the significance of 
dsRBD3 region of Staufen-1 could be checked in a certain trial which confirmed that 
dsRBD3 facilitate the binding in the nucleus between TAR element of HIV-1 RNAs 
and Staufen-1 [128] [138]. Additionally, data of our result was consistent with another 
article which revealed that interaction of Staufen-1 with the nucleocapsid domain of 
pr55Gag was promoted via dsRBD3 domain leading to the virus assembly and 
production of new infectious virions [132]. In addition, other trials confirmed that 
dsRBD3 domain has the ability to strongly bind to RNAs and ribosomal RNA, while 
dsRBD4 demonstrated a weak RNA binding activity as well as it has been observed 
by Northern blot analysis that single point mutation of dsRBD3 (F135A) did not 
interact with RNAs [123] [128]. Furthermore, Laurent Chatel-Chaix and his Co-
workers reported that Staufen-1 might be essential for HIV-1 assembly by binding via 
its dsRBD3 to the nucleocapsid region of Gag protein of HIV-1 resulting in Gag 
multimerization [130] [131]. Further attempt by another article suggesting that 
production of human Staufen-2 mutants impaired the direct Rev-Staufen binding and 
abolished Staufen-2 dependent induction of Rev transport activity; also diminished 
the titer of the new HIV-1 particles when compared to control cells transfected with 
HIV-1 alone [149]. These findings described that the importance of Staufen is not 
only elevating Rev induced viral mRNA transport activity but also Staufen plays an a 
critical role in the virus packaging. Interestingly, anti-retroviral chemical compounds 
could be designed based on preventing Staufen/Rev binding process. 
 
5.3 Investigation of the interaction of SIVmac251 coRev with human Staufen-1 
and its mutants. 
 
As noticed in the present study, the interaction of SIVmac251 coRev with 
Staufen-1 and its mutants (Staufen-1, Staufen-
1_F135A/ΔRBD3/ΔRBD4/ΔTBD/RBD5) was analyzed by CoIP assay. Because 
benzonase enzyme was used for degradation of RNA/DNA molecules; the binding 
process is independent of RNA. Our findings demonstrated that Staufen-1 and its 
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mutants was physically bound to SIVmac251 coRev exceptionally Staufen- 
1_F135A/ΔRBD3 mutants which showed lower binding efficiency due to lower 
expression level of these mutants observable by Western blotting when compared 
with the intensity of the Staufen-1 and other mutants signals. According to this result, 
it is speculated that dsRBD3 domain of Staufen-1 could be correlated with binding to 
SIVmac251 coRev. This data was agreed with results obtained in previous work 
which investigated that dsRBD3 region played a critical role in attaching Staufen-1 to 
either HIV-1 coRev or HIV-2 coRev [142] [143]. On the other hand, Hanke et al. 
reported that HERV-K113 Rec was successfully interacted via its dsRBD4 with 
Staufen-1 [141]. This was confirmed by numerous trials in which pull down binding 
assay revealed that HIV-1 Rev interacts with human Staufen-2 and that this physical 
binding up-regulates the Rev dependent RNA transcripts export activity through the 
nuclear membrane [149]; also, it was identified that dsRBD2 domain of Staufen 
mediates the posterior localization of the oskar mRNA of Drosophila oocyte, while 
actin-dependent prospero mRNA localization requires Staufen dsRBD5 [181]. 
 
5.4 Analysis of the effectiveness of coRev overexpression on the virus 
production 
 
Rev is a protein forming multimers in vivo [182] or in vitro [118]. The viral Rev 
protein carries nuclear localization domain (NLS) and nuclear export domain (NES) 
which aid in nucleocytoplasmic shuttling. The nuclear import of Rev is activated by 
interaction of NLS with the cellular receptor importin receptor β [108] [183] [184] 
[185]. NLS bears several arginine residues known as an argenine rich motif (ARM) 
[108] which is required for enhancement of Rev binding to Rev responsive element 
(RRE) of unspliced or partially spliced viral mRNAs followed by RNAs shuttling into 
the cytoplasm [108] [150]. By contrast, Rev is exported into the cytoplasm via 
recognition of NES by the cellular receptor CRM1/exportin 1 [186] [187] [188]. 
It is intriguing in the present study to examine SIVmac Rev overexpression on 
the virus production. For this regard, HEK-293T cells were cotransfected with 
SIVmac239 and SIVmac coRev/or each coRev mutants Δ31 (deletion of the first 
loop), Δ59 (NLS-deficient), M5 (NLS-deficient), or SLT40 (multimerization domain-
deficient) either with or without Staufen-1 overexpression. It has been found that 
cotransfection of SIVmac coRev or its mutants alone or in combination with 
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exogenous Staufen-1 negatively affected the synthesis of the virus progeny in the 
supernatants and the cell lysates. Moreover, in this study, coexpression of HIV-2 
coRev and Staufen-1 diminished the titer of the viral Gag protein and inhibited the 
Staufen-1 enhancement. This result might be attributed to inactivation of the nuclear 
viral RNAs transport by coRev cotransfection, therefore viral Gag protein was not 
produced. Our report was in agreement with earlier study that indicated that 
interacting high quantity of Rev protein with exportin receptor CRM1 led to 
impairment of the cellular mRNA transcripts transportation [189]. Another finding in 
our group demonstrated that no increase in the yield of the HIV-2 particles after 
overexpression of HIV-2 coRev or coRev mutants [143]. But, the negative effect of 
coRev indicated in our study was not matched with data also obtained in our study 
which provided evidence that the overexpressed HERV-K113 oricoRec was 
concerned with increasing the quantity of the viral Gag protein when the influence of 
titeration of oricoRec on formation of ori HERV-K113 ΔRec particles was 
investigated. In contrast to the inhibitory effect of SIVmac/HIV-1 coRev on the virus 
production, report of another work confirmed that overexpression of HERV-K113 Rec 
clearly assisted in the virus propagation [141] [145]. 
 
5.5 Influence of Staufen-1 and SIVmac251 coRev on nuclear RNA export  
 
During the retroviral infection, the viral genome produces viral mRNAs by 
transcription process. Afterwards, the viral mRNA transcripts are either completely, 
partially spliced or unspliced for biosynthesis of viral proteins to produce new virus 
particles [108]. The completely spliced viral mRNAs are exported into cytoplasm by 
the constitutive mRNA nuclear export pathway of the eukaryotic cells [190], whereas 
the partially spliced and the unspliced viral mRNAs localize in the nuclei of the 
infected cells until further splicing or degradation. Rev/Rec/Rex proteins bind to 
Rev/Rec/Rex responsive elements (RRE) present within the unspliced and partially 
spliced viral mRNAs then Rev binds to CRM1 leading to nuclear exit of the Rev 
bound mRNA transcripts into cytoplasm for the subsequent translation and formation 
of new virions [154] [191] [156] [192] [193]. These findings were completely agreed 
with results documented in the current study in which the cotransfected SIVmac251 
coRev showed a remarkable increase in the nuclear export of HIV-2 RRE containing 
mRNA transcripts and thereby elevation of the expression level of the firefly 
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luciferase reporter gene in spite of inhibition of the viral Gag protein generation after 
SIVmac coRev overexpression. Also, to assess the influence of SIVmac coRev 
mutations on Rev based mRNAs transport, each separate coRev mutant (coRevΔ31, 
M5 or SLT40) was cotransfected with shuttle construct (with luciferase reporter gene 
and HIV-2 RRE) into HEK-293T cells. It was investigated that coRev-SLT40 
(multimerization domain-deficient) contributed to elevating the nuclear RNA export 
into the cytoplasm; therefore inactivation of multimerization domain did not cause a 
negative effect on RNA transport exceptionally coRevΔ31 and M5 (NLS-deficient) 
that showed no RNA export activity. In another attempt, it was investigated that NLS 
domain activates the binding of Rev to RRE and mediates the Rev assembly into 
multimers as well [194] [195] [196]; therefore inactivation of this region by amino 
acids substitution might cause inhibition of nucleocytoplasmic shuttling. In our data, it 
has been found that inactivation of multimerization domain might not negatively affect 
RNA export induced by SLT40 mutant or probably multimerization region was not 
inhibited by two amino acids substitution. Additionally, our observation was matched 
with results described by Hoffmann and his Co-workers that suggested that 
oligomerization-defective Rev mutant was not important for formation of trans-
activation competent Rev:RRE complexes and nuclear RNA transportation [197]. 
Moreover, this was affirmed by certain data obtained in our group which indicated 
that HIV-1 coRev or HIV-2 coRev overexpression elicited the nuclear RNA export and 
biosynthesis of luciferase enzyme; also it was described that HIV-2 coRev SLT40 
mutant increased the luciferase activity similar to that induced by unmutated coRev, 
whereas NLS-deficient mutants abrogated the RNA export pathway [142] [143] [198]. 
It has been reported in earlier work that HIV Rev mutants displayed Rev based RNAs 
shuttling activities similar to unmutated Rev protein [153]. In addition, In contrast to 
these findings, it was observed that HIV-1 coRev mutants (M5, M10, SLT40) 
prevented the RNA transport exceptionally coRevΔ32 which exhibited lower RNA 
shuttle activity [142]. Also, it was displayed in the results presented in this study that 
no mRNA export activity and luciferase activity were detected upon overexpression of 
SIVmac coRev and shuttle construct lacking HIV-2 RRE so this confirms that 
presence of RRE is vital for Rev dependent RNA transport. The significance of viral 
Rev was further reported in earlier study in which inactivation of Rev´s leucine rich 
activation domain led to impairment of Rev mediated RNA transcripts shuttling [119]. 
Moreover, SIVmac coRev overexpression exhibited in this study higher RNA 
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transport activity that that induced by HIV-2 coRev because probably SIVmac coRev 
expression level is higher than that for HIV-2 coRev or maybe because the RNA 
transport activity or the efficiency of binding to RRE by SIVmac coRev is higher than 
that by HIV-2 coRev. Additionally, it has been reported in our study that Staufen-1 
overexpression inactivates the activity of Rev dependent nuclear RNA transportation 
pathway. Furthermore, the effect of the overexpressed Staufen-1 mutants on RNA 
transport evaluated in our work displayed that Staufen-1, Staufen-1_ΔRBD4 and 
ΔTBD/RBD5 also decreased Rev mediated HIV-2 RRE bound RNA export, while 
Staufen-1_F135A and ΔRBD3 (inactivation or deletion of dsRBD3 domain 
respectively) supported higher Rev dependent RNA transport activity because 
probably these mutants are non-functional Staufen-1; also no luciferase activity was 
remarkably detected after overexpression of  Staufen-1 mutants alone, therefore this 
finding proved the significance of SIVmac coRev in the RNA transportation pathway. 
The effect of Staufen-1 on Rev mediated RNA export could be assessed in previous 
work which proved that cotransfection with Staufen-1 had no influence on Rev based 
RNA transport for HIV-1 and HIV-2 [142] [143]. Based on that information, our 
hypothesis is that Staufen-1 may mediate the production of the lentiviral capsid 
particles by using other mechanisms apart from the nuclear RNA export pathway. For 
instances, Staufen-1 is associated with ribosomes and polysomes so it may induce 
the translation of mRNAs by enhancing attachment of the viral mRNA transcripts to a 
translation initiation factor called elF4E [129] [120] [122] as well as it was suggested 
by other studies that Staufen-1 might interact with nucleocapsid domain of HIV-1 Gag 
protein causing the virion packaging [130] [131].  
In contrast, Hanke et al. provided evidence that the overexpressed Staufen-1 
strongly promoted the Rec induced RNAs export in presence of RcRE from the 
nucleus into the cytoplasm [141]. Also, the same study demonstrated that the positive 
efficacy of Staufen-1 overexpression on the viral particle production is more than that 
caused by Staufen-1 in nucleocytoplasmic shuttling activity. Thus, there is additional 
Staufen-1 role, for example interaction of Staufen-1 with HIV-1/HERV-K113 Gag 
protein causing Gag multimerization [141] [130] [131]. In addition, earlier data by 
independent studies indicated that CRM1/Exportin-1 binds separately with both Rev 
and human Staufen-2 activating their RNA export activity [199] [200]. Therefore, it is 
speculated that viral Rev/Rec proteins and CRM1 may form export complexes which 
increase the efficiency of the viral mRNAs transportation or/and enhance the nuclear 
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transport of large viral RNAs [149]. Several previous publications demonstrated 
successful interaction of viral Rev proteins with some RNA binding host proteins such 
as human Rev-interacting protein (hRIP) and RNA helicase A (RHA), promoting Rev 
export activity [201] [202] [203]. Therefore, Rev-mediated RNA exit is required for 
virus replication, the interference with Rev activity [188] [204], for instance by 
blocking Rev’s capability to self-associate on the RRE, may assist in the 
development of novel antiretroviral therapies. 
 
5.6 Silencing endogenous Staufen-1 
 
Staufen-1 overexpression was involved in inducing biosynthesis of new 
retroviral capsid proteins; therefore it was necessary furthermore to analyze the role 
of human Staufen-1 in the viral replication cycle by investigating the influence of 
knockdown of the endogenous Staufen-1 expression on generation of SIVmac Gag 
protein. Downregulation of Staufen-1 expression was carried out by using small 
interfering RNAs (siRNA) that inhibit the translation of the Staufen-1 mRNA. For this, 
HEK-293T cells cotransfected with the virus and Staufen-1 specific shRNA vectors 
(pLVTHM-shStauen_A7, pLVTHM-shStauen_A2C4, pLVTHM-shStauen_B3, 
pLVTHM-shStauen_C1, pLVTHM-shStauen_C3, and pLVTHM-shStaufen-3086) 
showed 1.5-fold drop in the amount of the viral Gag protein in the cell lysates when 
compared to the value obtained by nonspecific shRNA. Thus, this result proved that 
Staufen-1 silencing is associated with diminishing the yield of the SIVmac Gag 
protein probably due to either reducing Rev mediated RNA shuttling activity or 
decreasing the rate of the viral mRNA translation. This observation was matched with 
other studies which suggested that knockdown of Staufen-1 had a remarkable 
negative impact on generation of HIV-2 and HERV-K113 Gag proteins [143] [145]. 
Also, in regard to Staufen-1 silencing, another publication demonstrated that the 
quantity of RNA in neurons dendrites was decreased after reduction of Staufen-1 
expression level [171]. Moreover, another attempt agreed with our finding indicated 
that silencing of Staufen-1 diminished influenza virus yield by 5-10-fold compared to 
that in control cells [205]. Conversely, it was indicated in earlier study that the 
downregulated Staufen-1 caused higher expression level of HIV-1 proteins [130]. In 
addition, depletion of Staufen-1 notably contributed to diminishing the cellular Gag 
gene expression [139]. 
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5.7 Assessment of the localization of SIVmac coRev mutants and binding to 
Staufen-1 
 
The virally encoded Rev trans-activator plays an essential role in the 
regulation of retroviral mRNA expression [151] [152]. Data involved in subcellular 
localization of HIV proteins (e.g. Rev) is of importance in assessing the viral 
pathogenesis and probably relevant for drug and vaccine development. HIV Rev 
protein is postranscriptional activator of retroviral gene expression. Rev protein is 
nucleocytoplasmic shuttle protein which is characterized by nuclear subcellular 
localization in several cell lines [153]. To determine SIVmac251 coRev domains 
required for Rev mediated nuclear RNA transport and interaction with Staufen-1, Rev 
mutations were generated either by N-terminal amino acids deletions called coRev 
Δ31, Δ59 or by Rev functional domain inactivation via amino acid substitution known 
as M5 (NLS-deficeint), SLT40 (multimerization-deficient). These mutants were 
produced depending on the high similarity between the amino acids sequences of 
HIV-1 Rev and SIVmac Rev as previously displayed. In the current study, HERV-
K113 oricoRec, HIV-1 coRev and SIVmac251 coRev were expressed in transfected 
HEK-293T cells. The expressed proteins were examined by immunofluorescent 
antibodies using Confocal Laser Scanning Microscope (cLSM) and were mainly 
localized in the cytoplasm in spite of expectations for detection of these proteins in 
the nucleus and in the cytoplasm due to presence of NLS and NES domains. A 
previous trial revealed that HIV-1 protein could be expressed and mainly found in the 
cytoplasm [206] as observed in our result but oricoRec were detected in the 
cytoplasm and the nucleus so this was in agreement with the result obtained in a 
Diploma thesis in our group in which it was found that the expressed oricoRec 
localize in the cytoplasm and the nucleus [145]. Other trials observed localization of 
HIV-1 coRev and HIV-2 coRev in the nucleus and the cytoplasm [96] [119] [207]. 
Additionally, all SIVmac251 coRev mutants generated in this study were expressed in 
transfected cells and detected by cLSM in the cytoplasm especially SIVmac Δ59 and 
M5 mutants which are possessing nonfunctional nuclear localization signals (NLS) 
due to deletion or inactivation of this domain respectively; thus, SIVmac coRev 
mutations did not affect the expression capability of coRev. In regard to localization of 
coRev mutants, HIV-1 coRev mutants and HIV-2 coRev mutants were also 
expressed and displayed in our group by cLSM [142] [143]. 
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To check the functionality of SIVmac251 coRev after mutations and to 
examine which functional domains within SIVmac coRev stimulate the interaction of 
coRev with Staufen-1, CoIP and Western blotting assays were performed by 
cotransfection of HEK-293T cells with Staufen-1 and SIVmac251 coRev or one of its 
mutants (coRevΔ31, Δ59, M5 or SLT40). CoIP demonstrated that SIVmac251 coRev 
and its mutant called SLT40 (multimerization-deficient) were successfully bound to 
human Staufen-1, whereas the other mutants failed to interact with Staufen-1. 
Information reported by Hanke et al. proved by CoIP assay that HERV-K113 
oricoRec was physically bound to human Staufen-1 [141]. Our data obtained in the 
present study described that Rev-Staufen-1 interaction process might not be 
mediated by the inactivated multimerization domain (SLT40); also disability of 
coRevΔ31 (deletion of the first loop), Δ59 and M5 lacking functional NLS to interact 
with Staufen-1 by CoIP might prove the influential role of the first loop and NLS 
domain in binding to Staufen-1. Interestingly, SIVmac coRev SLT40 mutant could be 
associated with enhancement of the highest RNA transportation activity and inhibitory 
effect on SIVmac239 production when compared to SIVmac coRev and the other 
coRev mutants. This data was confirmed by a certain study which provided evidence 
that nonfunctional NLS of HIV-1 coRev inhibited the interaction of coRev with 
Staufen-1 [142]. From these findings, determination of the viral Rev domains 
enhancing the attachment to Staufen-1 may aid in designing effective antiretroviral 
drugs. 
 
5.8 Rec mutant analysis 
 
Expression of HERV-K Rec protein is essential for the export of intron 
containing partially spliced or unspliced viral mRNAs from the nucleus into the 
cytoplasm for protein biosynthesis. Rec protein has several functional regions; 
Nuclear localization domain (NLS), Nuclear export signal (NES) and multimerization 
domains [82] [192] [81] [208]. Rec protein binds via its NES to Crm1 export protein 
forming complex which interacts with the unspliced and partially spliced viral mRNAs 
and transported from the nucleus into the cytoplasm for translation, then Rec enters 
back to the nucleus by its NLS. Also, it was found that the Rec protein was expressed 
and visualized in the nucleus by using immunofluorescence [145] [209] [210]. 
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By many investigators, it was shown that overexpression of Rec could be 
involved in increase in HERV-K expression level [141] [211]. Thus, in the present 
study, analysis of the impact of Rec mutation on the virus particle production could be 
targeted; also the influence of Staufen-1 overexpression on ori HERV-K113 ΔRec 
expression level could be evaluated. For this purpose, mutation via nine nucleotides 
deletion was introduced into splice donor 2 (SD2) region to inhibit the expression of 
Rec. In our results, it could be indicated that Rec deficient mutant showed no 
detectable viral Gag protein or viral RT activity after transfection of the cells with 1 µg 
ori HERV-K113 ΔRec either with or without encoding for exogenous Staufen-1. On 
the other hand, expression in trans of oricoRec mediated the viral expression level 
through induction of the viral RT activity and the biosynthesis of the viral Gag protein; 
also Staufen-1 cotransfection led to higher RT activity and viral particle production. 
Furthermore, in the current study, cotransfection of ori HERV-K113 ΔRec and 
different quantities of oricoRec DNA has exhibited notably higher viral Gag protein 
level with increase in the amounts of oricoRec DNA introduced into the cells for the 
transfection. Therefore, our data revealed the significant role of Rec expression in the 
viral particle production. Our finding was agreed with another attempt that proved that 
overexpression of Rec could efficiently enhance the production of the viral particles 
upon cotransfection of Rec and HERV-K Bogota (lacking pol, most of the env gene, 
and the rec gene); also it has been shown that viral like particles (VLPs) were 
produced and infectious when HERV-K Rec and unenveloped HERV-K virus were 
cotransfected into the cells [71] [211] [212]. 
Moreover, in this study, it was reported that viral Gag protein could be 
detected after increasing the concentration of ori HERV-K113 ΔRec transfected into 
the cells (80 µg) without encoding for oricoRec; this protein level was increased by 
Staufen-1 overexpression by 6-fold. On the other hand, cotransfection of 80 µg ori 
HERV-K113 ΔRec in the presence of oricoRec displayed higher viral Gag protein 
production by a factor of 11 than that in the absence of oricoRec; also Rec mediated 
Staufen-1 enhancement efficiently supported the expression of the viral proteins by a 
factor of 6. Thus, Rec mutation negatively affected the virus propagation; 
consequently, the previous results could prove that deletion of Rec has a significant 
impact on the Staufen-1 mediated enhancement of particle production. Nevertheless, 
the impact is not completely abrogated by the lack of Rec indicating an additional, 
Rec-independent mechanism of HERV-K(HML-2) enhancement by Staufen-1. Other 
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studies consistent with our conclusion investigated that although most complex 
retroviruses encode Rev-like proteins, simple retroviruses lacking a Rev depend on 
the direct recruitment of a host nuclear RNA export factor to the target cis-acting RNA 
known as a constitutive transport element (CTE) [213]. This factor has been identified 
as the host protein Tap in the case of the Mason–Pfizer monkey virus (MPMV) CTE 
[214] [215]. Importantly, CTEyTap dependent nuclear RNA transport is independent 
of Crm1 function [215] [216] [217]. 
Interestingly, it has been identified that HERV-K Rec is mechanistically 
analogous to HERV-K Np9 (involved in the malignancies) [80], HIV-1 Rev, SIVmac 
Rev, HTLV Rex. Like all these proteins, HERV-K-Rec interacts with both the Crm1 
nuclear export factor and with a cis-acting viral RNA target to induce nuclear 
transportation of unspliced RNAs into the cytoplasm for translation. In a previous 
study, it was examined that HERV-K RNA sequence is recognized by HIV-1 Rev 
[156]. These data provide important evidence for an evolutionary link between HIV-1 
and endogenous retroviruses that first was integrated into the human genome 30 
million years ago [156]. Based on these data, one of our goals in the present study 
was to assess the influence of expression of HIV-1 coRev, SIVmac251 coRev, HTLV 
coRex and Np9 on the expression level of ori HERV-K113 ΔRec without expressing 
oricoRec. By using Cavidi assay, cotransfection of HEK-293T cells with ori HERV-
K113 ΔRec alone or in combination with oricoRec, HIV-1 coRev, or SIVmac251 
coRev has shown detectable viral RT activity, while expression of Rex and Np9 was 
associated with viral RT activity lower than observed by cotransfection of ori HERV-
K113 ΔRec alone. Although HERV-K Np9 protein as alternative of Rec protein 
belongs to provirus type II [80], nonetheless did not show viral reverse transcriptase 
activity. Additionally, this study revealed that coexpression of Staufen-1 with ori 
HERV-K113 ΔRec alone or in combination with Rec, HIV-1 Rev, SIVmac Rev, or Rex 
increased the viral reverse transcriptase activity. In contrast, Np9 did not demonstrate 
a viral RT activation either with or without Staufen-1 overexpression. 
According to these findings in this experiment, it is reported that lentiviral Rev 
and Rex were capable of interacting with HERV-K RcRE and exporting the unspliced 
mRNAs into the cytoplasm for biosynthesis of the viral proteins demonstrating that 
HERV-K Rec is biologically similar to HIV-1 Rev, SIVmac Rev and Rex. This 
experiment therefore has significant implications for assessment of the evolution of 
present day exogenous retroviruses. 
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In agreement with our data, a certain attempt has shown that HIV Rev could 
be able to bind functionally to HERV-K RcRE causing the nucleocytoplasmic RNA 
shuttling; this confirms the similarity between HERV-K Rec and the lentiviral Rev 
proteins but the reverse was not done because HERV-K Rec cannot be bound to 
HIV-1 RRE [156]; also there is report indicated that transmissible units of HERV-K 
particles containing Bogota transcripts could be induced by overexpression of HIV-1 
protein in the presence or absence of HERV-K Rec [211]. Additionally, a previous 
article proved that HIV-1 Rev stimulated the exit of the unspliced RNA transcripts of 
HIV-2 and SIVmac [110]. Moreover, Rimsky et al. reported that HTLV-1 Rex could 
function instead of HIV-1 protein [218] as well as it could be demonstrated that a 
remarkable increase in HERV-W and HERV-K RNA in HIV-1 infected patients [155]. 
Expression in trans of HIV-1 accessory proteins Tat and Vif mediated the production 
of HERV-K Bogota particles as shown in a certain study [211]. The HIV-1 Tat protein 
likely stimulates expression of HERV-K viruses via activation of the binding of the 
transcription factors NF-κB and NFAT to the HERV-K LTR [219] [220], whereas HIV-
1 protein Vif participates in the transmissibility of HERV-K virus by inhibition of 
cytidine deaminases of the APOBEC family; these proteins cause mutations in the 
viral genome during reverse transcription [221] [222] [223]. These observations are 
also matched with those from other groups, who have demonstrated increased 
expression of HERV-K viruses and their structural proteins during HIV-1 infection 
[156] [224] [225] [226] [227]. 




Staufen-1 is a cellular protein involved in subcellular RNA transport and the 
translation and packaging of retroviral RNA into viral particles. In this study, several 
aspects of the impact of Staufen-1 on SIVmac, HIV-1 and HERV-K(HML-2) particle 
production were investigated.  
The results obtained show that, similar to the situation with HIV-1 and HERV-
K(HML-2), overexpression of Staufen-1 also enhances SIVmac particle production. 
However, the 3-4-fold increase in SIVmac particle production is slightly (2x) lower 
than that seen with HIV-1 and significantly lower than the 20-30-fold boost of HERV-
K(HML-2) production. This enhancement is not dependent on the general level of 
expression but appears to be an intrinsic property of the virus. As expected, 
downregulation of endogenous Staufen-1 expression using Staufen-1 specific 
shRNAs negatively affected SIVmac particle production. On the other hand, an 
excessive overexpression of Staufen-1 decreases HIV-1, but not HERV-K(HML-2) or 
SIVmac particle production, indicating that the optimal levels of cellular Staufen-1 are 
different for these viruses. Using luciferase reporter viruses, differences between the 
genera were also found with regard to the effect of Staufen-1 on RNA shuttling and 
translation. Whereas Staufen-1 overexpression enhances HERV-K(HML-2) 
production at these stages of replication, the opposite has been observed for the two 
lentiviruses. The positive net effect of Staufen-1 overexpression on HIV-1 and 
SIVmac particle production therefore appears to result primarily from improved 
packaging and assembly while, for HERV-K(HML-2), RNA transport and translation 
are also enhanced. Furthermore, similar to the situation with HIV-1 Rev, Staufen-1 
interacts directly with SIVmac Rev, with the Staufen-1 RBD3 domain being involved 
in this binding. 
HERV-K(HML-2) Rec has a significant impact on the Staufen-1 mediated 
enhancement of particle production. Nevertheless, the fact that this impact is not 
completely abrogated by the lack of Rec indicates the existence of an additional, 
Rec-independent mechanism of HERV-K(HML-2) enhancement by Staufen-1. In 
addition, overexpression of Rec promotes HERV-K(HML-2)  production.  
Finally, the study confirms previous reports that show a strong boost in particle 
production by Staufen-1 overexpression and the functional substitution of Rec by 
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HIV-1 Rev, SIVmac Rev and HTLV Rex proteins. In contrast Np9, the protein 
produced by type I HERV-K(HML-2), cannot functionally substitute Rec. 
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Abbreviations Long form 
® Registered Trademark 
°C Degree celcius 
AIDS Acquired Immunodeficiency Syndromes 
ALS Amyotrophic Lateral Sclerosis 
AP alkaline phosphatase 
APS Ammonium persulfate 
ARM Arginine-Rich Motif 
ATLL Adult T-cell Leukemia/Lymphoma 
ATP Adenosine triphosphate 
BSA Bovine Serum Albumin 
CLSM Confocal Laser Scanning Microscope 
CoIP Co-Immuno-Precipitation 
DAPI 4’,6-Diamidin-2’ phenylindoldihydrochlorid 
DMEM Dulbecco’s Modified Eagle Medium 
DMSO Dimethylsulfoxide 
DNA deoxyribonucleic acid 
dNTPs Deoxynucleotide triphosphates 
DTT Dithiothreitol 
E. coli Escherichia coli 
EDTA Ethylenediaminetetraacetic acid 
ELISA Enzyme-Linked Immunosorbent Assay 
ERVs Endogenous Retroviruses 
FCS Fetal calf serum 
GAPDH Glyceraldehyde 3-phosphate dehydrogenase 
Gp glycoprotein 
HAART Highly Active Anti-retroviral Therapy 
HBS HEPES Buffer Saline 
HEK Human Embryonic Kidney 
HEPES 4-(2-hydroxyethyl)-1-piperazineethanesulfonic 
acid 
HERV Human Endogenous Retrovirus 
HIV Human Immunodeficiency Virus 
HML Human MMTV-like 
HRP Horseradish Peroxidase 
HTLV Human T-cell Lymphotropic Virus 
ICTV International Committee for Taxonomy on 
Viruses 
IgG Immunoglobulin G 
Kb Kilo bases 
kDa Kilodalton 
LB Luria-Bertani 
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MMTV Mouse Mammary Tumor Virus 
MP Matrix Protein 
mRNA messenger RNA 
NC Nucleocapsid 
NES Nuclear Export Signal 
NLS Nuclear Localization Signal 
nm Nanometer 
nM Nanomole 
OPD o-Phenylenediamine dihydrochloride 
ori Original 
OWMs Old World Monkeys 
PBS Phosphate Buffured Saline 
PCR Polymerase Chain Reaction 
PFA Paraformaldehyde 
PIC Pre-Integration Complex 
PM Powdery Milk 
PMSF Phenylmethanesulfonylfluoride 
PR Protease 
PVDF Polyvinylidene flouride 
RA Rheumatoid Arthritis 
RBD RNA Binding Domain 
RER Rough Endoplasmic Reticulum 
Rev Regulator of Expression of Virions 
RISC RNA Interference Specificity Complex 
RLU Relative Light Unit 
RNA Ribonucleic acid 
RPMI Roswell Park Memorial Institute 
RRE Rev/Rec Responsive Element 
RSV Rous Sarcoma Virus 
RT Reverse transcriptase 
RT Room Temperature 
SA Splice Acceptor 
SD Splice Donor 
SDS-PAGE Sodium dodecyl sulfate polyacrylamide gel 
electrophoresis 
SHIV Simian/Human Immunodeficiency Virus 
SiRNA Short Interfering RNA 
SIV Simian Immunodeficiency Virus 
SIVmac Simian immunodeficiency virus of Rhesus 
Macaques 
SLE Systemic Lupus Erythematosus 
SU Surface Unit 
TAE Tris-Acetat-EDTA-Buffer 
Taq Thermophilus aquaticus 
TAR Trans-Acting Responsive 
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TBD Tubulin Binding Domain 
TEMED Tetramethylethylenediamine 
TM Trans-membrane 
tRNA Transfer-Ribonucleic acid 
UV Ultraviolet 
V Volt 
VLPs Virus-Like Particles 
VSV Vesicular Stomatitis Virus 
VSV RNA Interference Specificity Complex 
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